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ABSTRACT 
Ultrathin Zwitterionic Polymer Coatings to 
Improve Hemocompatibility of Silicon-
based Implantable Medical Devices 
By Zohora Iqbal 
 
Silicon-based bio-microelectromechanical systems (bioMEMS) have become increasingly 
attractive for medical implants due to their relative low cost and capacity for fabrication of 
intricate micro- and nanofeatures.  However, when silicon surfaces encounter blood, device 
failure can occur as plasma proteins adhere to the surface and the coagulation cascade is 
activated leading to thrombosis.  Modifying silicon surfaces with hemocompatible coatings may 
reduce protein adsorption and platelet activation, increasing the lifetime of the implant. 
Using bioMEMS technology, our group has developed silicon nanopore membranes (SNMs) for 
application in bioartificial organs.  Highly uniform pores of controllable size make SNMs 
attractive for immunoisolation and blood filtration.  To improve hemocompatibility of SNMs, 
this dissertation investigates sub-5 nm biomimetic polymer surface coatings.  Specifically, two 
ultrathin zwitterionic coatings, poly(sulfobetaine methacrylate) (pSBMA) and poly(2-
methacryloyloxyethyl phosphorylcholine) (pMPC), were developed and characterized via x-ray 
photoelectron spectroscopy, contact angle, atomic force microscopy and ellipsometry.  The 
coatings were tested under biological shear conditions and after exposure to five standard 
sterilization methods.  Anti-fouling and hemocompatible characteristics of the coatings were 
vii 
 
evaluated by measuring protein adsorption from single protein solutions of human serum 
albumin and fibrinogen, and examining platelet activation after exposure to fresh human blood 
and implantation in porcine model for up to 26 days.  
Characterization results showed successful sub-5 nm pSBMA and pMPC surface modifications.  
In this thickness range, SNMs remained patent and modified silicon substrates resisted bio-
fouling from single protein solutions of human albumin and fibrinogen, with pSBMA reducing 
protein adsorption by >80% compared to uncoated silicon.  Shear data suggests the coatings are 
robust and functional following shear rates up to 2000/s over 24 hours.  Additionally, they 
withstood sterilization procedures, with best performance of pSBMA and pMPC after electron-
beam sterilization and ethylene oxide gas treatment, respectively.  Scanning electron microscopy 
and immunohistochemistry following exposure to fresh human blood flow demonstrated 
pSBMA-silicon reduced platelet adhesion and activation by >97%.  Porcine implants with 
pSBMA-silicon substrates remained patent over 26 days, with no gross clots in the flow path and 
minimal presence of blood activation.  These promising in vitro and in vivo results will lead to 
further studies coupling SNM filtration and surface coatings, as well as clinical testing to 
determine the human response for use in bioartificial kidney and pancreas device applications. 
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CHAPTER I 
Surface Modifications to Improve 
Hemocompatibility for Implantable 
Bioartificial Organs 
 
1.1 Introduction 
Over the past 50 years, the electronics industry has led the way in designing semiconductor-
based integrated circuits, miniaturizing transistors down to nanoscale features.  Leveraging this 
technology, microelectromechanical systems (MEMS) was developed, allowing for the 
production of intricate micro- and nanoscale silicon devices with precision and speed.  From 
MEMS, “bioMEMS” was born, utilizing these devices for biological and healthcare applications.  
In addition to incorporating nanoscale features, these devices can also be integrated with 
electronics to produce biosensing instruments.  Advancement in bioMEMS has allowed for the 
development of novel tools, paving the way for personalized medicine and point-of-care 
diagnostic tools such as DNA sequencing,1 rapid protein analysis,2,3 and drug delivery.4  
The semiconductor used in bioMEMS is silicon, which is a relatively inexpensive material 
widely used in electronics.  Silicon is attractive for biological and implant applications because it 
has been shown to be non-cytotoxic.5,6  Additionally, various materials pertinent to implantable 
bioMEMS including silicon, polysilicon and silicon dioxide have been tested against a battery of 
tests laid out in ISO 10993, and were found to be non-leaching and non-irritant.7  With these 
added benefits, a growing number of implants are being designed using silicon as a substrate 
such as neuroelectrodes,8,9 drug delivery systems,4,10,11 biosensors, and diagnostic devices.12–14  
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One such device is the silicon nanopore membrane (SNM), currently being used to develop 
bioartificial organs for renal replacement15 and islet therapy.16  The following section describes 
SNM and its uses. 
1.2 Silicon Nanopore Membrane (SNM) 
 
Figure 1.1: Silicon nanopore membrane (SNM). a) Diced as part of a wafer, b) top view under scanning electron 
microscopy (SEM) showing uniform 7 nm pores, and c) membrane cross-section showing pore height of 0.4 µm with 
100 nm pore spacing. 
 
Using MEMS technology, our lab has developed silicon nanopore membranes (SNMs), shown in 
Figure 1.1.  Compared to conventional membranes, SNMs have highly uniform slit-pores that 
can be controllably tuned down to 5 nm width with less than 1% variation over a 100-mm 
diameter wafer.17  The fabrication process is briefly described below (Figure 1.2):18,19 
a) 500 nm of silicon dioxide (SiO2) is thermally grown on 400 µm-thick monocrystalline 
double-side polished silicon substrate (Figure 1.2(a)). 
b) 500 nm of undoped polysilicon is deposited at 580 °C using low pressure chemical vapor 
deposition (LPCVD) and annealed at 1075 °C for an hour (Figure 1.2(b)). 
c) Using photolithography, an array of 400 nm wide slits with 400 nm spacing is patterned 
and dry etched using reactive ion etching (RIE) (Figure 1.2(c)). 
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d) Based on the desired pore size, x nm, a conformal layer of SiO2 of x nm thickness is 
thermally grown at 800 °C (Figure 1.2(d)). 
e) A second polysilicon layer of 800 nm thickness is deposited by LPCVD (Figure 1.2(e)). 
f) The polysilicon and the top film of the thin oxide layer is blanket-etched until 450 nm of 
polysilicon remained, and the thin SiO2 vertical sidewall is exposed (Figure 1.2(f)). 
g) Polysilicon and thin layer of SiO2 is removed from the backside of the wafer and 1 µm of 
low temperature oxide (LTO) is deposited by LPCVD for protection of membrane 
features for next steps (Figure 1.2(g)). 
h) LTO on the backside of the wafer is used as a hard mask and an array of windows is 
patterned to create an etch mask for an array of windows. 
i) Windows are etched back using deep reactive ion etching (DRIE) (Figure 1.2(h)), and the 
pores are released in using concentrated hydrofluoric acid (Figure 1.2(i)).   
      
Figure 1.2: Step-wise fabrication process of SNM, with cross-section views shown.  Figure not drawn to scale. 
 
Using this process, reproducible, 450 nm-thin nanopore membranes can be produced with tight 
pore size distribution and minimally tortuous pores.  The resulting membrane is highly selective 
and low resistance to fluid flow.  Selectivity is further enhanced by the slit pore design in 
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comparison to cylindrical pores.20  Because the pores are defined by a thin oxide layer, 
controlling the time and temperature during oxide growth can tune the pore size for various 
sieving applications.  Additionally, the silicon surface can be readily functionalized to alter the 
surface chemistry.  These traits make SNMs attractive for biological applications such as 
filtration and immunoisolation for bioartificial organs.  
1.2.1  SNM for Bioartificial Kidney 
The kidney is an essential organ whose key function is to filter out excess fluid, electrolytes, and 
metabolic waste products from blood.  Mainly caused by diabetes and hypertension, end stage 
renal disease (ESRD) occurs when kidney function drops below 10% of its normal function.  
ESRD has become a major medical concern in the United States due to its increasing incidence 
rate, high mortality rate, and management expense.  As of 2015, there were >700,000 Americans 
suffering from ESRD.  However, only ~17,000 patients receive a kidney transplant annually.21  
Most of these patients rely of hemodialysis, where they are treated in dialysis centers thrice-
weekly in 3-4 hour sessions, resulting in yearly expense of >$88,000 per person.22  This 
treatment regimen allows for toxins to build up periodically between dialysis session, which are 
at least two days apart, leading to poor quality of life for patients.  Daily-extended hemodialysis, 
such as at-home nocturnal hemodialysis, allows patients access to dialysis for at least 6 hours 
daily.  This increased blood filtration treatment has been linked to improved quality-of-life 
indicators and patient outcomes.23,24 
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a) 
b)     
Figure 1.3: a) Dialysis conducted at dialysis center. b) SNM-based bioartificial kidney: implantable model and 
housing (left), SNM patterned and diced on silicon wafer (middle), and diced SNMs stacked into implantable 
bioartificial kidney. 
 
While daily-extended hemodialysis leads to better patient outcomes compared to the standard-of-
care,24,25 the current healthcare infrastructure cannot support daily-extended hemodialysis as a 
viable option.  Therefore, there is a need to develop novel technologies that can give rise to 
portable or implantable renal replacement therapy.  Polymer membranes used in hemodialysis 
treatment have wide pore size distribution and require large pressures to drive filtration, limiting 
permeability and selectivity, as well as possibility of miniaturization.19  SNMs, on the other 
hand, offer uniform pores at low resistance for efficient blood filtration, and its use advances the 
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technology toward the possibility of continuous renal replacement therapy through a portable or 
implantable device (Figure 1.3). 15,18,26     
1.2.2 SNM for Bioaritificial Pancreas 
Type 1 diabetes (T1D), typically diagnosed due to an absolute insulin deficiency, is caused by 
the destruction of pancreatic β-cells located in the islets of Langerhans.27  Current treatments of 
T1D include insulin infusion therapy and pancreas transplant.  For insulin infusion therapy, 
patients are responsible for measuring blood glucose and injecting insulin based on the glucose 
reading.  This method leaves a lot to be desired; usually given in a bolus, the pattern of insulin 
secretion does not mimic biological insulin release in the body.  Additionally, patients are 
responsible for calculating and setting the amount of insulin needed and human errors can lead to 
hypo- or hyperglycemia, which can be fatal.  Pancreatic transplants, on the other hand, are 
limited by donor availability.  Furthermore, patients with transplant must remain on global 
immunosuppression to protect the pancreas from the host’s immune response. 
One approach to overcome immune response is by protecting the graft islets using a semi-
permeable membrane.  This membrane must allow the passage of glucose, insulin, and nutrients, 
while blocking cells, proteins, and cytokines associated with immune response.  Immune cells—
on the order of 10 µm, and large proteins such as antibodies can be blocked by membranes with 
a molecular cutoff size in the range of 30 nm.  However, blocking cytokines such as Tumor 
Necrosis Factor-alpha (TNF-α), Interferon-gamma (IFN-γ) and Interleukin-1 beta (IL-1β) are 
also critical as they have been shown to be cytotoxic to islets.28,29  However, these cytokines 
have Stokes diameters of ~3-4 nm, making it difficult to separate them from small molecules 
such as glucose (0.82 nm) and insulin (2.64 nm) using polymeric membranes with broad pore 
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size distribution.30  Therefore, to design an implantable bioartificial pancreas, utilizing SNMs is 
attractive due to their high selectivity (Figure 1.4).   
 
Figure 1.4: SNM-based bioartificial pancreas. a) Schematic of implantable immunoisolation chamber for islet 
therapy; b) exploded (left) and assembled (right) view of intravascular bioartificial pancreas.16 
 
1.2.3  Challenges Facing Use of SNMs 
While SNMs have physical attributes that can make bioartificial organs such as the kidney and 
pancreas possible, thrombosis on implanted silicon in contact with blood remains a challenge.31  
Although previous research has shown silicon to be non-cytotoxic5,6 and non-leaching, 7 
hemocompatibility of silicon is still a concern as cells and proteins attach to the surface, fouling 
the membranes, reducing their functionality, and inciting coagulation.  Coagulation and 
thrombus formation can cause further complications leading to embolism. 
1.3 Hemocompatibility Concerns for Foreign Material 
The human body has built-in mechanism to protect itself from foreign invaders and implants 
must evade this defense.  Averting these defenses require a solid understanding of the 
immunological and coagulation processes.  The host reaction to an implant placed in tissue 
includes blood-material interaction, inflammation, foreign body reaction, and fibrous 
encapsulation.  These processes entail the activation of various inter-related protein cascades 
a) b) 
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found in blood such as the coagulation system and the complement system, as well as activation 
of leukocytes and platelets, leading to clotting and inflammation.32–34  For SNMs that are 
exposed to blood flow, minimizing reactions from blood-material interactions is critical.  
Therefore, a brief discussion on the blood-material interaction follows. 
1.3.1 Blood-Material Interaction 
 
 
Figure 1.5: Interaction of proteins, protein cascades, platelets and leukocytes with each other and biomaterial. 
Adapted from M.B. Gorbet, M.V. Sefton, Biomaterials 25 (2004) 5681-5703.35 
 
Within nanoseconds of contact with blood, plasma proteins adsorb to the implant surface. The 
protein type, amount, and conformation determine further activation of coagulation system, 
complement system, platelets and leukocytes (Figure 1.5).35   
As shown in Figure 1.6, contact with negative charges on a biomaterial can activate Factor XII 
(FXII) of the coagulation system.35  Activated Factor XII (FXIIa), in turn, sets off a cascade of 
enzymatic reactions leading to the production of thrombin from prothrombin.36  Thrombin plays 
a critical role in the coagulation system; it not only directly activates platelets but also converts 
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fibrinogen to fibrin, which polymerizes to start clot formation on the surface.36  Fibrin interacts 
with leukocytes that leads to an inflammatory response and expression of tissue factor on the cell 
surface.  Tissue factor further activates platelets as well as setting off the extrinsic coagulation 
cascade, increasing clot formation.37,38  Activated platelets also expose negatively charged 
phospholipids that interact with FXII and propagate the coagulation cascade.39–41   
In addition to directly catalyzing the reaction of converting prothrombin to thrombin, Factor Xa 
of the coagulation system assembles with Factor Va on the surface of activated platelets to 
increase thrombin production, which further promotes platelet activation.39,41   
Aside from fibrin, fibrinogen itself also interacts with the foreign surface.  Previous literature has 
shown that fibrinogen adhered to the surface exposes binding sites that allow for the activation of 
phagocytes and provides a substrate for platelets to attach to the biomaterial.42–45 
The complement system acts alongside the coagulation system, and the goal of the complement 
system is to tag a pathogen so it can be more readily destroyed by phagocytes.  Usually these 
proteins circulate the blood in inactive form, but in the presence of an antigen, or an antibody 
bound to an antigen, complement can get activated through three different pathways—classical, 
alternative, and lectin pathways.36 
For biomaterials, complement activation begins with a layer of adsorbed protein to the 
biomaterial surface.33  The classical complement pathway can be activated by the binding of C1q 
to IgG in the adsorbed protein layer on the biomaterial.46  C1q forms C1 by creating a complex 
with C1s and C1r. Activated C1s cleaves C4 to produce C4a and C4b.  C4b binds to the 
biomaterial surface and also binds a molecule of C2, which is then cleaved by C1s to produce 
C2a and C2b.  C2a remains bound to C4b to produce C4b2a which is a C3 convertase, which 
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catalyzes the reaction that converts C3 to C3a and C3b.  C3b binds to the surface and tags the 
surface for phagocytes, while C3a remains free floating and activates phagocytes.  Surface-
bound C3b can also start the alternative pathway by binding Factor B to itself.  Bound Factor B 
is then cleaved by factor D into Ba and Bb.  Bb remains attached to C3b, producing C3bBb, 
which is also a C3 convertase, producing more C3a and C3b, to initiate an amplification loop of 
the alternative pathway.36,47  Research has also shown that C3 itself can bind to the biomaterial 
surface and mimic C3b conformation which can set off the alternative pathway.48  Additionally, 
thrombin and FXIIa of the coagulation pathway are also able to convert C3 to C3a and C3b, 
leading to an inflammatory response via the alternative pathway.33,35 
The complement pathway also produces the anaphylatoxin, C5a by activating the C5 convertase, 
which is a C3 convertase with an additional C3b bound to it (C4b2a3b and C3b2Bb).36  C5a and 
C3a both activate leukocytes to incite an immune response and activated leukocytes express 
tissue factor which in turn activates platelets and promotes coagulation.     
Activation of coagulation and the inflammatory response not only causes attachment of proteins 
and cells to the surface, but can also cause clots further down the blood flow path of the device 
or beyond the device and into the bloodstream. 
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Figure 1.6: A simplified schematic of complement and coagulation activation when in contact with biomaterial. 
 
1.3.2 Hemocompatibility Testing Considerations for Biomaterials 
When testing hemocompatibility of biomaterials, there are two primary aspects to observe: 
degradation and leaching of harmful materials that may lead to cytotoxicity or inflammation and 
adhesion and activation of cells and platelets that can lead to inflammation and thrombosis.  To 
study these factors in detail, experiments are conducted in vivo and in vitro.  If run properly, 
preliminary in vitro testing can eliminate samples that are likely to fail in vivo.  “Proper” in vitro 
experimental setup, however, can vary.  Although basic guidelines of experimental setup are 
outlined in ISO 10993-4,49 adjustments must be made based on the implant and the conditions it 
will be exposed to.  Therefore, when designing in vitro blood experiments, it is recommended 
that the settings reflect the final implant conditions as much as possible. 
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For in vitro hemocompatibility experiments, the experimental fluid to be used requires careful 
consideration.  While whole blood is the closest to implant conditions, researchers often use 
fractionated blood components,50 such as plasma (platelet-rich-plasma, platelet-poor-plasma)51–53 
or serum.  Doing so allows for better control over length of experiment, as well as interference 
from other blood variables.  Blood can be sourced from humans,50,54,55 pigs,55 sheep,55 dogs,51 
rats,54 etc.  Although human blood is ideal, in some cases, it may be easier to access and run 
experiments using other types of animal blood.   
If fresh whole blood is used, the time length of experiments is critical.  Many proteins in whole 
blood can curdle ~4 hours after collection.49  Therefore, fresh whole blood experiments are not 
run for >4 hours.  Additionally, because pooling blood from different subjects can activate the 
blood, for hemocompatibility experiments, it is important to use blood from one individual for 
one set of experiments.  Finally, for fresh blood experiments, the blood must be collected in a 
non-activating manner and anticoagulated as described in the methods in Chapter 5, as well as in 
other previous literature.56  The type and amount of anticoagulant should be chosen based on 
experimental conditions.   
Aside from the experimental fluid itself, the testing conditions and platform used is also 
important.  To mimic biological conditions, blood experiments should be conducted at 37 °C.  In 
addition, the testing platform should be as close to the final condition as possible.  In previous 
research, some experiments are conducted under static conditions.50–52  However, flow 
conditions need to be analyzed for biomaterials that will be exposed to blood flow, in order to 
better understand the effect of shear stress through the device and how it may contribute to 
hemolysis and activation.57  In designing a dynamic blood flow system, the variables to consider 
include the ratio of contact time with biomaterial surface compared to other materials used in the 
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system and flow rates that set the shear rates.  Additionally, how the dynamic condition is set 
must also be well thought-out.  Many researchers use agitators to ensure the blood does not 
settle,58,59 while others use flow chambers56,60 and loops (i.e. circulation models)54,57,61 that are 
powered by a peristaltic pump.  Finally, the presence of a blood reservoir in a flow system can 
affect the outcome of the experiments, since blood settling in a reservoir can get auto-activated. 
Compared to in vitro experiments with whole blood, in vivo experiments allow for longer length 
of experiments.  Choosing the correct animal model for an implant is critical, since that 
determines the activation level of the blood.55  The location of the implant is also important 
because it defines the blood volume and the flow rate the implant experiences.  Introducing the 
implant in the body is an interesting challenge; biomaterials have been placed in the muscle62 as 
well as in shards in the artery or in anastomosis/arteriovenous shunts between the artery and 
vein.63,64  While some implants are placed in the muscle for ease of experimentation, implants 
that are meant for exposure to blood flow should be tested under blood flow conditions. 
Following both in vitro and in vivo experiments, post analysis of the biomaterial as well the 
experimental fluids need to be conducted.  Aside from visual thrombus formation, 
microscopy56,58,59 or radiolabeling64 can be used to examine clot formation or attachment and 
activation of cells and platelets.  For in vitro experiments, complement and coagulation cascade 
activation in the blood can also be analyzed using enzyme-linked immunosorbent assay 
(ELISA),58,59 and hemolysis can be tested using spectroscopy.65  For in vivo testing, histological 
testing can be done by taking sections, and leukocytes, collagen, and fibrosis buildup can be 
visualized.62,66 
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1.4   Methods of Surface Modifications to Improve Hemocompatibility 
Once a foreign material is introduced to blood, it initially interacts with plasma proteins.  This 
interaction defines the further reaction by the body such as activation of immune response, 
inflammation and coagulation.  Therefore, many researchers have taken the approach of creating 
a surface that will not allow interaction with proteins.67–69  This can be done by producing non-
fouling surfaces through steric hindrance, controlling surface wettability, or promoting adhesion 
of specific proteins.70  Often, researchers have attempted to mimic biological surfaces that 
already exist in nature, from producing a cellular wall such as endothelialization, to coatings of 
specific non-immunogenic, non-thrombotic materials such as phosphorylcholine and albumin 
passivation.  Changes in surface topography and roughness can also affect protein adhesion to 
the surface.71  In the section below, several leading approaches in surface modification to 
improve hemocompatibility are discussed, and their advantages and disadvantages are 
summarized in Table 1.1. 
1.4.1 Endothelialization 
Blood vessels are lined with a monolayer of endothelial cells that naturally prevent coagulation 
through cell surface components and cell secretions.  In addition to regulating platelet adhesion 
and activation, endothelial cells express several thrombin inhibitory glycoproteins such as 
heparan sulfate proteoglycan and thrombomodulin, and release fibrin degrading agents such as 
tissue-type plasminogen activator and urokinase.72  Typically used in cardiovascular implants 
such as synthetic grafts and stents, one approach to reaching hemocompatibility is by covering 
the surface of the implant with endothelial cells.72–75  Endothelialization can either be achieved 
pre-implantation in vitro76–79 or in situ,80,81 where cells are recruited from the bloodstream post-
implant.  However, the cells must remain confluent since any break in cell coverage can start 
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thrombus formation, and seeding cells in vitro often leads to cellular detachment when exposed 
to physiological shear stress.82  To address this issue, researchers have attempted to precondition 
endothelial cells with shear stress to strengthen their adhesion strength,83–85 in addition to 
modifying the biomaterial surface with peptides found in extracellular matrix such as 
fibronectin-derived RGD75,82 and laminin-derived YIGSR.75,86  
Because endothelial cells are immunogenic, autologous cells are often used.  However, 
harvesting and producing confluent autologous cells on implants can take ~3-24 months.72,74  
Therefore, in situ endothelialization—induction of self-endothelialization in vivo via 
transanastomotic migration, is also an approach being investigated.80,81  Endothelial cells are 
slow to proliferate.  Hence, endothelial progenitor cells (EPCs) can be seeded to create a rapid 
growth of endothelial cells.  This approach has been previously shown to improve long-term 
patency.87–89  Additional approaches for encouraging EPC growth include micropatterning the 
biomedical surface,90,91 transfusion of additional EPCs,92,93 and surface modification with 
antibodies such as CD34.80,94   
While endothelialization may be applied to the grafts leading to an SNM-containing implant, this 
approach cannot be applied for the membranes itself: nanopore membranes require open pores 
and presence of confluent cells would restrict filtration. 
1.4.2 Albumin Passivation 
Albumin is the most abundant protein in blood and does not play any direct role in immune 
response or hemostasis.  It is considered a “sticky” protein, and adsorbs to both hydrophilic and 
hydrophobic surfaces, although it has a much greater affinity for hydrophobic surfaces.50,95  
Albumin is typically applied by simple adsorption process to a foreign surface, and when a 
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surface is fully covered by albumin, it has been shown to reduce platelet adhesion and 
activation.50,54,57  To make albumin more adherent to a material, the substrate surface can be 
modified by grafting long alkane chains.50   
While albumin passivation works well for short-term blood contact applications, this method is 
highly susceptible to denaturation, degradation and replacement.  These challenges make it 
difficult to use for long-term implants.   Once adsorbed to the surface, albumin can alter its 
conformation, which can encourage adsorption of more activating proteins such as fibrinogen.  
When an albumin passivated surface is exposed to a cocktail of proteins, as is present in blood, it 
can often be displaced by larger, less abundant proteins such as IgM and fibrinogen, via a 
process called the Vroman effect.96,97  These proteins can then initiate activation of blood.  To 
eliminate the Vroman effect, researchers have covalently bonded albumin to the surfaces.98  
However, this still does not address the possibility of denaturation and degradation. 
1.4.3 Bioactive Surface Modifications 
Unlike albumin passivation, bioactive surface modifications rely on blood component 
interactions with the surface.  For example, surface coatings such as lysine, urokinase, heparin 
and hirudin, as well as coatings that release nitric oxide (NO), expect interaction with the surface 
and actively attempt to deactivate clot formation. 
Plasminogen, a protein that is converted to plasmin in the fibrinolytic pathway in order to 
degrade fibrin, has lysine binding sites.  Tissue plasminogen activator (t-PA), which is needed 
for fibrinolysis, also binds lysine.70,99  Therefore, by incorporating lysine into a biomaterial, it 
has been shown to selectively capture plasminogen and t-PA, and convert plasminogen to 
plasmin, which in turn can dissolve nascent clots on the surface.100,101  This process is further 
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improved with the presence of polyethylene glycol (PEG)102,103 and poly(2-hydroxyethyl 
methacrylate) (polyHEMA) spacers.52,104   
Other bioactive coatings that attempt to dissolve clots include surfaces incorporating urokinase 
and thrombomodulin.  Urokinase, which also converts plasminogen to plasmin, thus breaking 
down fibrin, has been shown to reduce clot formation in vitro105 and in vivo.62,106,107  However, in 
vivo experiments showed urokinase degradation after one month modified-catheter implantation 
in rabbit muscles.62 Thrombomodulin, biologically present on endothelial cell surfaces, converts 
thrombin from its procoagulant form to anticoagulant form and activates protein C, which 
inactivates factors Va and VIIIa of the coagulation pathway.108  When covalently immobilized 
onto a material, thrombomodulin has been shown to increase fibrinogen clotting time109 and 
reduce blood activation in vitro,59 as well as decrease platelet deposition over one hour in 
vivo.63,64  However, further studies need to be conducted to show long term stability and 
functionality under flow conditions. 
Heparin and hirudin are biomolecular drugs that are administered as anticoagulants.  Heparin, a 
glycosaminoglycan (GAG) similar to endothelial cell surface proteoglycan heparan sulfate, is 
found in the human body sequestered in the granules of mast cells.  It binds and alters the 
conformation of antithrombin (AT) to increase its inhibitory properties by a factor of 100-
1000.110  Aside from thrombin itself, AT binds and inhibits several other coagulation cascade 
proteins such as FXa, FIXa, FXIa, and FXIIa.111  Heparin is widely used in the medical device 
industry and research: immobilized onto catheters, stents and ventricular assist devices as well as 
extracorporeal devices such as oxygenators.110,112,113  While heparin is applied by ionic bonding, 
physical adsorption,56 bulk material incorporation,114 it can have increased lifetime when 
covalently bonded onto the surface via its many available carboxyl and hydroxyl groups.115  
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However, covalent bonding requires careful consideration to ensure that the thrombin binding 
site remain available.110  Therefore, end-point-attached heparin has shown improved 
performance.116  In addition to in vitro studies demonstrating the efficacy of heparin coatings, 
many in vivo studies have also illustrated that heparin-coated surfaces significantly decrease clot 
formation.110,115  A one year study with heparin-modified PTFE graft implanted in humans 
demonstrated a reduction in graft failure by 37%.117  By using PEG as a spacer, further 
improvements are made to heparin activity.118  However, more studies need to be conducted to 
find out if the use of heparin causes other complications in the human body.  Since heparin 
naturally remains sequestered in granules of mast cells and its full functionality there is yet to be 
determined, long-term exposure of heparin in blood may have side effects.  Also, heparin binds 
other bioactive molecules such as growth factors, the effects of which are unknown.119  An 
additional setback of heparin is that it is unable to bind complexed thrombin (i.e. thrombin bound 
to fibrin or another thrombin molecule), allowing clot formation to stem from these molecules.120 
Unlike heparin, which inhibits thrombin indirectly via AT activation, hirudin, a small peptide 
derived from the salivary glands of medicinal leeches, inhibits thrombin by directly binding to its 
active site.121,122  It is able to inhibit free-floating thrombin molecules, as well as thrombin bound 
to fibrin.123  Additionally, upon binding thrombin, hirudin interferes with the active site of 
thrombin that interacts with platelets.124  Recombinant hirudin can be applied such that its 
bioactivity is fully preserved,125 and has been shown to reduce thrombus formation and platelet 
adhesion, and increase clotting time in vitro on several biomaterials such as nitinol,126 
Dacron©,127 polyester,128 and silk fiber films.129,130  A 2-hour in vivo study using a canine model 
also showed reduced thrombus formation, with lower plasma protein adsorption and platelet 
adhesion on hirudin-modified surfaces of Dacron© grafts.131  One of the major limitations of 
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using hirudin is that the bond between hirudin and thrombin is very strong, and has a dissociation 
constant of only 1.98e-14 M.132  Therefore, the bond is practically irreversible, reducing the 
lifetime and effectiveness of hirudin for long term applications.  To overcome this problem, 
hirudin derivatives are being developed and they are in the preliminary testing phase.125,126 
Nitric Oxide (NO) is a gas naturally released by endothelial cells that plays a role in regulating 
inflammation in the body.  Released at a slow rate (0.5e-10 to 4e-10 mol/cm2/min), NO prevents 
platelet and leukocyte adhesion and activation.133  Therefore, unlike the anticoagulants 
previously discussed, utilizing this biomimetic approach would eliminate side effects.  
Modification of biomaterials using NO donors such as N -diazeniumdiolates and S -nitrosothiols 
has been widely studied and have been shown to be very effective.134–136  These molecules can 
be blended into the polymeric biomaterial, covalently bonded to the biomaterial surfaces, or 
covalently bonded to the backbone of a polymeric biomaterial.  These compounds are solid and 
stable under normal conditions and decompose through hydrolysis at physiological conditions 
(37 °C and pH 7.4).  The major limitation of this surface modification is that it relies on a 
reservoir of NO donors.  Therefore, long term application (>2 months) is yet to be demonstrated.  
Additionally, there will be an accumulation of by-products, which could be toxic and must be 
contained.  Further improvements of the coatings are being investigated by combining NO-
release with other anti-inflammatory coating approaches, such as thrombomodulin, heparin, and 
PEG.137–139 
1.4.4 Inorganic Coatings 
Among the metal oxide coatings, titanium oxides have been widely studied.  Titanium forms an 
inert oxide layer on its surface when exposed to air.  Although inert and stable in physiological 
conditions, natural titanium oxide adsorbs fibrinogen, and has been shown to adhere and spread 
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platelets within 5 s of blood exposure in vitro.140   However, there are many factors that play a 
role in the hemocompatibility of titanium oxides and nitrides such as coating thickness, surface 
roughness, crystallinity (anatase, rutile, amorphous, polycrystalline), contamination and doping.  
These properties can be controlled by applying the oxide/nitride films via methods such as 
sputtering, ion beam enhanced deposition, and metal plasma immersion ion implantation.141–144  
These approaches show improved hemocompatibility of biomaterials with titanium oxides and 
nitride coatings both in vitro and in vivo.143–146  Overall, trend shows that platelet adhesion and 
fibrinogen adsorption is decreased for TiNxOy compared to TiO2, which points towards a surface 
that is lower in hydrophobicity and contains increased polar components.147 
Diamond-like carbon (DLC) coating is a low friction, inert surface modification that is highly 
corrosion and wear resistant, utilized in load bearing implants such as for hip/knee joints, as well 
as for stents.148,149  Typically deposited using chemical or physical vapor deposition (CVD or 
PVD),148,150 the DLC films have high residual stress, which often causes delamination.148,151  
However, residual stress can be reduced by doping DLC with elements such as silver, nitrogen or 
titanium, as well as by adding metal interlayers.148,151,152  Although DLC coatings improve 
biomaterials (i.e. stainless steel), they are known to adsorb plasma proteins such as albumin and 
fibrinogen, as well as adhere and spread platelets.153,154 Structure and chemical bonding, surface 
roughness, and surface energy can influence interactions with blood and biological 
components,154,155 and increased polar components help improve hemocompatibility.150,156 
Pyrolytic carbon, a material resembling graphite, has demonstrated excellent thromboresistant 
properties.157  This material has revolutionized the heart valve industry: St. Jude bileaflet valves 
(since 1977) as well Carbomedics bileaflet valves (since 1986) are fully fabricated of pyrolytic 
carbon, and have been implanted in more than 1.8 million patients over the years.158  The success 
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rate for these heart valves are high, with <2% of operative risk worldwide and negligible 
thromboembolism and endocarditis.158  Goodman, et al has demonstrated that pyrolytic carbon 
significantly adheres and activates human platelets in vitro, which may result in 
thromboembolism.159   For this reason, patients receiving pyrolytic carbon mechanical heart 
valves are required to take anticoagulants for life.145,159  Other researchers, are investigating 
surface modifications on pyrolytic carbon in order to improve its hemocompatibility and reduce 
the need for the use of anticoagulants.145 
1.4.5 Hydrophobic/Omniphobic Coatings 
Silicone materials, i.e. polydimethylsiloxane (PDMS), is known for its flexibility, durability, 
inertness and nontoxicity.160  These properties lend themselves towards implant applications.  
Silicone is used in the medical industry as a direct biomaterial as well as a surface coating for 
applications such as breast implant, pacemaker leads, catheters etc.  Additionally, small-diameter 
vascular poly(ether) urethane graft with PDMS incorporated in has shown improved 
hemocompatibility in vitro with human anticoagulated blood.161  However, PDMS is naturally 
hydrophobic, making it more susceptible to platelet activation and increased plasma protein 
adsorption.162  Additionally, PDMS elicits a high level of foreign body response, which can lead 
to thrombogenesis.  Therefore, in order to increase hemocompatibility, there is ongoing work to 
modify PDMS surfaces with more hydrophilic polymers, such as polyethylene glycol and 
poly(sulfobetaine methacrylate).163–165 
Many hydrophobic coatings are generated using fluorinated carbon.  Polytetrafluoroethylene 
(PTFE), and expanded polytetrafluoroethylene (ePTFE) are fluoropolymers commonly utilized 
in implant applications ranging from vascular grafts to soft tissue augmentations.166  Although 
relatively successful, it is also known to cause thrombosis, especially in implants with small 
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cross-sectional (<5mm) flow paths.  Therefore, a significant amount of research is dedicated to 
improving the compatibility of this material.167–169  Nonetheless, they are inert, stable and 
chemical resistant, which makes fluorocarbons very attractive for implants.  Aside from PTFE, 
other fluorinated carbon coatings used for biological applications include, but are not limited to: 
vinylidene fluoride (VDF),170 chlorotrifluoroethylene (CTFE),170 perfluorohexane,171 
trifluoroehyl methacrylate (TFEMA).172  These fluorocarbon surface modifications have shown 
reduced platelet activation compared to untreated surface170,173,174 when applied to a variety of 
materials, such as polyester, polysulfone, polyethylene, polyurethanes via plasma deposition or 
graft polymerization.170,171,173,175 
There are several approaches taken to improve hemocompatibility of fluorinated carbon coatings.  
For example, TFEMA was copolymerized with vinylphosphonic acid (VPA), which resulted in a 
surface contact angle greater than 110° and has led to reduced platelet adhesion.172  In another 
approach, combining hydrophilic and hydrophobic elements in one coating to create amphiphilic 
surface has also improved its non-fouling properties.176  Co-polymerization of perfluorodecyl 
acrylate (PFDA) and diethylene glycol dimethyl ether (DEGDME) via plasma deposition has 
shown to further increase the hemocompatibility and protein fouling resistance compared to 
fluorinated surfaces.175   
Recently, slippery liquid-infused porous surface (SLIPS) has attracted a lot of attention.  A 
biomimetic coating inspired by Nepenthes pitcher plant, it consists of a nano/microstructured 
surface infused by a lubricating fluid.  This coating is truly unique because it can utilize any 
combination of solid nanostructured surface and liquid layer to resist target fouling.69,177,178  One 
classic example is a fluorinated porous substrate (e.g. Teflon nanofibers) with perfluorinated 
liquid layer (e.g. 3M Fluorinert FC-70).  This coating is omniphobic, and is able to resist fouling 
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from blood very effectively.179 In vivo work in a porcine model demonstrated efficacy of the 
coating for 8 hours in catheters.180  Over time, however, the lubricant layer slips away with the 
flowing fluid.  Therefore, long term application using SLIPS would require large reservoirs of 
the lubricant built into the system, as well as a method to get the lubricant to the surface. 
1.4.6 Hydrophilic Polymer Coatings 
Polyethylene glycol (PEG) is a hydrophilic surface coating considered to be the “state-of-the-
art.” Its brush structures are thought to resist protein fouling and platelet adhesion by 
coordinating water molecules around itself and producing steric hindrance.164,181–183  When PEG 
(length of 6-9 monomers) is applied on SNMs, the membranes remain patent and functional.184  
Additionally, PEG-coupled silicon implanted in a rat femoral artery for 28 days showed 
significant reduction in thrombus formation in comparison with uncoated silicon.31  However, 
PEG is susceptible to oxidative degradation under physiological conditions,185–187 and extending 
implant lifetime (>1 month) remains a challenge.  Nonetheless, PEG is often used in conjunction 
with other coatings as a spacer or as part of a co-polymer to lend its non-fouling 
properties.102,103,118 
Over the last several decades, many researchers have focused their attention on zwitterionic 
coatings.  Biomimetic zwitterions of phosphorylcholine, sulfobetaine and carboxybetaine have 
excellent non-fouling properties.  These coatings are highly hydrophilic and can resist protein 
adsorption and cell adhesion by strongly interacting and coordinating water molecules.   
2-methacryloy-loxyethylphosphorylcholine (MPC), originally designed by Nakabayashi, et al., 
mimics the polar heads of the phospholipid bilayer that make up the cell membrane.188–191  
Polymers and hydrogels of MPC (pMPC) have demonstrated reduction in protein adsorption, as 
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well as platelet and leukocyte adhesion and activation,192–196 while showing no cytotoxic 
effects.197  Therefore, thromboresistant pMPC coating was applied to various implants, such as 
glucose sensors,189 blood filtration,198 ePTFE grafts, and stents.199,200  Additionally, the non-
fouling functionality of pMPC coating has been verified over coating thickness ranging from 20 
to 110 nm.201  MPC was also shown to be highly durable, even under load bearing conditions.202  
However, one major drawback of pMPC is that the monomer is difficult to synthesize and results 
in low yield, making it expensive to produce. 
Over the last decade, Jiang et al. have developed polysulfobetaine methacrylate (pSBMA) and 
polycarboxybetaine methacrylate (pCBMA).203,204  Both polymers are non-cytotoxic,205 and have 
demonstrated ultra-low protein fouling (i.e. <0.3 ng/cm2 of fibrinogen) with a significant 
reduction in platelet adhesion and activation.53,203,206–213  Additionally, pSBMA and pCBMA are 
highly resistant to bacterial adhesion and biofilm formation.208,209,214–216  These properties make 
them well-suited for implant applications. 
pSBMA is biomimetic of taurine, a compound commonly found in animal tissue and bile.  
Surfaces have been successfully modified with pSBMA using various methods ranging from 
ATRP,53,212,214,217 reverse ATRP,218 plasma-induced polymerization,219 as well as simple 
grafting-to method via use of a catechol208 or click chemistry.220  Utilizing these methods, 
pSBMA has been used to modify gold,207,214 graphene,218 glass,212 silica nanoparticles,221 
silicon,58,213 as well as other polymers such as PDMS,163,165,222 cellulose,53,210 polyurethane,206 
poly(vinylidene fluoride) (PVDF),219 for use in a wide range of applications from blood 
purification,210 glucose sensors,223 and non-adherent wound dressing215 to waste water 
purification.218 
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For many of these applications, long term stability is required.  pSBMA was shown to be stable 
in vitro in various static aqueous solutions, such as phosphate buffered saline (PBS), human 
blood plasma, and distilled water over 28 days or less.205,206,213,223  In vitro experimentation with 
static fresh human blood over 2 hours also demonstrate that pSBMA-coupled silicon 
significantly reduces platelet adhesion compared to silicon.58  In vitro human blood flow 
experiments with sulfobetaine-modified vascular catheters showed a significant difference in 
blood activation after only 5 min of blood flow.224  In vivo work with pSBMA include hydrogels 
of pSBMA that have been implanted subcutaneously in mice over 4 weeks.  However this 
resulted in a capsule thickness and foreign body giant cell count that is comparable to control 
polyHEMA hydrogels.205  Smith et al. also conducted in vivo experiments using sulfobetaine 
modified catheters in a canine model that show significantly reduced thrombus formation.  
However, the experiments only spanned 4 hours.  Therefore, to our knowledge, there is very 
limited data of pSBMA performance in in vivo long-term blood flow conditions.  Another aspect 
that requires further study is the effect of polymerization conditions and coating thickness since 
there are mixed results reported in literature: While some studies have demonstrated that varying 
polymerization time for 5 min to 480 min (yielding varying coating thicknesses) does not result 
in a difference in protein adsorption and platelet adhesion,53 others have shown that for pSBMA 
a coating thickness of 62 nm results in optimal protein fouling resistance.217 
While pCBMA, a biomimetic of glycine betaine, has demonstrated similar fouling-resistive 
behavior compared to pSBMA, one advantage of pCBMA is that it offers ease of 
functionalization through its carboxylate groups.  Photopolymerized pCBMA hydrogels with 
high mechanical strength and stability have been shown to withstand degradation in oxidative, 
acidic and basic environments.225  Additionally, when pCBMA hydrogel (created using a CBMA 
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cross-linker) was implanted subcutaneously in mice for 3 months, it produced significantly 
reduced collagen density and foreign body reaction compared to control polyHEMA hydrogel.66  
However, in order to synthesize the monomer CBMA, the precursor β-propiolactone is required, 
which is a carcinogen, making CBMA difficult to produce in-house. 
There are many ways to graft zwitterionic coatings on to a surface.  Grafting on the surface as 
opposed to grafting to the surface makes a big difference in the properties of the surface coating.  
Zwitterionic polymers can be grafted onto the surface (grown on the surface) using atom transfer 
radical polymerization (ATRP).  Using a halogenated initiator covalently bonded to a surface, 
radical polymerization can propagate from the initiator using methacrylate backbone of the 
monomer.226  Graft-to methods, such as click chemistry220 or utilizing self-assembled 
monolayers typically leads to lower grafting density.  The methods and conditions of grafting 
make a difference in the packing density, polymer chain configuration/crosslinking as well as the 
polymer chain length.  These factors in turn play a crucial role in how the surface is hydrated and 
how water molecules are arranged, and therefore, the performance of the coating.227–229   
Table 1.1: Surface modification approaches, and their pros and cons for application on silicon nanopore 
membranes. 
Coating Type Coating Description Advantages Disadvantages 
Endothelialization 
-endothelial cells (which 
make up the outer walls 
of blood vessels) line in 
surface of implant 
-ideal biomimetic 
condition 
-no systemic effect 
-cell viability/cell 
adhesion to foreign 
material remain a 
challenge 
-months/years for 
harvesting and growing 
-difficult to attain full 
coverage for >2 cm2 
surface area 
-to achieve best results 
cells must be harvested 
from host system 
-break in coverage is 
highly thrombogenic 
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Coating Type Coating Description Advantages Disadvantages 
Albumin Passivation 
-albumin is the most 
abundant protein in 
blood 
-adsorption or covalent 
bonding of albumin to 
implant surface 
 
-works well for short 
term applications 
-adsorbs to all types of 
surface, especially 
hydrophobic surfaces 
-covalent bonded 
albumin does not work 
as well 
-susceptible to 
denaturation, 
degradation, and 
replacement (Vroman 
effect) 
Lysine 
-lysine binds 
plasminogen and tissue 
plasminogen activator, 
converting plasminogen 
to plasmin; plasmin 
dissolves fibrin 
-immobilize lysine to 
implant surface 
 
-does not bind other 
proteins 
-breaks down clots 
only at implant surface 
and has no systemic 
effect  
-% activity decreases 
rapidly in the first hours 
of exposure to blood 
flow 
-long-term application 
has yet to be proven 
Urokinase 
-urokinase converts 
plasminogen to plasmin; 
plasmin dissolves fibrin 
-immobilize urokinase 
to implant surface 
 
-no systemic effect 
-works well for short 
term implants 
-degrades in <1 month 
when implanted in 
muscle 
Thrombomodulin 
-binds thrombin and 
converts it to 
anticoagulant form; 
Activates protein C, 
which regulates proteins 
in coagulation cascade 
-immobilize 
thrombomodulin to 
implant surface 
 
-amplifies regulation of 
coagulation pathway 
via activation of 
protein C 
-long term in vivo data 
>1 hour yet to be 
collected 
Heparin/Heparin 
Derivatives 
-binds and increases the 
functionality of 
antithrombin, which 
inhibits thrombin and 
other factors in the 
coagulation cascade 
-immobilize heparin to 
the implant surface 
-shown to reduce clot 
formation in vitro and 
in vivo for stents and 
catheters 
-already in use in 
industry 
-may have unknown 
physiological effects 
-resistant to fibrin-
bound thrombin 
-relies on the presence 
of antithrombin 
-risk of heparin-induced 
thrombocytopenia 
Hirudin 
-derived from medicinal 
leeches, directly binds 
and inhibits thrombin 
-immobilize hirudin to 
the implant surface 
-directly blocks 
thrombin, including 
thrombin bound to 
fibrin 
-binds to active site of 
thrombin that interacts 
with platelets 
 
-thrombin-hirudin 
interaction has very low 
dissociation constant; 
therefore, irreversible 
interaction leads to one-
time interaction with 
thrombin for each 
hirudin molecule 
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Coating Type Coating Description Advantages Disadvantages 
Nitric Oxide (NO) 
-NO donors 
blended/covalently 
bonded to implant 
surface attempt to 
mimic natural release of 
NO by endothelial cells 
to prevent adhesion and 
activation of platelets 
and leukocytes 
-biomimetic  
-unlike other 
anticoagulants, NO 
released at 
physiological rate will 
not have additional side 
effects 
-shown to reduce 
adhesion and activation 
of platelets and 
leukocytes  
 
-short lifetime (based 
on size of NO reservoir) 
-possibility of toxicity 
from accumulation of 
byproducts 
Titanium 
Oxide/Nitrides 
coating 
-oxides and nitrides are 
deposited on surfaces 
via ion beam enhanced 
deposition, sputtering 
etc. 
-naturally inert 
-polarity, 
hydrophobicity, 
crystallinity, thickness 
etc. can be controlled 
via deposition method 
-utilized in industry on 
artificial heart valves 
 
-thick coating is 
required for 
hemocompatibility 
-natural oxide adheres 
platelets and adsorbs 
fibrinogen 
Diamond Like 
Carbon (DLC) 
coating 
 
-amorphous carbon of 
sp2 bonded matrix with 
sp3 nodules, sometimes 
hydrogenated 
-typically deposited on 
substrates using 
chemical or physical 
vapor deposition 
 
-low friction 
-high corrosion and 
wear resistance 
-low toxicity 
-utilized in industry on 
joints and load-bearing 
implants 
 
-adsorbs large amounts 
of plasma proteins 
-adheres platelets 
-has structurally high 
residual stress leading 
to delamination 
Pyrolytic Carbon -graphite-like carbon 
-utilized in industry for 
mechanical heart 
valves 
 
-without the use of 
anticoagulants adheres 
and activates platelets 
 
Silicone/ 
Polydimethylsiloxiane 
-polymers based 
alternating silicon and 
oxygen atoms 
-inert and nontoxic 
-durable 
-flexible 
 
-hydrophobic 
-high level of foreign 
body reaction 
 
Fluorinated/Teflon 
coatings 
-hydrophobic surface 
created by fluorinated 
carbon 
-resists thrombus 
formation 
-coatings currently 
utilized for large grafts 
and catheter 
 
-hydrophobic 
-adsorbs plasma 
proteins 
-high failure rate and 
thrombosis formation 
for grafts/channels less 
than 5 mm diameter 
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Coating Type Coating Description Advantages Disadvantages 
Slippery liquid-
infused porous 
surface (SLIPS) 
-biomimetic of 
Nepenthes pitcher plants 
-nano/microstructured 
substrates with infused 
lubricating fluid 
 
-surface repels proteins 
and cells very 
efficiently 
-liquid layer already 
FDA approved 
-very hydrophobic 
-reservoir of fluid layer 
required 
Oligo/Polyethylene 
glycol 
-applied as a brush-
structure to create steric 
hindrance/produce 
water coordination to 
resist fouling 
-regarded as “gold 
standard” 
 
-hydrophilic 
-uniform ultrathin 
coatings can be 
achieved 
-shown to work in vivo 
to resist fouling over 1 
month 
-susceptible to 
oxidation; known to 
degrade under 
biological conditions in 
applications >1 month 
Phosphorylcholine 
brush polymer 
-very hydrophilic 
zwitterion-based 
molecule mimicking the 
polar heads of 
phospholipids 
-coordinates water 
molecules—hydration 
layer resists fouling 
 
-biomimetic 
-hydrophilic 
-resists fouling and 
thrombus formation via 
hydration layer 
-utilized in industry 
(BTG) 
-monomer difficult to 
synthesize, expensive 
Sulfobetaine brush 
polymer 
-very hydrophilic 
zwitterion-based 
molecule mimicking 
taurine 
-coordinates water 
molecules—hydration 
layer resists fouling 
-biomimetic 
-hydrophilic 
-resists fouling and 
thrombus formation via 
hydration layer 
-low cost of monomer 
-easy to synthesize 
monomer 
 
-long term stability 
under blood flow 
conditions not yet 
demonstrated in 
previous literature 
-not optimized for ultra-
thin (sub-5 nm) 
thickness 
Carboxybetaine 
brush polymer 
-very hydrophilic 
zwitterion-based 
molecule mimicking 
glycine betaine 
-coordinates water 
molecules—hydration 
layer resists fouling 
-biomimetic 
-hydrophilic 
--resists fouling and 
thrombus formation via 
hydration layer 
-easily functionalizable 
through carboxylate 
groups 
 
-carcinogenic precursor 
for monomer synthesis 
reaction 
 
1.5 Research Objective 
While many approaches are attempted to achieve hemocompatibility, there is no one method that 
fits all applications.  For use on SNMs in bioartificial organs, a coating must meet several 
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criteria: the coating must not only be non-fouling and non-activating, but also needs to be 
ultrathin and uniform to maintain pore patency and tight pore size distribution of the membranes.  
Additionally, it must be hydrophilic in order to preserve the low resistance of SNMs.  Finally, it 
must remain stable over the implant lifetime.  Given these conditions, zwitterionic pSBMA and 
pMPC were investigated as possible surface modifications for SNMs.  Preliminary work with 
pSBMA on SNMs has demonstrated successful surface modification and SNM pore patency.213  
However, as the zwitterionic coatings are reduced in coating thickness to meet the “ultrathin” 
criteria, further exploration of zwitterionic coatings on SNM was needed prior to determining the 
suitability of these coatings for bioartificial organs.   
In this study, pSBMA and pMPC coating methods was optimized to be ultrathin and functional.  
They were then characterized via x-ray photoelectron spectroscopy, contact angle, atomic force 
microscopy and ellipsometry.  The coatings were tested under biological shear conditions, and 
against five standard sterilization methods.  Non-fouling and hemocompatible properties of the 
coatings were evaluated by measuring protein adsorption from single protein solutions and 
examining platelet activation after exposure to fresh human blood.  Control PEG-coupled silicon 
was used as a comparison.  In addition, pSBMA-silicon was implanted in a porcine model for up 
to 26 days and evaluated for hemocompatibility.  These experiments demonstrate the possibility 
of utilizing ultrathin zwitterionic pSBMA and pMPC coatings for implant applications. 
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CHAPTER II 
Development, Optimization and 
Characterization of Ultrathin Zwitterionic 
Surface Modifications 
 
 
2.1  Introduction 
With advancements in bio-microelectromechanical systems (bioMEMS), silicon has become a 
common substrate for novel implant devices, such as neuroelectrodes,1,2 drug delivery systems,3–
5 biosensors and diagnostic devices,6–8 and artificial organs.9–12  One such device is the silicon 
nanopore membrane (SNM):  these membranes are highly uniform in geometry and low in 
fluidic resistance, making them attractive for blood filtration and immunoisolation in renal 
replacement9,13,14 and islet therapy.11,15  These applications require SNMs to come in direct 
contact with blood flow.  While silicon has been shown to be non-cytotoxic, non-leaching and 
non-irritant,16–18 the surfaces must also be non-activating and non-fouling for use as membranes 
in biological applications.   
To attain desired interfacial properties, rather than using alternative materials, the surface of the 
substrate is often modified.19  For SNMs, there are specific surface traits that are desired: a) the 
surface must be non-fouling and non-activating; b) the surface must be hydrophilic to lower the 
resistance of the membranes; c) the applied surface coatings must be durable, ultrathin and 
uniform to maintain pore patency and tight pore size distribution; and d) the surface modification 
must be applicable to silicon.  Based on these requirements, two zwitterionic coatings were 
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chosen for investigation with SNMs: sulfobetaine methacrylate (SBMA) and 2-
methacryloyloxyethyl phosphorylcholine (MPC).  
Zwitterionic polymeric brush structures are extremely hydrophilic and have shown enhanced 
hemocompatibility.  Using a methacrylate backbone, polymer brushes and hydrogels can be 
controllably grown with atom-transfer radical polymerization (ATRP).20–22  The zwitterions 
branch off from the methacrylate backbone and electrostatically interact with each other.  More 
importantly, they create a hydration layer on the surface by coordinating water molecules 
through hydrogen bonding and electrostatic interactions.21,23  This hydration layer resists protein 
fouling24–28 and thrombus formation.20,23,29   
As a control, polyethylene glycol (PEG) surface modification was used, which has previously 
demonstrated excellent resistance to protein adsorption and platelet adhesion.30,31  Our previous 
research shows PEG-modified silicon significantly reduced thrombus formation and 
inflammation following 4-week implantation in rat veins.32  However, PEG is also known to 
autoxidize under biological conditions, making it impractical for long term implant 
applications.33 
We coated silicon substrates with PEG, polymerized SBMA (pSBMA), and polymerized MPC 
(pMPC).  Each of the coatings was applied at sub-5 nm thickness, and characterized using 
various surface characterization methods: elemental composition was determined using x-ray 
photoelectron spectroscopy (XPS), which captures ~10 nm of the surface; static water contact 
angle was measured using goniometry to evaluate the changes in wettability; ellipsometry was 
used to determine the change in coating thickness; and atomic force microscopy (AFM) was used 
to examine the surface roughness after coating.  Additionally, the coatings were applied to SNMs 
61 
 
and the hydraulic permeability was measured.  Based on hydraulic permeability, the effective 
pore size of the membranes was determined. 
To our knowledge, surface modification using pSBMA and pMPC at sub-5 nm scale has not 
previously been utilized or well characterized.  Therefore, for best results at this scale, protocol 
optimization was conducted.  During ATRP, there are many parameters that can change the 
polymer properties.  For example, altering the concentration of reagents, time and temperature of 
polymerization, and/or washing conditions post-polymerization can affect the length of polymers 
grown as well as the grafting density of the polymers.  To optimize the coating protocol, these 
variables were changed, and the coating performance was evaluated.  This chapter presents two 
such experiments where polymerization time and post-polymerization washing conditions were 
tested.  Based on experiments such as these, the optimal conditions were selected for future 
experiments presented in this thesis. 
The first of the two optimization experiments presented shows the effect of variation in reaction 
time.  Polymerization reaction time plays a critical role in the length of the polymer chain.  
While desired coating thickness must be sub-5 nm, polymer coating that is too thin can also be 
ineffective since it may expose the substrate surface underneath. 
The second optimization experiment presented shows variation in washing conditions.  After 
polymerization, it is important to remove excess reagents so they do not interfere with polymer 
performance.  One example is the ATRP catalyst, copper (I) bromide (CuBr), which is difficult 
to remove from silicon surfaces.  Therefore, a rigorous washing regimen was developed that 
includes organic as well as aqueous solvents.  For this optimization experiment, four organic 
solvents were tested: methanol, ethanol, toluene, and chloroform. 
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Each of the optimization experiments was followed by characterization by ellipsometry and 
goniometry.  Additionally, the performance of the coatings were evaluated using adsorption of 
proteins on the surface.  Specifically, human fibrinogen and bovine serum albumin (BSA) were 
used, as reported in previous literature.26,31,33–35  BSA was chosen as model protein for non-
specific surface binding, while fibrinogen was chosen for its role in thrombus formation.30,36,37 
2.2  Materials and Methods 
2.2.1 Silicon Surface Modification 
Unless otherwise stated, chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).   
2.2.1.1 Synthesis of ATRP Initiator, BrTMOS 
ATRP initiator, 2-bromo-2-methyl-N-3[(trimethoxysilyl)propyl]-propanamide (BrTMOS) was 
synthesized as previously reported.26,33  Briefly, under nitrogen (N2) protection, 11 mmol of σ-
bromoisobutyryl bromide (98%) was added dropwise to a mixture of 10 mmol (3-
aminopropyl)trimethoxysilane (97%) and 10 mmol trimethylamine in 50 mL of anhydrous 
tetrahydrofuran (THF) over 30 minutes.  The exothermic reaction was kept on ice to reduce 
heating, and allowed to continue overnight.  After removing the precipitate, THF was evaporated 
from the filtrate using a rotary evaporator (Buchi, Flawil, Switzerland) and the concentrated oil 
was dissolved in 20 mL of dichloromethane.  The solution was then washed with 10% potassium 
bisulfate (2 x 20 mL), cold deionized (DI) water (1 x 20 mL), and saturated sodium chloride 
solution (2 x 20 mL), respectively, using a separation funnel.  Finally, the organic phase was 
collected and dried using anhydrous magnesium sulfate (MgSO4).  After filtering out the MgSO4, 
dichloromethane was evaporated off, yielding the final product, BrTMOS.  1H NMR (400MHz, 
CHCl3) was conducted on the colorless oil to verify BrTMOS formation: δ 6.90 (s, 1H, NH), 
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3.49 (s, 9H, SiOCH3), 3.26 (t, 2H, CH2N), 1.95 (s, 6H, CH3), 1.66 (m, 2H, CH2), 0.66 (t, 2H, 
SiCH2).  NMR spectrum is included in Appendix A.  Chemical structure of BrTMOS is shown 
below: 
Si N
H
O
Br
O
O
O
 
2.2.1.2  Sample Preparation 
Sulfuric acid (H2SO4, 96%), hydrogen peroxide (H2O2, 30%), and hydrofluoric acid (HF, 49%) 
were purchased from Avantor Performance Materials, (Center Valley, PA, USA).  Double-side-
polished, 400 μm thick, p-type silicon wafers (Ultrasil Corporation, Hayward, CA, USA) were 
diced in 1 x 1 cm2 chips.  SNMs were fabricated following procedures previously described.9,38  
All samples were rinsed in acetone, methanol, isopropanol and water (1 x 5 min, each).  To 
remove residual organics, the substrates were cleaned using a freshly made solution of 
“piranha”—a 3:1 ratio of H2SO4 to H2O2 for 20 min.  After rinsing in DI water (2 x 10 min) all 
samples were placed in HF for 2 min to etch away silicon dioxide (SiO2, thermally grown to 
produce slit pores for SNMs).  The substrates were rinsed again with DI water (3 x 10 min) and 
placed back in a fresh “piranha” solution for 20 min to activate the surface.  Following a final 
rinse with DI water (3x 10 min), all substrates were dried on the hot plate at 60 °C for 1 hour. 
2.2.1.3  Surface Polymerization 
2.2.1.3.1  Zwitterionic Surface Modification 
The following zwitterionic surface modifications protocol presented are the ultimate conditions 
based on the optimization experiments.  The substrates were placed in a 1% (v/v) BrTMOS 
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solution in bicyclohexyl for 2 hours.  The surfaces were then rinsed with chloroform, ethanol, 
and water, respectively, to remove excess BrTMOS.   
The chemical structures of zwitterionic monomers, 2-(methacryloyloxy)ethyl]dimethyl-(3-
sulfopropyl)ammonium hydroxide (SBMA), and 2-methacryloyloxyethyl phosphorylcholine 
(MPC), are shown in Table 2.1.  A degassed solution of 468 mg (3 mmol) of 2,2’-bipyridyl 
(≥98%) and individual monomers—SBMA: 1.06g (3.8 mmol), and MPC: 506 mg (1.9 mmol)—
and 22.3 mg (0.1 mmol) of copper (II) bromide (99%) was prepared in 5:5 mL of 
methanol:water.  This mixture was added to a reaction chamber housing four substrates and 143 
mg (1 mmol) of copper (I) bromide (99.999%) under nitrogen protection, and polymerization ran 
for 15 min for pSBMA and 7 min for pMPC.  The substrates were then rinsed with chloroform, 
ethanol, Dulbecco’s phosphate buffered saline (D-PBS, UCSF Cell Culture Facility, San 
Francisco, CA, USA), and water, respectively, and dried using a stream of nitrogen gas.  
 
Table 2.1: Chemical structure of PEG-silane, SBMA and MPC monomer. 
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2.2.1.3.2  PEG Surface Modification 
Silicon surfaces were modified with PEG as previously described.10,11  Briefly, 2-
[methoxy(polyethyleneoxy)6-9propyl]trimethoxysilane (PEG-silane), as shown in Table 2.1, was 
purchased from Gelest (Morrisville, PA, USA) and covalently bonded to silicon by immersing 
the substrates in a solution of 285 µl PEG-silane in 25 mL of toluene for 2 hours at 70 °C.  The 
substrates were then rinsed three times at 10 min intervals with toluene, ethanol, and water, 
respectively, to remove excess PEG, and stored dry under ambient condition until use. 
2.2.2  Surface Coating Characterization 
2.2.2.1 X-ray Photoelectron Spectroscopy (XPS) 
XPS was conducted using a Surface Science Instruments S-probe spectrometer with a 
monochromatized Al Kα x-ray source (serviced by Service Physics, Bend, OR, USA).  Data was 
collected under a vacuum of pressure less than 5e10-9 torr, with an x-ray spot size of 800 μm.  To 
calculate the composition, survey spectra used a pass energy of 150 eV, while high resolution 
scans used a pass energy of 50 eV.  The take-off angle was 0°, yielding a sampling depth of ~10 
nm.  Data was analyzed using the Hawk Data Analysis Software (Service Physics).  The binding 
energy scales were calibrated by setting C1s peak to 285.0 eV.  Three measurements were taken 
per sample group for survey spectra, and one spot was analyzed for high resolution.   
2.2.2.2 Goniometry  
Static contact angle measurements were taken using Attension Theta Lite from Biolin Scientific 
(Stockholm, Sweden).  A droplet size of ~3.5 μl of water placed on the substrate and the angle 
between the droplet and substrate was measured in air over 10 s at 0.1 s interval.  A minimum of 
3 measurements were taken for each sample set. 
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2.2.2.3 Ellipsometry 
Ellipsometry was conducted using Gaertner Stokes Ellipsometer using a 6328 Å HeNe laser at 
70° incidence angle.  A refractive index of 1.403 was used for PEG and 1.45 was used for 
pSBMA and pMPC, respectively.  As was previously done for transparent films with known 
index of refraction,33 coating thickness was iteratively solved for by entering in measured 
reflection and transmission data into Fresnel equations.  A minimum of 3 locations on individual 
substrate was collected and averaged over each sample set. 
2.2.2.4 Atomic Force Microscopy (AFM) 
Atomic force microscopy (AFM) was conducted using NanoScope Scanning Probe Microscope 
(Bruker, Santa Barbara, CA, USA), running on tapping mode with the triangular ScanAsyst-
fluid+ tip (Bruker) with a spring constant of 0.7 N/m.  A scan rate of 0.977 Hz, with 512 
samples/line sampling rate was used to generate AFM images.  At least three different locations 
on each type of surface were scanned and the root mean square roughness (Rq) values were 
averaged over three 1 µm2 areas.  NanoScope Analysis Software (Bruker) was used to process 
images and determine roughness values. 
2.2.2.5  Hydraulic Permeability Measurement 
Surface modifications on SNMs with porous area of 36 mm2 were conducted, and change in pore 
size was calculated based on membrane permeability.  Hydraulic permeability of the membrane 
was measured before and after surface modification using the setup shown in Figure 2.1.  An 
SNM sits on the chip seat in the two-chamber filtration manifold, and a gasket creates a seal 
between the feed and the filtrate side.  A peristaltic pump draws water from the reservoir to 
maintain a constant cross flow rate.  A pressure gauge measures the pressure right before the 
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flow reaches the manifold.  Finally, a resistor is placed in series following the manifold to 
control the transmembrane pressure before the feed is returned to the reservoir.  The filtrate is 
collected into a syringe open to ambient air and the volume is measured.  
Given the rectangular geometry of the pores, where the width (w) of the pore is much smaller 
than its length (L) and height (h), resistance (R) through the membrane can be characterized by 
the following equation: 
𝑅𝑅 =  ∆𝑃𝑃
𝑄𝑄
=  12𝜇𝜇ℎ
𝑤𝑤3𝐿𝐿𝐿𝐿
  Eqn. 2.1 
where ΔP is the transmembrane pressure, Q is the volumetric flow rate, μ is the viscosity of 
water, and n is the number of pores.  Using the hydraulic permeability setup to set the resistance, 
the transmembrane pressure was controlled and the filtration rate was measured.  With these two 
values, and knowing the viscosity of water, number of pores (1.56e7 pores), length (2.325 µm) 
and height (400 nm) of the pores, the width of the pores (the nominal feature) was calculated. 
 
Figure 2.1: Hydraulic permeability setup.  A peristaltic pump draws water from the reservoir and maintains a 
constant flow rate.  A pressure gauge measures the pressure immediately before flow reaches filtration manifold, 
where SNM is positioned for filtration.  The feed crossflow is returned to the water reservoir, while the filtrate 
volume is measured using a syringe over time. 
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2.2.3  In Vitro Protein Adsorption  
2.2.3.1  Human Fibrinogen Enzyme-Linked Immunosorbent Assay (ELISA) 
Human fibrinogen adsorption on the surfaces of the substrates was determined by conducting 
enzyme-linked immunosorbent assay (ELISA) following protocol published previously.33  
Substrates were placed in 24-well tissue-culture polystyrene (TCPS) plates and incubated with 
D-PBS for 1.5 hours.  D-PBS was replaced with 0.5 mL of single protein solution: 1 mg/mL 
concentration of human fibrinogen was added and allowed to incubate at 37 °C for 1.5 hours.  
All substrates were rinsed five times with D-PBS.  Surfaces were then blocked with bovine 
serum albumin (BSA, ≥98%) using 1 mg/mL BSA solution for 1.5 hours.  The substrates were 
rinsed five times with D-PBS, and transferred to new 24-well TCPS wells.  Next, the samples 
were incubated with 10 μg/mL anti-human fibrinogen conjugated with horseradish peroxidase 
(HRP) (coagulation factor I) (HRP) (USBiological, Salem, MA, USA) for 1.5 hours.  The 
substrates were washed with D-PBS five times and transferred to a new well.  A reaction mixture 
was made in 0.05 M citrate phosphate buffer (pH 5.0, Sigma-Aldrich) with 0.5 mg/mL of o-
phenylenediamine (OPD, VWR Inc. Visalia, CA, USA) and 0.03% hydrogen peroxide.  Reaction 
mixture (0.5 mL) was added to each well, and the reaction was allowed to run at 37 °C for 20 
minutes.  The reaction was stopped by adding 0.5 mL sulfuric acid (1 M).  The solution was 
transferred to 96 well plates, and light absorbance at 490 nm was determined using a microplate 
reader.  A minimum of 3 substrates were analyzed for each sample set, and light absorbance 
reading was normalized to tissue culture polystyrene (TCPS) control.  
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2.2.3.2 Bovine Serum Albumin (BSA) Adsorption 
BSA adsorption was evaluated following protocol previously published.39  A 0.5 mg/mL of 
fluorescein isothiocyanate conjugated bovine serum albumin (FITC-BSA) was well mixed in D-
PBS, and protected from light using aluminum foil.  Samples were placed into a 24-well plate, 
and 1 mL of FITC-BSA solution was added to each sample.  The samples were protected from 
light and incubated at 37 °C for 1 hour.  Each chip was rinsed three times using D-PBS to 
remove unadsorbed proteins, and placed in a new well with 1 mL of D-PBS.  Imaging was done 
using a Nikon TI-E Microscope (Nikon Instruments, Melville, NY, USA) at 100x magnification.  
Five representative locations (top left, top right, center, bottom left and bottom right) were 
imaged per chip and three chips were imaged per sample group.  One representative image is 
presented in this chapter.  The images were then quantified for fluorescence from FITC-BSA 
using ImageJ software (National Institutes of Health), and the average and standard deviation 
values are reported.  
2.3  Results 
2.3.1  Optimization of Polymerization Time 
The effect of reaction time on pSBMA polymerization on silicon is presented in Figures 2.2-2.5.  
In this experiment, two time-points were evaluated: 10 min and 20 min.  Figure 2.2 represents 
the effect of polymerization time on the coating thickness and the contact angle.  Results show 
that a 10 min reaction time yields an average thickness of 4.4 nm and a contact angle of 18.5°.  
With 20 polymerization time, pSBMA coating thickness increases to an average of 5.7 nm and 
contact angle decreases to 5.5°.  
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Figure 2.2: Effect of polymerization time variation (10 and 20 min) on pSBMA coating thickness and surface 
contact angle. 
 
Following characterization, coating performance was evaluated using adsorption from single 
protein solutions as a metric.  Adsorption of human fibrinogen is quantified using ELISA in 
Figure 2.3 and adsorption of BSA is depicted and quantified based on imaging in Figures 2.4 and 
2.5, respectively.  Results show pSBMA with 20 min polymerization had the least fibrinogen 
adsorption, reducing fibrinogen adsorption by ~71% compared to uncoated silicon.  PEG and 
pSBMA with 10 min polymerization reduced fibrinogen adsorption by ~17% and ~23%, 
respectively, compared to uncoated silicon. 
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Figure 2.3: Relative human fibrinogen adsorption before and after surface modification.  Lowest adsorption was 
observed with 20 min polymerization of pSBMA.  Data is normalized to tissue culture polystyrene (TCPS). 
 
Figure 2.4, depicting FITC-BSA adsorption on silicon surface before and after surface 
modification, demonstrates that surfaces are visually similar with and without coatings.  When 
quantified, and normalized to uncoated silicon, it is evident that PEG-silicon demonstrates a 
significant reduction in BSA adsorption compared to silicon, reducing it by ~79%.  pSBMA, 
regardless of polymerization time, has no significant difference in performance when compared 
to silicon. 
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Figure 2.4: FITC-BSA adsorption on silicon (a) before and (b-d) after surface modification with PEG and pSBMA 
(10 min and 20 min polymerization). 
 
 
Figure 2.5: FITC-BSA adsorption on silicon before and after surface modification with PEG and pSBMA (10 min 
and 20 min polymerization).  Fluorescence has been quantified using 5 representative images per sample following 
substrate incubation with FITC-BSA. 
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2.3.2  Optimization of Wash Conditions Following Polymerization 
The effect of various wash conditions following pSBMA polymerization is presented in Figures 
2.6-2.9.  Post-polymerization washing entails wash steps using aqueous and organic solvents.  In 
this optimization experiment, various organic solvents were tested to see which solvent best 
removed residues without harming the surface coating.  Four organic solvents were tested for 
washing: ethanol, methanol, toluene, and chloroform.  Figure 2.6 represents effect of the various 
washes on the coating thickness and the contact angle.  Results show that with pSBMA coating, 
contact angle remained <11° for all washes, the lowest reaching 6.75° with chloroform washing.  
Coating thickness ranged from 3.7 to 4.8 nm, with the maximum thickness measured for 
methanol washing. 
 
 
Figure 2.6: Effect of post-polymerization wash conditions on polymer thickness and water contact angle.  Four 
organic solvents were tested: ethanol (EtOH), methanol (MeOH), toluene and chloroform. 
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Figure 2.7: Human fibrinogen adsorption quantified using ELISA before and after surface modification for varying 
organic solvent wash conditions.  Data has been normalized to tissue culture polystyrene (TCPS). 
 
Human fibrinogen adsorption was measured using ELISA over the various wash conditions and 
presented in Figure 2.7.  Results show that all pSBMA coating, regardless of wash conditions, 
reduce fibrinogen adsorption by at least 56% compared to uncoated silicon.  Control PEG-
coating, however, did not significantly reduce fibrinogen adsorption compared to uncoated 
silicon. 
FITC-BSA adsorption was also evaluated and presented in Figure 2.8 and 2.9.  Figure 2.8 shows 
that washing with methanol led to a considerably higher BSA adhesion compared to the rest of 
the substrates.  Images were quantified based on fluorescence and normalized to uncoated 
silicon.  Results show control PEG reduces protein adsorption by ~59%.  Aside from pSBMA-
silicon washed with methanol, all other groups lowered BSA adsorption.  The lowest protein 
adsorption was observed with chloroform washes, reducing BSA adsorption by ~89% compared 
to uncoated silicon. 
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*figure continued on next page 
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Figure 2.8: Representative images of FITC-BSA adsorption on silicon surfaces before and after surface 
modification with varying wash conditions.  Controls, (a) uncoated silicon, (b) PEG-silicon, and (c) BrTMOS-
silicon and varying wash conditions after pSBMA polymerization of (d) ethanol (EtOH), (e) methanol (MeOH), (f) 
toluene, and (g) chloroform are presented. 
 
Figure 2.9: Average FITC-BSA adsorption on surface quantified from representative images.  Data is normalized to 
uncoated silicon. 
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2.3.3  Final Surface Coating Characterization Following Optimization Experiments 
 
Figure 2.10: XPS survey spectra of uncoated silicon, PEG-silicon, BrTMOS-silicon, pSBMA-silicon and pMPC-silicon. 
Table 2.2: Change in contact angle, coating thickness and surface elemental composition between unmodified 
silicon, PEG-silicon, BrTMOS-silicon, pSBMA-silicon, pMPC-silicon.  *Uncoated silicon contact angle increases 
based on increasing time interval between “piranha” treatment and when contact angle measurement is taken.   
 
No Coating PEG-Silicon BrTMOS-Si pSBMA-Si pMPC-Si 
Contact Angle (H
2
O)  52.8 ± 2.6°* 43.8 ± 1.0° 61.1 ± 7.3° 8.5 ± 2.4° 11.5 ± 0.9° 
Thickness (nm) -- 0.8 ± 0.2 0.41 ± 0.18 3.46 ± 0.64 4.4 ± 0.59 
      
Elemental 
Composition 
(%) 
Si, 2p 56.8 ± 0.8 52.1 ± 3.1 53.3 ± 0.5 20.6 ± .4 24.8 ± 0.8 
O, 1s 28.5 ± 1.8 32.2 ± 0.4 27.4 ± 1.5 27.6 ± 0.5 30.3 ± 0.6 
C, 1s 14.0 ± 2.2 15.6 ± 2.8 17.1 ± 1.1 44.9 ± 0.6 38.3 ± 0.4 
N, 1s 0.4 ± 0.1 0.2 ± 0.1 1.5 ± .1 3.9 ± 0.1 3.0 ± 0.2 
Br, 3d 
  
0.6 ± 0.4 0.2 ± 0.1 0.3 ± 0.0 
S, 2p 
   
2.8 ± 0.1  
P, 2p     3.4 ± 0.4 
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Figure 2.10 presents the XPS survey spectra of unmodified and modified silicon, and the contact 
angle, coating thickness and surface elemental composition is summarized in Table 2.2.  All 
coatings are below 5 nm and hydrophilic as desired.  For elemental composition, uncoated 
silicon samples mainly consist of silicon (Si 2p, 100 eV) and oxygen (O 1s, 532 eV), as 
expected.  There is also a presence of adventitious carbon of ~14%.  With PEG modification, 
there is a slight increase in carbon (C 1s, 285 eV), as well as O 1s, and decrease in Si 2p.  
BrTMOS-coupled silicon shows a 3.1% increase in C 1s and 3.5% decrease in Si 2p.  There is 
also 1.1% and 0.6% increase in N 1s (~400 eV) and Br 3d (~69 eV), which are signature 
elements of BrTMOS. Based on the stoichiometric ratio, 1:1 ratio of bromine to nitrogen is 
expected.  However, data shows a ratio of 1.8:1.  This trend has been seen previously, and may 
be explained by the instability of C-Br bond under XPS.26   
Following BrTMOS modification, pSBMA and pMPC are polymerized.  With pSBMA 
polymerization, there is a 27.8% increase in C 1s and 32.7% decrease in Si 2p, as well as 
presence of signature elements, N 1s (2.4% increase) and sulfur, S 2p (2.8% increase).  pMPC 
polymerization also shows increased presence of C 1s (24.3% increase) and a decrease in Si 2p 
(32.0% decrease).  As expected, there is an increase in signature elements—2.6% increase in N 
1s and 3.4% increase in phosphorus (P 2p, 133 eV). 
Following successful modification on silicon, SNM surfaces were modified and hydraulic 
permeability was measured.  Based on the permeability, the effective pore size was calculated to 
be 10.4, 9.5, 2.3 and 2.4 nm for uncoated SNM, PEG-SNM, pSBMA-SNM and pMPC-SNM. 
Surface topography (2-D and 3-D) is illustrated in Figure 2.11.  Average root mean square 
surface roughness (Rq) of uncoated silicon was measured to be 0.54 nm.  Because higher surface 
roughness has been linked to increased protein adsorption in previous studies,40  lower surface 
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roughness is preferred.  All surfaces visually look different:  Unmodified silicon is fairly smooth, 
with uniformly distributed nanocavities, and its roughness is on the same scale as noted previous 
literature.41  Keeping unmodified silicon as baseline, PEG-silicon has more peaks, increasing 
surface roughness by 0.2 nm, while BrTMOS-silicon has slightly smaller features, with reduction 
in nanocavities that were present on bare silicon.  Additionally, there is also an uneven 
distribution of tight peaks in BrTMOS-silicon sample, typically on the scale of sub-10 nm.   
With pSBMA modification, the peaks that were present on BrTMOS-silicon surface is no longer 
visible.  Rather, they are replaced by nanoscale broad peaks on the scale of 25 nm.  Since AFM 
was conducted in dry, ambient conditions, these mushroom-like features could be formed by the 
interaction between adjacent polymer chains, or polymer chains curling in on itself.  pMPC 
modification resulted in very uniform surface, lowering surface roughness by 0.1 nm compared 
to BrTMOS-silicon.  With zwitterionic surface modifications, there were no significant increase 
in surface roughness. 
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Figure 2.11: (Left) 2-D and (right) 3-D surface topography of (a) uncoated silicon (Rq = 0.54±0.03 nm), (b) PEG-
silicon (Rq = 0.70±0.04), (c) BrTMOS-silicon (Rq = 0.52±0.02), (d) pSBMA-silicon (Rq = 0.54±0.10) and (e) pMPC-
silicon (Rq = 0.40±0.02). 
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Figure 2.12: Effective pore size of silicon nanopore membrane (SNM) before and after surface modification. 
 
2.4  Discussion 
Ultrathin film pSBMA and pMPC zwitterionic polymers were evaluated for application on 
silicon membranes.  Surface grafting protocols were optimized to meet the desired thickness of 
sub-5 nm while still retaining non-fouling properties.  This chapter presents two such 
optimization experiments and the final characterization of the coatings after optimal conditions 
were reached. 
Polymerization time, as well as concentration of reagents and catalysts in ATRP reaction can 
affect grafting density and length of polymer.42  The first optimization experiment presented 
evaluated 10 min and 20 min polymerization time for pSBMA.  In both cases, the contact angle 
decreased to below 20° and coating thickness was at least 4.4 nm, indicating successful 
polymerization.  With increased polymerization time from 10 min to 20 min, contact angle 
decreased and average thickness increased, suggesting higher degree of polymerization with 20 
min reaction time.  However, 20 min polymerization led to >5 nm coating thickness, which is 
beyond the acceptable range for application on ~10 nm-pore SNMs.   
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The effect of coating thickness on performance was assessed by conducting protein adsorption.  
Results show human fibrinogen resistance is 1.7 times lower with 20 min polymerization 
compared to 10 min polymerization.  Average BSA adsorption with 20 min polymerization time 
was ~14% lower than 10 min polymerization.  However, the change in BSA adsorption was not 
statistically significant.  The results indicate that 20 min polymerization leads to better 
performance than 10 min polymerization.  Further experiments with variation in time 
demonstrated that a polymerization time of 15 min yields a coating thickness below 5 nm and is 
able to reduce protein adsorption significantly compared to uncoated silicon (data presented in 
Chapter 5).  
The second optimization experiment presented tested varying organic solvents for washes 
following polymerization.  Once polymerization is complete, it is critical to wash away excess 
reagents without harming the polymers.  Since zwitterions are highly soluble in water, excess 
zwitterionic monomers can be easily washed away by rinsing with aqueous solution.  However, 
CuBr is insoluble in water.  Previous literature has utilized methanol or ethanol rinses to wash 
ATRP-polymerized surfaces.33,43,44  In this optimization experiment, four organic solvents were 
tested: methanol, ethanol, toluene and chloroform.  However, in contrary to previous literature, 
results imply that rinses with methanol and ethanol are not enough to remove CuBr adhered to 
the silicon surface.  Methanol wash led to the maximum coating thickness and the highest BSA 
adsorption, indicating that the elevated coating thickness could be from residues from the 
reaction.  Ethanol showed improved performance of surface coating compared to methanol.  
Nonetheless, it also resulted in significantly higher BSA adsorption compared to toluene and 
chloroform.  
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While there was no significant difference between the wash groups for fibrinogen adsorption, 
based on BSA adsorption on the surfaces, substrates washed with chloroform outperformed 
substrates washed with the other tested solvents.  This may be explained by the halogen-halogen 
interaction between the choline atom in chloroform and the bromine atom in copper (I) 
bromide.45  This interaction may assist in dissolving CuBr and loosen attached molecules from 
the silicon substrates. 
Results from the optimized coating protocol demonstrate successful polymerization of pSBMA 
and pMPC that meet the thickness, surface energy and performance requirements.  While 
ellipsometry and goniometry data imply that the surface has been modified, XPS data, which 
provide the elements and their bonding, confirms the changes in surface chemistry.  Further 
proof of surface modification can be seen in the physical changes at the surface represented in 
the AFM data.  Surface roughness data collected from AFM show that pSBMA and pMPC 
coatings do not increase surface roughness compared to unmodified silicon.  Moreover, the 
standard deviation in Rq is low.  These properties allow us to maintain our uniformity of SNMs 
after their surface is modified. 
The change in effective pore size (pore width) for SNMs due to surface modification was 
calculated based on the hydraulic permeability, as has been done previously.46  Initially, the pore 
size is ~10.5 nm.  Following pSBMA and pMPC coupling, the pore size of membranes decreased 
by 8.2 nm and 8.1 nm, respectively.  Under these experimental conditions, pSBMA thickness on 
solid silicon chips was ~4.4 nm.  Therefore, if the walls of the pores are conformally coated, we 
expect to see a change of ~8.8 nm in pore size.  The discrepancy of ~0.4 nm indicates a slower 
rate of reaction inside the pores compared to the membrane surface.  Because polymer grafting 
84 
 
on to silicon is diffusion-dependent and the space within a nanopore is narrow compared to the 
open surface, the diffusion rate is slower.  
Although there is a difference in the coating thickness between the surface and the pore walls, 
data suggests that the coating within the pores is conformal.  Using Equation 1, and assuming all 
else is constant, pore width is proportional to the cube root of the flow rate through the 
membrane: 𝑤𝑤 ∝  𝑄𝑄13.  Permeability measurements are based on at least three different pressure 
points.  A nonconformal coating would render this equation inapplicable, and the calculated pore 
size would vary under different pressures.  However, at each pressure point, ranging from 1 to 9 
psi, the pore size remains approximately constant, implying conformal coating within the pores. 
2.5  Conclusions 
A growing number of silicon-based biomedical implants are being designed due to silicon’s-
precision and versatility in micro- and nanoscale features.  For blood-contacting implants, the 
activation of blood needs to be limited to avert thrombus formation and retain device 
functionality.  For devices with critical nanoscale features exposed to blood, ultrathin, 
zwitterionic pSBMA and pMPC coatings under 5 nm thickness are promising options.  This 
chapter demonstrates that ultrathin zwitterionic coatings can be successfully applied onto silicon 
and SNMs.  Further work testing robustness of the coatings, as well as their performance in 
biological conditions is presented in subsequent chapters. 
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CHAPTER III 
Stability of Ultrathin Film Polymer Coatings 
Under Shear Conditions 
 
 
3.1 Introduction 
Silicon-based bio-microelectromechanical systems (bioMEMS) are commonly utilized in a 
diverse set of implantable medical devices, such as neuroelectrodes,1,2 drug delivery systems,3–5 
biosensors and diagnostic devices.6–8  Our lab has developed a unique bioMEMS-based 
membrane, the silicon nanopore membrane (SNM), which offers highly uniform and controllable 
pores with variation <1% across the wafer.9  As shown in Figure 3.1, low fluidic resistance 
SNMs with ~10 nm pore size have been developed for blood filtration and immunoisolation 
applications in renal replacement9–11 and islet therapies.12,13  These applications bring silicon in 
direct contact with blood flow, and therefore, biocompatibility and resistance to fouling is 
critical.  Previous research has shown silicon to be non-cytotoxic.14,15  Additionally, various 
materials pertinent to implantable bioMEMS including silicon, polysilicon and silicon dioxide 
have been tested against a battery of tests laid out in ISO 10993, and were found to be non-
leaching and non-irritant.16  However, the blood-contacting surfaces must also be non-activating 
and non-fouling over the lifetime of the implant. 
To enhance the hemocompatibility, the substrate surface is often modified.17  Polyethylene 
glycol and oligoethylene glycol (PEG and OEG, respectively) are hydrophilic surface 
modifications that have demonstrated excellent non-fouling properties, shown to lower protein 
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adsorption and platelet adhesion.18,19  In our previous research, PEG-modified SNM has shown 
functionality retention after 90 hours of an anticoagulated whole blood hemofiltration 
experiment.9  Additionally, PEG-silicon showed significantly reduced thrombus formation and 
inflammation after 4 weeks of implantation in rat veins.20  However, PEG is susceptible to 
 oxidative degradation, making it impractical for long term implants.21–23  Recently, hydrophilic 
zwitterionic polymer surface modifications have demonstrated significantly reduced protein 
fouling24–28 and thrombosis formation.29–31  Several biomimetic zwitterions, such as sulfobetaine, 
carboxybetaine and phosphorylcholine, have been used with a methacrylate backbone to build 
polymer brushes and hydrogels.31–33  It is hypothesized that the zwitterions are able to coordinate 
Figure 3.1: a) top view and b) side view of silicon nanopore membrane (SNM) with pore length of 2μm, width of 
7 nm and height of 360 nm, developed for applications in (c) filtration during renal replacement therapy for 
artificial kidney and (d) immunoisolation chamber for islet therapy in bioartificial pancreas.  Image (b) was 
reprinted from S. Song et al./ Scientific Reports, ©2016, with permission from Nature Publishing Groups. 
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water molecules and produce a stable hydration layer due to their hydrogen bonding and 
electrostatic interactions.30,32  This hydration layer allows the surface to be in stealth mode and 
resist protein adsorption and cell adhesion.  Additionally, due to the methacrylate backbone, 
these polymer brushes can be controllably grown on the surface to a desired thickness using 
atom-transfer radical polymerization (ATRP).34 
Table 3.1: Chemical structure of PEG-silane, SBMA and MPC monomer. 
 
 
For surface-modified implants, it is critical that the polymer coatings are stable in physiological 
conditions.  Previous work demonstrated that sulfobetaine coating is stable under static 
physiologic conditions mimicked by submersion in D-PBS at 37 °C for 30 days.35  Smith, et al. 
showed that following exposure to serum for 60 days, sulfobetaine can still retain functionality.36  
Although coating thickness is affected, PEG was also shown to perform well after four weeks of 
incubation in PBS.22  For implants that require contact with blood flow, coatings are subjected to 
shear, and the effect of physiological shear on ultrathin film polymer coatings has not been well-
characterized.  Therefore, in this chapter we investigate the effect of shear on three different 
ultrathin film surface modifications shown in Table 3.1: PEG, polysulfobetaine methacrylate 
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(pSBMA) and poly(2-methacryloyloxyethyl phosphorylcholine) (pMPC).  In order to be 
applicable to SNMs, these coatings have been applied at ~5 nm or less in thickness.  
Fundamental changes in the coatings, such as surface chemistry, wettability and thickness were 
analyzed after they were subjected to physiological shear for 24 hours.  Additionally, protein 
resistance of the surface modifications was also evaluated against human serum albumin.     
3.2  Materials and Methods 
3.2.1  Sample Preparation 
Double side polished, 400 µm thick, p-type silicon wafers were obtained from Ultrasil 
Corporation (Hayward, CA, USA) and diced into 1 cm2 chips.  The chips were cleaned by 
“piranha,” a solution of 3:1 ratio of sulfuric acid (96%) to hydrogen peroxide (30%) for 20 min.  
The chips were then rinsed with reverse osmosis purified water (RO water) at 5-minute intervals 
(3X).  Afterwards, they were exposed to hydrofluoric acid for 5 min to remove the native silicon 
dioxide that spontaneously forms on silicon surfaces exposed to atmospheric oxygen.   The chips 
were again rinsed with RO water at 5-min intervals (3X), followed by activation of the surface 
via a final piranha clean and RO water rinse as described above.  The silicon chips were then 
dried under a stream of nitrogen gas and kept on a hotplate at 110 °C for 1 hour. 
3.2.2  Surface Modification 
3.2.2.1  PEG Surface Modification 
Silicon surfaces were modified with PEG as described in previous literature.13,37  Briefly, 2-
[methoxy(polyethyleneoxy)propyl]trimethoxysilane (PEG-silane) was purchased from Gelest, 
Inc. (Morrisville, PA, USA) and covalently bonded to silicon by immersing the substrates in a 
solution of 285 µl PEG-silane in 25 mL of toluene for 2 hours at 70 °C.  The substrates were then 
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rinsed three times at 10 min intervals with toluene, ethanol, and water, respectively, to remove 
excess PEG, and stored dry under ambient conditions until use. 
3.2.2.2  Zwitterionic Surface Modification 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless stated 
otherwise.  Zwitterionic surface modifications were conducted as described in previous 
publication.35  Briefly, a surface initiator, 2-bromo-2-methyl-N-3[(trimethoxysilyl)propyl]-
propanamide (BrTMOS), was synthesized.35  The substrates were placed in a 1% (v/v) BrTMOS 
solution in bicyclohexyl for 2 hours.  The surfaces were then rinsed with chloroform, ethanol, 
and water, respectively, to remove excess BrTMOS.   
Zwitterionic monomers, 2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium 
hydroxide (SBMA) and 2-methacryloyloxyethyl phosphorylcholine (MPC), are shown in Table 
3.1 respectively.  A degassed solution of 468 mg (3 mmol) of 2,2’-bipyridyl (≥98%) and 
individual monomers—SBMA: 1.06g (3.8 mmol), and MPC: 506 mg (1.9 mmol)—and 22.3 mg 
(0.1 mmol) of copper (II) bromide (99%) was prepared in 5:5 mL of methanol:water.  This 
mixture was added to a reaction chamber housing four substrates and 143 mg (1 mmol) of copper 
(I) bromide (99.999%) under nitrogen protection and polymerization ran for 15 min for pSBMA 
and 7 min for pMPC.  The substrates were then rinsed with chloroform, ethanol, Dulbecco’s 
phosphate buffered saline (D-PBS, UCSF Cell Culture Facility, San Francisco, CA, USA), and 
water respectively, and dried using a stream of nitrogen gas.    
3.2.3  Flow Chamber Design and Fabrication 
Shear flow cells were fabricated out of cast acrylic sheets and silicone. The top and bottom piece 
was laser cut from a 12x12 in2, 5/16 in thick optically clear cast acrylic sheet (McMaster-Carr, 
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Santa Fe Springs, CA, USA).  The channel was created from 0.01 in thick silicone rubber (high-
purity silicone rubber sheet, 55A Durometer, McMaster-Carr).   
  
 
The device shown in Figure 3.2 (a) and (b) was designed to hold seven chips on the bottom piece 
with the inlet and outlet through-holes on the top piece.  A gasket was used to create the flow 
path and set the channel height.  The shear rates in human arterioles does not exceed 1650/s.38  
Therefore, for our experiments, we explored shear rates of 500/s, 1000/s, 1500/s and 2000/s to 
cover the range of shear rates experienced in the human body.  As shown in Figure 3.2(c), the 
substrates were exposed to D-PBS flow at 37 °C for 24 hours at varying flow rates.  A constant 
channel height of 220 μm was used and flow rate was varied to adjust the shear rate.  Since the 
flow chamber creates a flat rectangular channel, the shear rate at the surface, ?̇?𝛾𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤 is given by: 
?̇?𝛾𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤 =  𝜏𝜏𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝜇𝜇 = ∆𝑃𝑃𝜇𝜇𝜇𝜇 �ℎ2�  Eqn. 1 
Figure 3.2: a) device design for shear variation study, b) device 
made from cast acrylic, with silicone gasket setting channel height. 
c) setup for 24-hour shear rate variation study set in a 37°C 
incubator. Shear was varied by controlling the flow rate set by a 
peristaltic pump. Flow is driven from the reservoir by the 
peristaltic pump through the flow cells and back to the reservoir. 
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where L, h, 𝜏𝜏𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤, µ and ΔP are the length and height of the flow path, shear stress at the wall, 
dynamic viscosity of the fluid, and pressure difference across the flow path, respectively.  Wall 
shear rate based on the volumetric flow rate (Q) and dimensions of the flow path is given by: 
?̇?𝛾𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤 = 6ℎ2𝑤𝑤 𝑄𝑄  Eqn. 2 
where w and h are the width and height of the flow path.  These equations were applied with the 
following assumptions: (a) the fluid is Newtonian and incompressible, (b) steady state is reached 
and the flow is fully developed, and (c) edge effects are negligible and the flow is laminar.  
Therefore, the flow rate was set to 1.6, 3.2, 4.8, and 6.4 ml/min to achieve a shear rate of 500, 
1000, 1500, and 2000/s, respectively.  Computational fluid dynamics (CFD) analysis using 
ANSYS Fluent v18.2 (Ozen Engineering, Inc, Sunnyvale, CA, USA) (Figure 3.3) demonstrates 
the flow is fully developed and velocity is constant throughout the channel.   
Samples not exposed to D-PBS was used as controls for comparison.  Following flow exposure, 
the samples were removed from the flow cells, and surface chemistry, contact angle, and coating 
thickness was analyzed.  Finally, protein resistance of the substrates was evaluated via human 
serum albumin adsorption.  
 
 
Figure 3.3: ANSYS simulation showing fully developed flow before substrates are reached, and uniform velocity 
across the length and width of the channel. 
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3.2.4  Surface Characterization 
3.2.4.1 X-Ray Photoelectron Spectroscopy (XPS) 
X-ray photoelectron spectroscopy (XPS) was conducted using a Surface Science Instruments S-
Probe photoelectron spectrometer with a monochromatized Al Kα X-ray beam and a low energy 
electron flood gun for charge neutralization of non-conducting samples.  A pass energy of 150 
eV and 50 eV was used to generate the survey spectra and high resolution spectra, respectively.  
Samples were pressurized to <5e-9 torr and a 0° take-off angle was used, corresponding to 
sampling depth of ~10 nm. For each sample, XPS was measured at four locations with a spot 
size of ~800 µm.   Elemental composition calculations were performed using Service Physics 
Hawk version 7 software (Bend, OR, USA).  
3.2.4.2  Contact Angle 
Change in surface hydrophilicity was measured using sessile drop contact angle goniometry 
(Attension Theta Lite, Biolin Scientific, Stockholm, Sweden).  A ~3.5 µl water droplet was 
placed on the substrate in air and the contact angle between the droplet and the substrate was 
measured.  Data points was collected every 0.1 s over 10 s, and averaged.  A total of six data 
points was collected from each sample subset. 
3.2.4.3  Ellipsometry 
Surface coating thickness was measured using an LSE Stokes ellipsometer (Gaertner Scientific, 
Skokie, IL, USA) with a 6328 Å HeNe laser at an incidence angle of 70°.  Measured reflection 
and transmission data was entered into Fresnel equations and with the known refractive index, 
the thickness of the transparent film was iteratively solved for.  In the cases of both zwitterionic 
and PEG surface coatings, an index of refraction of 1.45 was used.35  Although exposure to 
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higher temperature, saline solution, and shear flow may lead to degradation and/or 
conformational changes within the polymers, the refractive index was assumed to be constant.  
Spatial homogeneity was characterized by measuring three locations on three separate chips per 
sample set.  A total of nine measurements were averaged, and the mean and standard deviation 
are reported.   
3.2.4.4  Human Serum Albumin Adsorption 
Protein adsorption on the substrates was quantified via enzyme linked immunosorbent assay 
(ELISA).  The substrates were incubated in a 1 mg/mL solution of human serum albumin (HSA) 
in D-PBS for 90 minutes at 37°C.  Surface protein concentrations were measured using ELISA 
as described in published methods.26,35 Briefly, all substrates were rinsed 5 times with 0.5 mL of 
D-PBS following HSA incubation, and were blocked using bovine serum albumin39 (BSA, 
≥98%, Sigma-Aldrich) at 1 mg/mL concentration for 1.5 hours.  The substrates were rinsed 5 
times with 0.5 mL of D-PBS, and transferred to fresh chambers.  The samples were then 
incubated with 10 μg/mL anti-human serum albumin antibody conjugated with horseradish 
peroxidase for 1.5 hours (Abcam, Cambridge, MA, USA).  After another rinse (5 times with 0.5 
mL of D-PBS), the substrates again rinsed and transferred to fresh chambers.  A solution of 0.5 
mg/mL of o-phenylenediamine (OPD, VWR Inc. Visalia, CA, USA) and 0.03% hydrogen 
peroxide in 0.05 M citrate phosphate buffer (pH 5.0, Sigma-Aldrich).  This reaction was 
protected from light using aluminum foil for 20 min at 37 °C, and subsequently stopped by 
adding 0.5 mL of 1M sulfuric acid. The light absorbance of the solutions was measured at 490 
nm.  Each sample type was tested in triplicate and the background (control with no HSA added) 
was subtracted.  All HSA protein adsorption data was normalized to tissue culture polystyrene 
(TCPS) which was used as a positive control.   
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3.2.6  Statistical Analysis 
A minimum of three measurements were collected for all samples in each analysis.  Statistical 
significance was determined by ordinary one-way analysis of variance (ANOVA) since 
comparisons were drawn only within each coating subset.  Significance was defined at p <0.05.  
Level of significance is indicated by the number of asterisks: p ≤ 0.05 = *; p ≤ 0.01 = **; p ≤ 
0.001 = ***; p ≤ 0.0001 = ****.  Analysis was conducted using Graphpad Prism software (San 
Diego, CA, USA).   
3.3  Results 
3.3.1  XPS 
Table 3.2 shows the elemental composition of unmodified silicon, PEG-, pSBMA-, and pMPC-
modified silicon when not exposed to shear.  These controls demonstrate that with increased 
polymer modification the carbon content, silicon content is decreased.  Additionally, signature 
elements are present as expected—PEG shows increased C-O bonds, pSBMA has increased 
sulfur and nitrogen, and pMPC has increased phosphorus and nitrogen presence. 
For unmodified silicon, XPS data is presented in Table 3.3.  As expected, Si 2p (100 eV) and O 
1s (528 eV) make up the majority of the elemental composition.  This arises from the substrate 
monocrystalline silicon and native silicon dioxide that grows on the surface of silicon when 
exposed to ambient air.  Additionally, in the unmodified silicon control, there is 9.8% C 1s and 
0.4% N 1s adventitious carbon and nitrogen present, respectively.  When exposed to shear, there 
is at least a 6.3% elevation in carbon concentration, with the maximum of 13.9% increase for 
1500/s shear rate.  Increase in C 1s is also coupled with an increase in O 1s and N 1s (~400 eV), 
indicating contamination. 
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XPS measurements on the effect of shear on PEG-coating is presented in Table 3.4.  In 
comparison to control unmodified silicon, control PEG-silicon presents 27.4% increase in carbon 
concentration.  Based on the high resolution data, it is evident that most of the additional carbon 
is from C-C/C-H and C-O/C-N bonds.  C-N bonds can be ruled out since there is only 0.1% N 1s 
present, leaving mainly C-O bonds as is expected of PEG.  With exposure to shear, carbon 
concentration decreases by more than 50% compared to control, and there is a slight increase in 
nitrogen content.  Given the elemental make-up of PEG, it is difficult to determine whether the 
carbon expressed in XPS is due to contamination or PEG itself. 
XPS data presented in Table 3.5 demonstrates that compared to control unmodified silicon, 
control pSBMA-silicon shows a 45.7% decrease in silicon and a 47.1% increase in carbon.  In 
addition, with modification, there is a presence of N 1s, S 2s (~228 eV) and Br 3d (~69 eV).  The 
ratio of sulfur to nitrogen is approximately 1:1.2.  The additional nitrogen is likely due to a 
presence of adventitious nitrogen as well as nitrogen in the underlying BrTMOS initiator.  With 
shear, there is ~18-20% increase in silicon, and ~20-23% decrease in carbon.  Additionally, 
sulfur concentration slightly decreases by ~0.5% or less.  It should also be noted that there is a 
trace amount of phosphorus contamination (<0.5%). 
As shown in Table 3.6, control pMPC-silicon shows a 42.2% decrease in silicon and 42.9% 
increase in carbon compared to control unmodified silicon.  There is also the presence of N 1s, P 
2s (~190 eV), and Br 3d, which are the signature elements of pMPC.  With shear, there is 
negligible to no decrease in phosphorus and nitrogen concentration.  However, there is a ~19-
26% decrease in carbon and ~16-24% increase in silicon.  The lowest carbon concentration is 
observed for shear rate of 1000/s. 
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3.3.2  Contact Angle 
 
 
Figure 3.4:  Contact angle for each surface modification with varying shear rates.  Significance was defined at p 
<0.05.  Level of significance is indicated by the number of asterisks: p ≤ 0.05 = *; p ≤ 0.01 = **; p ≤ 0.001 = ***; 
p ≤ 0.0001 = ****. 
 
The effect of shear on the surface hydrophilicity is represented in Figure 3.4.  Following surface 
cleaning with piranha, contact angle was below 10° due to the hydroxylation of silicon.  
However, with time, the contact angle increases as the surface loses the hydrophilicity.  The 
contact angle for unmodified silicon was measured at 27.3° one week following piranha 
treatment.  There is no significant difference found between the control unmodified silicon and 
silicon substrates exposed to shear.  The maximum difference in the uncoated silicon subset from 
control was due to 1500/s shear rate, yielding a difference of 6.0° from control unmodified 
silicon. 
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With PEG modification, contact angle increases to 42.9°.  Although no trend could be elucidated 
with varying shear, there was a significant decrease in contact angle for PEG-silicon when 
exposed to shear.  The lowest angle measured was 25.3° for a shear rate of 1500/s.   
pSBMA and pMPC both contain zwitterionic moieties, and as such, they are very hydrophilic.  
Control substrates of pSBMA-silicon and pMPC-silicon are 10.9°, and 12.4°, respectively.  With 
shear, the contact angle significantly increases for both coatings.  However, in general, there are 
no significant differences between any of the shear groups within each subset with the exception 
of shear rates of 1000/s and 2000/s for pSBMA-silicon.  For both zwitterionic coatings, 
following exposure to shear, the contact angle settled at ~30°.  The highest contact angle of 30.9° 
and 35.8° was measured at 2000/s shear rate for pSBMA and pMPC, respectively. 
3.3.3  Ellipsometry 
Change in coating thickness was measured using ellipsometry and data is presented in Figure 
3.5.  Uncoated silicon, without exposure shear, was used as baseline control for native oxide 
thickness measurement.  With shear, “thickness” is increased, which may be due to 
contamination and/or native oxide growth under these conditions.  Initial thickness of PEG is 
0.95 nm.  With shear, the coating thickness measurements appears to increase, but is only 
significant for 1000/s and 1500/s shear rates.  Although there is no trend evident with shear, 
1500/s shear rate leads to the largest increase in thickness for both PEG, and unmodified silicon. 
Zwitterionic polymers pSBMA and pMPC started out with thickness of 4.7 and 5.2 nm, 
respectively.  In both cases, exposure to shear led to a decrease in thickness.  However, with 
varying shear, there is no significant difference noted.  Following shear, coating thickness was 
~2.5-2.8 nm for pSBMA and ~2.2-2.3 nm for pMPC. 
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Figure 3.5: Change in thickness with varying shear rates for each surface modifications.  Data has been normalized 
to native oxide measured in uncoated silicon that has not been exposed to D-PBS.  Significance was defined at p 
<0.05.  Level of significance is indicated by the number of asterisks: p ≤ 0.05 = *; p ≤ 0.01 = **; p ≤ 0.001 = ***; 
p ≤ 0.0001 = ****. 
 
3.3.4  ELISA 
Following exposure to shear, coating functionality was characterized by measuring protein 
resistance against human serum albumin.  The amount of protein adsorption for each surface 
coating before and after shear is plotted in Figure 3.6.  All data has been normalized to positive 
control tissue culture polystyrene.  For unmodified silicon, there was no significant difference in 
protein adsorption between control and substrates exposed to shear.  PEG modification yielded 
little difference in protein resistance from unmodified silicon.  Biological shear of PEG-silicon 
did not increase the protein adsorption.   
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Control pSBMA and pMPC coated silicon improved protein resistance by ~71% and ~93%, 
respectively, compared to uncoated silicon.  Like PEG, exposure to shear did not lead to 
increased protein adsorption for pSBMA-silicon.  For pMPC-silicon, shear of 1000/s and above 
led to increased protein adsorption by a factor of ~2.3.  Nonetheless, all pSBMA and pMPC-
coated substrates reduced protein adsorption by greater than 70% compared to unmodified 
silicon. 
 
Figure 3.6:  Protein adsorption for uncoated, PEG-, pSBMA-, and pMPC-silicon before and after exposure to shear 
rates of 500-2000/s.  Data is normalized to positive control tissue culture polystyrene (TCPS). Significance was 
defined at p <0.05.  Level of significance is indicated by the number of asterisks: p ≤ 0.05 = *; p ≤ 0.01 = **; p ≤ 
0.001 = ***; p ≤ 0.0001 = ****. 
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3.4  Discussion 
For implantable devices in contact with blood flow, the effect of shear rate must be investigated.  
Our implantable organs require ultrathin film polymer surface coatings to be subjected to 
biological shear.  Shear rates in the human body can be can be as high as 1650/s.38  Increasing 
shear leads to faster removal of solutes from the surface, which may lead to increased 
degradation of surface coatings.  Previously, isolated studies of coating degradation were 
conducted under static conditions.22,35  This chapter explores the effect of biological shear on 
ultrathin polymer surface modifications.  Specifically, three hydrophilic, brush-structure coatings 
that are of ~5 nm or less in thickness were examined: PEG, pSBMA and pMPC.  The experiment 
was run for 24 hours in physiological temperature of 37 °C and shear rates of 500-2000/s were 
achieved over these surfaces using varying flow rates of D-PBS.  Using D-PBS has its 
drawbacks when compared to blood or serum: there are no enzymes, proteins, or cells present in 
D-PBS.  Hence, the effect of these biological components will not be reflected via these 
experiments.  Nonetheless, PBS is often used in previous literature in place of blood due to its 
similarity in pH and saline content,22,35 
and for this study, it allows us to do 
sensitive surface analysis that would be 
compromised by proteins and cells 
attached on the surface.    
Due to shear and exposure to D-PBS, 
uncoated silicon gathered organic 
contamination over 24 hours of flow.  
Both XPS and ellipsometry data 
Figure 3.7: Schematic of elemental breakdown of unmodified 
silicon based on high resolution and spectral XPS data.  Data 
illustrates change in oxygen found in XPS is due to 
contaminants, not silicon dioxide.  Image not drawn to scale. 
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indicated a change in surface chemistry with shear.  Since both C 1s and O 1s concentration 
increased, the change in thickness may be due to contamination and/or increase in native oxide 
growth on the surface.  However, as illustrated in Figure 3.7, calculations based on the high-
resolution and spectral XPS data indicate that the additional oxygen arising in shear exposed 
surfaces is bound to carbon rather than silicon.  Therefore, with shear, the elevated thickness 
found using ellipsometry is likely due to contamination and not due to oxide growth.  The 
experiment was conducted in a clean, but not sterile, environment, which may have led to 
bacterial growth on the surface over time.  The highest level of contamination was found with 
1500/s shear rate.  Overall, despite additional contamination, ELISA results did not indicate a 
significant difference in protein resistance with shear compared to control. 
While all three surface analyses confirmed successful surface modification, there was no change 
in protein resistance for PEG-coupled silicon compared to uncoated silicon.  Initially, ~1 nm 
thick PEG coating is present on the control.  However, PEG-coated silicon did not improve 
protein resistance over unmodified silicon.  Although previous literature shows a significant 
decrease in bacterial growth and biofilm formation following PEG modification,40,41 our data 
suggests attachment of organic contaminants, possibly due to bacterial growth on the surface.  
Based on data provided by the manufacturer (Gelest), the PEG chains should be 6-9 monomer 
units in length.  However, mass spectrometry of Gelest PEG solution (data presented in 
Appendix B) shows a variety of chain lengths present.  Therefore, chains grafted to silicon may 
be smaller than expected and/or the grafting density may be low, leading to lower protein 
resistive function.   
Based on the three surface analyses conducted, PEG degradation is difficult to explain due to its 
similarity to carbon contamination in elemental signature.  With shear, there is an increase in the 
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apparent thickness, up to 3 nm higher with 1500/s shear rate than control PEG coating.  We see a 
similar pattern in uncoated silicon, suggesting there may be optimal conditions leading to higher 
biological burden for the 1500/s shear rate.  Increase in carbon content, specifically C-O bonds, 
is typically indicative of PEG.42   When compared to control, with shear, we see a decrease in C 
1s concentration, which is reflected in decreased C-C/C-H and C-O bonds.  There is also <1% 
increase in N 1s concentration, which may be due to contamination.  Because these same bonds 
are present in organic contamination, there could be three possibilities: PEG degraded 
completely and surface contaminants are resulting in elevated thickness; PEG degraded partially, 
enough to allow surface contaminants to attach to the surface; or none of the PEG degraded, but 
initial PEG grafting density was not enough to resist contaminants.  The last option is highly 
unlikely because it would lead to greater C 1s concentration than PEG control.  However, partial 
or full degradation of PEG from the surface cannot be differentiated.    
For pSBMA-silicon, while there was no significant difference in surface chemistry and thickness 
between 500-2000/s shear rates, exposure to shear and D-PBS led to changes in surface 
characteristics.  Control pSBMA coating had a starting contact angle of ~10.9° and thickness of 
~4.7 nm.  These results, combined with the elemental signature of nitrogen, sulfur and an ester 
group (O-C=O), indicated pSBMA was successfully grafted to the silicon.  With shear, decrease 
in C 1s was evident.  For example, for a shear rate of 2000/s, there was a 40% reduction in C 1s, 
23% reduction in S 2s and 25% reduction in O-C=O groups.  However, since both carbon and 
ester groups are present in control unsterilized, unmodified substrates, and sulfur is unique to 
SBMA, change in surface chemistry is best determined on the change in sulfur content.  
Ellipsometry data presented ~40% decrease in coating thickness following exposure to shear.  
This change appears to be due to removal of SBMA from the surface, as well as conformational 
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change in pSBMA chains.  Despite these alterations at the surface, there was no increase in 
protein adsorption with shear and functionality of the coating was preserved. 
pMPC followed similar trend as pSBMA: while there were changes in the surface characteristics 
with shear, their nonfouling properties were still retained.  With an initial thickness of ~5.2, XPS 
of pMPC-silicon showed the presence of signature elements and bonds, such as N 1s, P 2s, and 
O-C=O.  Like pSBMA, there was a significant decrease in carbon concentration following 
exposure to shear and D-PBS.  A shear rate of 1000/s yielded the least thickness and 
concentration of elemental signature.  Under this condition, C 1s shows a 50%, P 2s shows a 
25% and O-C=O shows a 10% decrease.  Additionally, there was a ~62% decrease in coating 
thickness.  Because phosphorus is the unique signature element in pMPC, tracking its change 
indicates that there was approximately 25% removal of MPC from the surface, while about 37% 
change in thickness is due to conformational change in the pMPC chains.  While ELISA result 
shows that shear affected the performance of pMPC coatings, all pMPC samples still led to a 
>75% decrease in protein adsorption compared to unmodified silicon.  Therefore, exposure to 
shear did not change functionality. 
For the zwitterion-coated samples, removal of SBMA and MPC could originate from either 
uncrosslinked monomers present at the surface or breakdown of pSBMA monomer chains.  If, 
over time, further removal of monomer chemical signature takes place, especially at the same 
rate, it is likely due to the degradation of the polymer.  However, if the chemical signature 
stabilizes over time, uncrosslinked polymers are likely washed away with exposure to shear 
stress.  Therefore, there is a need for future study that incorporates shear rate over time. 
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3.5  Conclusions 
While surface modified implants are often exposed to blood flow, isolated studies of the effect of 
shear, especially on ultrathin polymer coatings, have not been examined.  The results presented 
in this chapter demonstrate that between the range of biological shear rates from 500-2000/s, ~5 
nm zwitterionic surface modifications retain their functionality.  However, exposure to shear for 
24 hours using D-PBS increased contact angle, and reduced surface polymer concentration and 
coating thickness.  These changes may be due to removal of uncrosslinked monomers or partial 
polymer degradation.  However, further studies of shear coupled with time must be conducted to 
separate the differences. 
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CHAPTER IV 
Sterilization Effects on Ultrathin Film 
Polymer Coatings for Silicon-based 
Implants 
 
Substantial portions of this chapter have been published in Journal of Biomedical Materials 
Research Part B: Applied Biomaterials, 2017:00B:000-000. 
 
 
4.1  Introduction 
Implantable medical devices based on silicon are increasingly attractive due to their precisely-
defined micro- and nanoscale features which can be produced at low cost and integrated with 
microelectronics.  These devices include microelectrodes for neuroprosthetics,1 controlled drug 
delivery systems,2,3 immunoisolation chambers for cell transplants,4–8 and nanofilters for renal 
replacement therapy.9,10  Such applications bring silicon in direct contact with body fluids, 
including blood.  According to the US Centers for Disease Control and Prevention (CDC), any 
medical device in contact with sterile biological fluids is categorized as a “critical item” and 
must be sterilized.  For implants, the sterility assurance level (SAL) must be at least 10-6, which 
is equivalent to the probability of one in a million spores surviving the sterilization process.  This 
SAL level is reached by a number of physical and chemical processes: high temperature 
exposure, chemical and chemical plasma exposure, and irradiation.11  These treatments eradicate 
microbes and spores.  However, their harsh characteristics can cause cross-linking, bond 
disruption, and/or oxidation of the medical device components, possibly causing undesirable 
damage to functionalized surfaces. 
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Our lab has developed silicon nanopore membrane (SNM) technology for use in bioartificial 
organs, including implantable bioartificial kidney,9,12,13 and bioartificial pancreas,7 as shown in 
Figure 4.1.  SNMs consist of uniform, sub-10 nm slit shaped pores produced on silicon 
substrates.  This highly permeable and selective membrane allows for convective clearance of 
solutes similar to a functioning glomerulus in a healthy kidney.  In the bioartificial pancreas, the 
SNM provides protects encapsulated islets from the host’s immune factors, while allowing the 
passage of glucose, insulin, and other small molecules. 
 
Figure 4.1: Silicon nanopore membrane (SNM) developed for bioartificial organs.  SNM (a) top view depicting pore 
length of 2 µm and pore width of 7 nm, and (b) side view depicting 360 nm pore height, reprinted from S. Song et 
al./ Scientific Reports (6), ©2016, with permission from Nature Publishing Group (c) Concept of an artificial kidney 
based on SNM renal replacement therapy. (d)  Immunoisolation chamber for encapsulated islets in a bioartificial 
pancreas. 
 
In order to successfully create bioartificial organs, biocompatibility of the SNM is essential. To 
this end, the biocompatibility of silicon is enhanced by the application of ultrathin polymer 
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coatings that minimize biofouling and degradation of the underlying substrate.14–17 For our 
bioartificial kidney and pancreas, we are investigating three surface modifications.  These 
coatings were selected for their hydrophilicity and controllable degree of polymerization:  
polyethylene glycol (PEG), polysulfobetaine methacrylate (pSBMA) and poly(2-
methacryloyloxyethyl phosphorylcholine) (pMPC).  PEG is a widely used non-fouling surface 
modification.16,18–24 The surface remains hydrated and brush-like PEG chains creates steric 
repulsion to resist fouling.14,25  pSBMA and pMPC are zwitterionic polymer brushes that have 
also previously demonstrated excellent non-fouling properties.15,26–29  These biomimetic 
polymers coordinate water molecules in a manner that resists protein and cell adhesion.30   
Silicon itself is not known to be affected by conventional sterilization techniques such as 
autoclave and gamma radiation.31  However, the effect of sterilization on thin-film polymeric 
surface coatings applied to silicon is not well characterized.  Previous studies have shown effects 
of sterilization on hydrogels, crosslinked polymers, and surface modifications that are orders of 
magnitude thicker.32–34  However, effect of sterilization on sub-10 nm thick brush-like polymer 
structures of PEG, pSBMA and pMPC have not been reported.  Therefore, the work presented in 
this chapter focuses on the effect of common sterilization modalities on silicon coated with PEG, 
pSBMA, and pMPC.  The modified substrates were sterilized using five techniques approved by 
the CDC: autoclave, dry heat, hydrogen peroxide (H2O2) plasma, ethylene oxide (EtO) gas, and 
electron beam (E-beam) irradiation.  We utilized various surface characterization techniques to 
examine the physical and chemical effects of sterilization.  X-ray photoelectron spectroscopy 
(XPS) was conducted to determine the changes in chemical composition at the surface.  Contact 
angle measurements were taken to determine the change in surface wettability, and change in 
polymer thickness was measured using ellipsometry.  Together, these three tests give us insight 
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into the conformation change and/or degradation of the polymer chains.  Finally, protein fouling 
capacity with and without sterilization was measured using enzyme-linked immunosorbent 
assays (ELISA). 
 
4.2 Materials and Methods 
4.2.1 Sample Preparation 
Double side polished, 400 µm thick, p-type silicon wafers from Ultrasil Corporation (Hayward, 
CA, USA) were diced into 1 cm2 chips.  The chips were cleaned by “piranha,” a solution of 3:1 
ratio of sulfuric acid (96%) to hydrogen peroxide (30%) for 20 min.  Next, they were exposed to 
hydrofluoric acid for 5 min to remove native silicon dioxide that spontaneously forms on silicon 
surfaces exposed to atmospheric oxygen.  The silicon was then activated by another piranha 
treatment.  The substrates were dried under a stream of nitrogen gas and used immediately for 
surface modification. 
4.2.2 Surface Modification 
4.2.2.1 PEG Surface Modification 
Silicon surfaces were modified with PEG as previously described.7,13  Briefly, substrates were 
dried on a hotplate at 110 °C for 1 hour.  PEG-silane, 2-
[methoxy(polyethyleneoxy)propyl]trimethoxysilane (shown in Table 4.1), purchased from Gelest 
(Morrisville, PA, USA), were covalently bonded to silicon by immersing the substrates in a 
solution of 285 µl PEG-silane in 25 mL of toluene for 2 hours at 70 °C.  Excess PEG was 
removed by rinsing the substrates three times at 10 min intervals with toluene, ethanol, and water 
respectively. 
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4.2.2.2 Zwitterionic Surface Modification 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless stated 
otherwise.  Zwitterionic surface modifications were conducted as described in previously 
published literature.35  Detailed description of surface modifications can be found in Chapter 2, 
Materials and Methods. Briefly, a surface initiator 2-bromo-2-methyl-N-
3[(trimethoxysilyl)propyl]-propanamide (BrTMOS) as shown in Table 4.1, was synthesized.35  
The substrates were placed in a 1% (v/v) BrTMOS solution in bicyclohexyl for 2 hours.  Excess 
BrTMOS was removed from the surfaces by rinsing them with chloroform, ethanol, and water 
respectively.   
 
Table 4.1: Chemical structures of PEG-silane, BrTMOS-silane linker for zwitterioinic coatings, SBMA monomer 
and MPC monomer. 
1, 2-
[methoxy(polyethyleneoxy)propyl]trimethoxysilane 
(PEG-silane) O
O Si
O
O
O
6-9
 
2-bromo-2-methyl-N-3[(trimethoxysilyl)propyl]-
propanamide (BrTMOS) 
Si N
H
O
Br
O
O
O
 
2-(methacryloyloxy)ethyl]dimethyl-(3-
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O
O
N+ S
O
O
O
-
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SBMA monomer, 2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide, and 
MPC monomer, 2-methacryloyloxyethyl phosphorylcholine, are shown in Table 4.1.  Degassed 
solution of 468 mg (3 mmol) of 2,2’-bipyridyl (≥98%) and individual monomers—SBMA: 1.06g 
(3.8 mmol), and MPC: 506 mg (1.9 mmol)—and 22.3 mg (0.1 mmol) of copper (II) bromide 
(99%) was prepared in 5:5 mL of methanol:water.  This mixture was added to a nitrogen 
protected reaction chamber containing four substrates modified with BrTMOS and 143 mg (1 
mmol) of copper (I) bromide (99.999%).  Polymerization ran for 15 min for pSBMA and 7 min 
for pMPC.  The substrates were then rinsed with chloroform, ethanol, Dulbecco’s phosphate 
buffered saline (D-PBS, UCSF Cell Culture Facility, San Francisco, CA, USA), and water 
respectively, and dried using a stream of nitrogen gas.    
4.2.3 Sterilization Processes 
Five sterilization processes were evaluated: autoclave, dry heat, H2O2 plasma treatment, EtO gas 
treatment and E-beam sterilization.  Autoclave was conducted using STERIS Amsco Century, 
SV-120 Scientific Prevacuum Sterilizer (Mentor, OH, USA), where substrates were exposed to 
high pressure steam for 30 minutes at 121 °C.  For dry heat sterilization, substrates were placed 
in a 160 °C oven for 2 hours.36  H2O2 plasma treatment was conducted using STERRAD® 100S 
Sterilization System (standard cycle).  EtO gas treatment was conducted with a 2-hour exposure 
time at 132 mBar and 55°C by D2EO (San Jose, CA, USA). Lastly, E-beam sterilization was 
performed by STERIS (Petaluma, CA, USA), at an applied dosage range of 21.0 to 21.9 kGy.     
4.2.4 Surface Characterization 
4.2.4.1 X-ray Photoelectron Spectroscopy (XPS) 
XPS was conducted using a Surface Science Instruments S-Probe spectrometer with a 
monochromatized Al Kα X-ray beam.  A pass energy of 150 eV was used to generate the survey 
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and high resolution spectra.  Samples were placed in a vacuum of <5e-9 torr and a 0° take-off 
angle was used, corresponding to sampling depth of ~10 nm. XPS readings were measured at 
three locations with a spot size of ~800 µm for each sample.  Elemental composition calculations 
were performed using Service Physics Hawk version 7 software (Bend, OR, USA).  
4.2.4.2 Goniometry (Contact Angle) 
Surface hydrophilicity was measured using sessile drop contact angle goniometry (Attension 
Theta Lite, Biolin Scientific, Stockholm, Sweden).  A ~3.5 µl water droplet was placed on the 
substrate in ambient air and the contact angle between the droplet and the substrate was 
measured.  Data points was collected every 0.1 s over 10 s, and averaged.  Six data points was 
collected from each sample subset group. 
4.2.4.3 Ellipsometry 
Surface coating thickness was measured using LSE Stokes ellipsometer (Gaertner Scientific, 
Skokie, IL, USA) with a 6328 Å HeNe laser at an incidence angle of 70°.  With known refracting 
index, and measured reflection and transmission data, Fresnel equations were used to iteratively 
solve for thickness of the transparent film.  An index of refraction of 1.45 was used for both 
zwitterionic and PEG surface coatings.35  Although sterilization processes may lead to 
conformational changes and cross-linking within the polymers, refractive index was assumed to 
be constant.  Measurements on three locations on three separate chips per sample set were taken 
to characterize spatial homogeneity.  A total of nine measurements were averaged, and the mean 
and standard deviation is reported.   
4.2.4.4 ELISA 
Resistance to protein fouling was determined using ELISA using published methods.27,35  
Substrates were hydrated in D-PBS for 90 minutes.  D-PBS was replaced with 1 mg/mL solution 
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of human serum albumin (HSA) in D-PBS for 90 minutes and the samples were incubated at 
37°C.  All substrates were rinsed 5 times with 0.5 mL of D-PBS following HSA incubation, and 
were blocked using bovine serum albumin37 (BSA, ≥98%, Sigma-Aldrich) at 1 mg/mL 
concentration for 1.5 hours.  The substrates were rinsed 5 times with 0.5 mL of D-PBS, and 
transferred to fresh chambers.  The samples were incubated with 10 μg/mL anti-human serum 
albumin antibody conjugated with horseradish peroxidase for 1.5 hours (Abcam, Cambridge, 
MA, USA).  After another rinse (5 times with 0.5 mL of D-PBS), the substrates again rinsed and 
transferred to fresh chambers.  A solution of 0.5 mg/mL of o-phenylenediamine (OPD, VWR 
Inc. Visalia, CA, USA) and 0.03% hydrogen peroxide in 0.05 M citrate phosphate buffer (pH 
5.0, Sigma-Aldrich).  This reaction was protected from light using aluminum foil for 20 min at 
37 °C, and subsequently stopped by adding 0.5 mL of 1M sulfuric acid. The light absorbance of 
the solutions was measured at 490 nm.  Each sample type was tested in triplicate and the 
background (control with no HSA added) was subtracted.  All HSA protein adsorption data was 
normalized to tissue culture polystyrene (TCPS) which was used as a positive control.   
4.2.5 Statistical Analysis 
A minimum of three measurements were collected for all samples in each analysis.  Statistical 
significance was determined by ordinary one-way analysis of variance (ANOVA) since 
comparisons were drawn only within each coating subset.  Significance was defined at p <0.05.  
Level of significance is indicated by the number of asterisks: p ≤ 0.05 = *; p ≤ 0.01 = **; p ≤ 
0.001 = ***; p ≤ 0.0001 = ****.  Analysis was conducted using Graphpad Prism software (San 
Diego, CA, USA).   
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4.3  Results 
4.3.1 X-ray Photoelectron Spectroscopy (XPS) 
A comparison of survey XPS spectra for each of the unsterilized substrate types is shown in 
Figure 4.2.  Figure 4.3(a) - (d) present the corresponding spectra after the various sterilization 
methods for each of the surface modifications, and the elemental composition is summarized in 
Table 4.2.  An example of high resolution XPS data is presented in Table 4.3.  Measurements 
show there is a presence of Si 2p (100 eV) and O 1s (528 eV) peaks from the monocrystalline 
silicon substrate and native silicon dioxide in all substrates.  The unmodified (uncoated) silicon 
shows a presence of ~8% adventitious carbon, with the exception of H2O2 plasma treated 
substrates, where the carbon content was ~16%.  With H2O2 plasma treatment, the unmodified 
silicon exhibits an elevated level of oxygen and a presence of nitrogen, sodium and fluorine.  
Since these elements are not significantly present on the other substrates, it is possible that they 
are contaminants arising from sample mishandling.  Besides H2O2 treated samples, high 
resolution data shows less than 5% change in crystalline silicon and silicon dioxide content 
between sterilized and unsterilized silicon substrates. 
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Figure 4.2: XPS traces of control unsterilized unmodified silicon, PEG-silicon, pSBMA-silicon, and pMPC-silicon 
demonstrating successful surface modification of silicon. 
 
Figure 4.3: XPS traces of (a) unmodified silicon, (b) PEG-silicon, (c) pSBMA-silicon, and (d) pMPC-silicon over 
varying sterilization conditions demonstrating the survival of surface coatings on silicon following sterilization. 
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Table 4.2: Percent of elemental composition following sterilization processes for each surface modification and 
control unmodified silicon.  Unmodified silicon results demonstrate the level of adventitious carbon to be between 7-
9%.  PEG, pSBMA, and pMPC signature elements are present following sterilization, indicating that the polymers 
remain on the surface despite harsh sterilization treatments. 
Sample Sterilization % Elemental Composition 
  Si 
(2p) 
O (1s) C (1s) N (1s) S (2s) P (2s) Br 
(3d) 
Contaminants 
(Na, F, Zn) 
Unmodified 
Silicon 
Autoclave 62.4 ± 
0.8 
28.6 ± 
1.1 
9.0 ± 
1.0 
     
Dry Heat 66.4 ± 
0.6 
27.6 ± 
0.2 
6.0 ± 
0.5 
     
H2O2 
plasma 
46.9 ± 
4.4 
31.9 ± 
0.3 
16.3 ± 
2.1 
1.2 ± 
0.2 
   3.7 ± 3.0 
EtO 62.8 ± 
1.9 
29.6 ± 
0.4 
6.8 ± 
1.4 
    0.8 ± 0.8 
E-beam 63.3 ± 
1.8 
28.8 ± 
0.9 
7.2 ± 
1.8 
    0.7 ± 0.6 
No 
Sterilization 
61.5 ± 
4.5 
29.3 ± 
1.4 
7.8 ± 
2.2     1.4 ± 1.5 
          
PEG on 
Silicon 
Autoclave 52.1 ± 
10.0 
33.0 ± 
0.8 
15.0 ± 
9.9 
     
Dry Heat 52.4 ± 
3.1 
31.3 ± 
0.3 
16.3 ± 
2.8 
     
H2O2 
plasma 
52.1 ± 
1.6 
32.4 ± 
0.6 
14.3 ± 
1.9 
1.2 ± 
0.2 
    
EtO 52.5 ± 
2.0 
32.1 ± 
2.0 
15.2 ± 
2.8 
0.2 ± 
0.3 
    
E-beam 55.6 ± 
2.0 
32.9 ± 
1.6 
11.4 ± 
0.6 
     
No 
Sterilization 
49.7 ± 
3.0 
31.8 ± 
1.3 
18.4 ± 
1.8 
0.1 ± 
0.1    
 
          
pSBMA on 
Silicon 
Autoclave 12.3 ± 
1.4 
26.1 ± 
0.4 
53.3 ± 
1.1 
4.3 ± 
0.1 
3.7 ± 
0.1 
 0.3 ± 
0.0 
 
Dry Heat 12.2 ± 
0.8 
25.7 ± 
0.3 
53.6 ± 
0.7 
4.7 ± 
0.1 
3.8 ± 
0.1 
 0.1 ± 
0.0 
 
H2O2 
plasma 
14.6 ± 
2.5 
29.9 ± 
0.7 
47.9 ± 
1.3 
4.3 ± 
0.4 
3.1 ± 
0.4 
 0.3 ± 
0.0 
 
EtO 16.7 ± 
1.3 
26.5 ± 
0.5 
49.4 ± 
0.6 
4.1 ± 
0.2 
3.0 ± 
0.4 
 0.3 ± 
0.0 
 
E-beam 10.8 ± 
1.0 
28.2 ± 
0.5 
51.6 ± 
0.9 
5.1 ± 
0.4 
3.7 ± 
0.3 
0.3 ± 
0.1 
0.3 ± 
0.0 
 
No 
Sterilization 
20.0 ± 
3.0 
27.1 ± 
0.2 
45.6 ± 
2.7 
3.8 ± 
0.3 
2.9 ± 
0.2 
0.2 ± 
0.1 
0.4 ± 
0.0 
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Sample Sterilization % Elemental Composition 
  Si 
(2p) 
O (1s) C (1s) N (1s) S (2s) P (2s) Br 
(3d) 
Contaminants 
(Na, F, Zn) 
pMPC on 
Silicon 
Autoclave 32.9 ± 
0.1 
29.9 ± 
1.2 
32.0 ± 
1.7 
3.1 ± 
0.2 
 1.3 ± 
0.1 
0.5 ± 
0.1 
0.3 ± 0.5 
Dry Heat 34.4 ± 
1.5 
31.6 ± 
1.1 
29.4 ± 
0.4 
2.8 ± 
0.1 
 1.0 ± 
0.1 
0.1 ± 
0.0 
0.7 ± 1.2 
H2O2 
plasma 
37.6 ± 
0.6 
34.3 ± 
0.4 
25.2 
±0.6 
2.2 ± 
0.2 
 0.7 ± 
0.1 
  
EtO 30.5 ± 
2.1 
30.3 ± 
0.5 
33.2 ± 
1.1 
3.0 ± 
0.3 
 1.6 ± 
0.1 
0.8 ± 
0.0 
0.4 ± 0.7 
E-beam 34.7 ± 
1.4 
31.2 ± 
0.6 
28.9 ± 
1.0 
2.7 ± 
0.4 
 1.4 ± 
0.1 
0.5 ± 
0.1 
0.5 ± 0.5 
No 
Sterilization 
34.6 ± 
0.7 
29.5 ± 
0.2 
31.2 ± 
0.6 
2.7 ± 
0.2  
1.4 ± 
0.1 
0.6 ± 
0.1  
 
 
Table 4.3: XPS high resolution data with breakdown of high resolution bond composition for Si (2p), C (1s), and N 
(1s).  Despite changes in chemical content, presence of signature elements and bonds demonstrate surface 
modification survival post-sterilization. 
Sample Sterilization % Elemental Composition 
 
    Sicryst 
Si 
(SiO2) 
O C-C,H 
C-
O,N 
O-
C=O 
N-
C NR3
+ NOx S P Br Contaminants 
Unmodified 
Silicon 
Autoclave 52.7 9.0 28.3 7.9 1.6 0.6        
Dry Heat 57.0 9.3 27.8 4.5 0.8 0.6        
H2O2 
plasma 37.0 8.5 31.9 10.7 3.1 3.2 
      5.6 
EtO 54.0 9.1 29.9 4.9 1.0 0.4       0.8 
E-beam 53.4 8.3 29.8 5.7 1.3 0.4       1.0 
No 
Sterilization 52.0 9.5 30.4 4.7 1.4 0.6 
      1.4 
                 
PEG on 
Silicon 
Autoclave 48.9 9.4 33.6 3.1 4.7 0.4        
Dry Heat 40.5 8.3 31.6 4.1 14.9 0.6        
H2O2 
plasma 42.3 8.8 31.7 8.4 4.4 3.1 
      1.2 
EtO 45.6 9.1 33.3 4.3 6.8 0.9        
E-beam 45.7 9.2 34.0 5.3 4.8 1.0        
No 
Sterilization 39.5 8.3 32.0 5.12 14.0 0.9 
      0.2 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
  131 
 
Sample Sterilization % Elemental Composition 
 
    Sicryst 
Si 
(SiO2) 
O C-C,H 
C-
O,N 
O-
C=O 
N-
C NR3
+ NOx S P Br Contaminants 
pSBMA on 
Silicon 
Autoclave 11.3 2.7 25.7 20.9 28.0 3.2 0.7 3.6  3.8  0.4  
Dry Heat 10.5 2.6 25.5 23.6 25.1 4.3 0.5 4.2  3.9    
H2O2 
plasma 12.5 2.9 29.4 19.1 22.9 5.4 0.9 3.7 
 3.0  0.3  
EtO 12.6 2.6 27.1 21.0 25.4 3.3 0.5 3.5 0.3 3.4  0.3  
E-beam 8.4 2.3 27.7 22.1 25.4 4.6 0.5 4.3 0.3 3.9  0.2 0.4 
No 
Sterilization 17.5 4.0 27.2 17.7 23.0 3.3 0.5 3.1 0.1 2.9 
 0.3 0.4 
                 
pMPC on 
Silicon 
Autoclave 26.8 6.1 28.6 15.0 16.3 2.6 1.2 1.6 0.2  1.2 0.5  
Dry Heat 27.9 6.3 32.4 10.8 15.4 3.2 1.4 1.6   0.9 0.1  
H2O2 
plasma 31.2 6.3 33.8 10.3 10.5 4.7 0.8 1.6 
  0.8   
EtO 22.6 5.9 30.6 14.8 15.9 3.3 1.2 1.4 0.7  1.6 0.8 1.3 
E-beam 29.8 6.4 31.7 10.4 14.5 3.0 0.8 1.6   1.3 0.5  
No 
Sterilization 29.2 5.6 29.5 11.1 17.8 2.2 0.9 1.7 0.1 
 1.3 0.6  
 
With PEG-coupled to silicon, the concentration of Si 2p decreased by ~12% and O 1s and C 1s 
increased by ~3% and ~11%, respectively.  High resolution data (Table 4.3) shows the increase 
in carbon is mainly due to an increase in C-O bonds, which is expected in PEG coatings.25  After 
sterilization, a slight decrease in carbon content was observed.  Percentage of carbon content 
ranged between ~11% and ~16% compared to ~18% seen in the unsterilized counterpart.  Except 
for dry heat-treated samples, this decrease in carbon is mainly due to reduced C-O bonds.  
Overall, for sterilized samples, maximum presence of C-O bonds are found after dry heat 
treatment, while H2O2 plasma sterilization exhibited the minimum C-O bonds.  Nonetheless, 
percent of C-O bonds are greater in sterilized samples compared to unmodified silicon, 
indicating presence of some PEG on all sterilized substrates. 
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Compared to unmodified silicon, control pSBMA-coupled silicon exhibited a sharp decrease in 
Si 2p concentration (by >40%), and an increase in C 1s content (by >37%).  There is also a 
presence of signature elements, N 1s (~400 eV) and S 2s (~228 eV), as well as Br 3d (~69 eV), 
indicating successful pSBMA surface modification.  High resolution XPS data (Table 4.3) shows 
a 3.1% NR3+ concentration and a 2.9% sulfur concentration, which is a ratio of ~1:1, and 
matches stoichiometric pSBMA elemental ratio.  After sterilization, silicon concentration of 
these samples slightly decreased.  Sterilized samples had Si 2p concentration ranging from ~11% 
to ~17% compared to the 20% silicon content of the unsterilized pSBMA substrates.  However, 
concentration of C 1s, O 1s, N 1s and S 2s on sterilized pSBMA-silicon surfaces remained 
comparable or higher than the unsterilized counterparts.  It should also be noted that there is a 
negligible amount of phosphorus contaminant present (<1%) for E-beam sterilized and non-
sterilized substrates. 
Unsterilized control pMPC-coupled silicon shows a decrease in Si 2p and an increase in C 1s 
content, as expected.  Signature elements for pMPC, phosphorus P 2s (~190 eV) and N 1s, are 
also present, suggesting successful polymerization of pMPC on the silicon surface.  High 
resolution XPS data (Table 4.3) shows a 1.7% NR3+ concentration and a 1.2% phosphorus 
concentration, yielding a ratio of ~1:1, which is consistent with pMPC stoichiometric ratio.  
Overall, except for H2O2 treatment, sterilization of pMPC-silicon did not result in a large change 
in elemental composition.  With H2O2 plasma sterilization, the largest drop in carbon 
concentration was observed compared to the other sterilization techniques, as well as the lowest 
level of phosphorus and nitrogen.  It should also be noted that the starting concentration of 
carbon is lower and silicon is higher in pMPC substrates compared to pSBMA substrates, 
indicating a lower degree of polymerization for starting pMPC than for pSBMA. 
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4.3.2 Contact Angle 
 
Figure 4.4: Contact angle measurements before and after sterilization for surface modifications and unmodified 
silicon.  Hydrophilicity—a fundamental property of the surface modification—of PEG was most affected by H2O2 
plasma, pSBMA by autoclave, and pMPC by dry heat. Level of significance is indicated by the number of asterisks: 
p ≤ 0.05 = *; p ≤ 0.01 = **; p ≤ 0.001 = ***; p ≤ 0.0001 = ****. 
 
Contact angle data are presented in Figure 4.4.  The sessile water droplet was stable over 10 
seconds.  For control unmodified silicon substrate has a contact angle of 32°.  With PEG surface 
modification, the contact angle increased to 43°.  Zwitterionic coatings decreased the contact 
angle to 15° and 25° for pSBMA and pMPC, respectively.  The contact angle measurements are 
all below 90° and demonstrate that all three surface modifications are hydrophilic.  However, 
significant changes in surface wettability are observed with sterilization treatments, especially 
for uncoated and pMPC-coated substrates.  The contact angle for pSBMA-silicon was most 
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affected by autoclave, increasing by 15°.  PEG-silicon was most affected by peroxide treatment, 
decreasing by 14°.  
4.3.3 Ellipsometry 
 
Figure 4.5: Coating thickness measured by ellipsometry for PEG, pSBMA, and pMPC.  Change in coating thickness 
could be due to chain scission or polymer conformation change.  Largest decrease in thickness for all three coatings 
was due to peroxide treatment. Level of significance is indicated by the number of asterisks: p ≤ 0.05 = *; p ≤ 0.01 
= **; p ≤ 0.001 = ***; p ≤ 0.0001 = ****. 
 
Surface coating thickness was determined using ellipsometry, and the data is reported in Figure 
4.5.  The thickness for each of the unsterilized control coatings are 0.9, 7.1 and 2.7 nm for PEG, 
pSBMA and pMPC, respectively.  Sterilization with H2O2 plasma led to statistically significant 
differences for all coatings.  Table 4.4 presents the change in thickness relative to the unsterilized 
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control samples, revealing substantial reduction in coating thickness following several of the 
sterilization processes tested.  Thickness of PEG decreased by >30% when treated with dry heat, 
peroxide and E-beam irradiation, while pSBMA and pMPC exhibited >20% thickness change 
with dry heat and peroxide treatment.  pSBMA was also greatly affected by steam treatment in 
the autoclave, decreasing in thickness by 29%. 
 
Table 4.4: Relative change in coating thickness following sterilization treatments.  Data is normalized to 
unsterilized surface modified counterparts. 
 PEG pSBMA pMPC 
Autoclave -1% -29% -13% 
Dry Heat -32% -21% -24% 
H2O2 -64% -43% -30% 
EtO 1% -12% 3% 
E-beam -46% 3% -10% 
 
4.3.4 ELISA 
HSA protein adsorption data is shown in Figure 4.6.  It illustrates that both unsterilized pSBMA 
and pMPC coated silicon chips display excellent non-fouling properties, and reduce protein 
adsorption by 90% and 95%, respectively compared with unmodified silicon.  In contrast, PEG-
coated chips only yielded a 10% reduction compared to unmodified silicon.   
Overall, the sterilization processes tested did not cause a significant change in protein adsorption 
for unmodified silicon.  For the surface-modified silicon, sterilization seemed to adversely affect 
the coatings as evidenced by increased protein fouling.  For PEG on silicon, E-beam radiation 
caused a significant increase in HSA adsorption compared to its unsterilized counterpart.  Dry 
heat and EtO treatment significantly increased HSA adsorption on pSBMA-silicon.  Lastly, all 
tested sterilization methods caused a significant increase in HSA adsorption for the pMPC-
silicon surfaces. 
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Figure 4.6: Relative human serum albumin (HSA) adsorption on PEG, pSBMA and pMPC-modified and unmodified 
silicon surfaces.  Data has been normalized to tissue culture polystyrene (TCPS).  There is a statistically significant 
reduction in protein adsorption with surface modification.  Following sterilization, protein adsorption generally 
increases.  Level of significance is indicated by the number of asterisks: p ≤ 0.05 = *; p ≤ 0.01 = **; p ≤ 0.001 = 
***; p ≤ 0.0001 = ****. 
 
4.4 Discussion 
For development of implantable medical devices, the effect of sterilization on the device and its 
surface modifications must be considered.  This chapter evaluated the effects of five common 
sterilization modalities for three ultrathin surface modifications on silicon—PEG, pSBMA and 
pMPC.7,9,35  These polymer films are grafted to/from the surface in brush-like structures at less 
than 10 nm thickness.  Zwitterionic polymers, pSBMA and pMPC, have a presence of charged 
moieties, but are overall charge neutral.  Since sterilization processes are harsh treatments that 
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are destructive to living organisms, it is anticipated that they could adversely affect the chemical 
and physical characteristics of the polymers and therefore, affect their functionality.   
A total of five sterilization techniques were examined and the data is presented in this chapter: 
Autoclave and dry heat are the two high-temperature sterilization processes tested.  For 
polymers, exposure to high temperature can lead to thermal degradation via oxidation, as well as 
molecular rearrangement and cross-linking, affecting chemical properties.38,39  Autoclave is the 
most widely used sterilization method for medical instruments.  However, steam is known to 
affect the surface energy of many polymers through spontaneous rearrangement, leading to a 
change in their hydrophilicity.40 
In contrast, H2O2, EtO and E-beam sterilization are all room temperature treatments.  
Nonetheless, H2O2 plasma sterilization is a fairly corrosive process where reactive free radicals 
bombard the surfaces to kill microbes.  Additionally, it has also been shown to modify exposed 
surfaces, reducing polymer strength, and changing morphology, composition and wettability.40  
Toxic EtO gas sterilization is often used in the medical field for devices that cannot withstand 
steam, dry heat or irradiation.  However, it can leave behind dissolved residues in polymers, 
requiring long aeration periods post-sterilization.41  Lastly, E-beam sterilization uses a beam of 
charged electrons to alter the chemical bonds in biological materials such as DNA strands, 
leading to chain scission and crosslinking.42 
Because these sterilization processes denature, crosslink, and degrade chemical structures in 
living things, they can also bring about significant changes in the properties of polymers, 
especially ultrathin surface coatings.  Therefore, to evaluate alterations in these polymers caused 
by sterilization, the change in their hydrophilicity, elemental composition, thickness and non-
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fouling capacity was measured.  Table 4.5 summarizes the effect of sterilization on each surface 
modification based on hydrophilicity, coating thickness, and protein resistance. 
PEG-silicon: Compared to unsterilized silicon, unsterilized control PEG-silicon only exhibited a 
11% reduction in protein adsorption.  This is in contrast to previous literature, which has 
demonstrated that PEG on silicon can reduce albumin adsorption by 75% compared to uncoated 
silicon.19,43  We examined and confirmed PEG surface modification on silicon via its surface 
chemical composition, contact angle, and coating thickness prior to sterilization.  However, it 
should be noted that PEG chain length and surface grafting density can affect protein resistance, 
and the “graft to” method used in this dissertation for PEG surface modification generally yields 
poor surface density compared to “graft from” method.44  Therefore, our low reduction in protein 
adsorption could be due to low grafting density.   
PEG on silicon was least affected by autoclave and EtO treatments, while dry heat, H2O2, and E-
beam treatments affected its properties and protein resistance.  Within the PEG subset, dry heat, 
H2O2, and E-beam treatments caused 32, 64, and 47% decrease in coating thickness, 
respectively.  Additionally, except for dry heat treatment, all other sterilization processes show a 
decrease in C-O bonds via XPS analysis.  The adverse effect on physical and chemical surface 
properties correlate with ELISA data, which exhibit a corresponding increase in protein 
adsorption.  H2O2 plasma treatment also significantly decreased surface wettability, which may 
be indicative of chain scission and ionization of PEG polymers after treatment.  Despite having 
decreased C-O bonds compared to unsterilized controls, when all metrics are considered, EtO 
and autoclave appeared to have minimal effects on PEG coatings. 
pSBMA-silicon: Differences in surface elemental composition and coating thickness of pSBMA-
silicon reflect a possible change in pSBMA polymer chain conformation or crosslinking after 
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sterilization.  XPS data shows an increase in carbon and a decrease in silicon following all five 
sterilization processes.  Increase in nitrogen and sulfur content is also evident, which are the 
signature elements of pSBMA.  Except in the case of e-beam sterilization, there was a decrease 
in coating thickness for the sterilized substrates.  While part of the decrease in coating thickness 
could be due to chain scission of the polymers, the lower thickness measurements coupled with 
the increased pSBMA signature elements measured via XPS demonstrates a compression of the 
polymer layer from crosslinking or conformational change.  To examine crosslinking in more 
detail, polymer swelling behavior may be the subject of a future study.  However, these 
alterations in polymer layer did not lead to a significant negative impact in protein resistance.   
Of the three surface coatings examined, pSBMA had the highest initial coating thickness, 
measuring 7.1 nm for the unsterilized control samples.  It may be that the relatively higher 
polymer chain length allowed conformational and crosslinking changes to occur without 
compromising its effectiveness at protein resistance. 
E-beam sterilization led to the lowest impact on pSBMA coating, while autoclave, dry heat, 
H2O2 or EtO treatments exhibited mixed low, moderate and severe impacts on various properties.  
When comparing within the subset of sterilized pSBMA samples, XPS showed the lowest carbon 
concentration for H2O2 plasma treated samples, followed by EtO.  H2O2 exposure also caused the 
lowest contact angle and the greatest change in thickness, a decrease of over 43%, on pSBMA-
silicon substrates.  This alteration indicates possible chain scission.  However, since the original 
polymer coating thickness was greater than the damage caused by these sterilization processes, 
the non-fouling property of pSBMA was still preserved.     
pMPC-silicon: All five sterilization methods tested adversely affected pMPC-coatings.  Aside 
from EtO treatment, all sterilization methods resulted in at least 10% change in pMPC coating 
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thickness, with a maximum change of 30% decrease using H2O2 treatment.  However, compared 
to unsterilized samples, XPS results show minor change in carbon concentration.  Unlike the 
pSBMA coating, the starting pMPC chains are shorter (2.7 nm thick for unsterilized substrates) 
and their resulting lower degree of freedom limits alterations in chain conformation.  H2O2 
treated pMPC samples resulted in significant drop in carbon concentration (31% to 25%), 
indicating possible chain scission and polymer degradation.  Overall, all sterilization methods 
tested led to substantial increase in contact angle and protein adsorption for pMPC-silicon 
substrates.  However, it is possible that the damage done by sterilization may have been more 
tolerable with a thicker brush coating.  These results indicate that EtO treatment had the least 
adverse effects on pMPC samples.  
 
Table 4.5: Summarization of the effect of sterilization on hydrophilicity (H), coating thickness (CT), and the protein 
resistance (PR) of surface modifications. 
Surface 
Modification Impact 
Autoclave Dry Heat H2O2 EtO E-beam 
H CT PR H CT PR H CT PR H CT PR H CT PR 
PEG 
Low 
               
Moderate      
          
Severe     
           
                 
pSBMA 
Low    
            
Moderate   
             
Severe 
               
                 
pMPC 
Low           
     
Moderate  
              
Severe 
               
 
4.5  Conclusions 
Sterilization treatments can be especially harsh on polymer surface modifications on implantable 
medical devices.  Therefore, this chapter presented data examining the effects of various 
sterilization processes on thin-film polymeric brushes on silicon.  Results show H2O2 plasma 
  141 
 
treatment adversely affected all three polymer coatings.  In contrast, autoclave and EtO treatment 
appear to be well suited to PEG, E-beam sterilization to pSBMA, and EtO treatment for pMPC 
coatings.  These findings will be useful for any silicon medical devices that utilizes ultrathin 
zwitterionic or PEG coatings for their applications.   
As the use of novel polymers and functional surfaces become more prevalent in medical devices, 
effect of sterilization treatment on them must be carefully assessed.  Our results illustrate that 
these effects are unique to the various surface coating chemical and physical properties. 
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CHAPTER V 
Hemocompatible Ultrathin Film Surface 
Modifications on Silicon: Study In Vitro 
 
 
5.1  Introduction 
Due to the precision and versatility of micro- and nanoscale features it offers, silicon has become 
a common substrate material for novel biomedical devices.  Many of these devices are often in 
direct contact with blood, such as neuroelectrodes,1,2 drug delivery systems,3–5 biosensors and 
diagnostic devices,6–8 and artificial organs.9–12  To advance the area of bioartificial organs, our 
lab has developed silicon nanopore membranes (SNMs) for blood filtration in renal 
replacement9,13,14 and immunoisolation in islet therapy. 11,15  SNMs are highly uniform and low 
resistance membranes with controllable pore size on the order of ~10 nm and variation of <1% 
across the wafer.9  Because their applications require SNMs to come in direct contact with blood 
flow, hemocompatibility and non-fouling properties are essential.  While silicon has been shown 
to be non-cytotoxic, non-leaching and non-irritant,16–18 the surfaces must also be non-activating 
and non-fouling for implant applications. 
To improve hemocompatibility of a substrate, the surface is often modified.19  Specifically, 
hydrophilic, polymeric brush structures on the surface have shown enhanced hemocompatibility.  
One such coating is polyethylene glycol and oligoethylene glycol (PEG and OEG, respectively), 
which has demonstrated excellent resistance to protein adsorption and platelet adhesion.20,21  Our 
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previous research shows PEG-modified silicon significantly reduced thrombus formation and 
inflammation following 4-week implantation in rat veins.22   
Another group of hydrophilic polymer brush surface modifications is zwitterionic coatings.  
Using a methacrylate backbone, polymer brushes and hydrogels are built to a desired thickness 
with atom-transfer radical polymerization (ATRP).23–25  These biomimetic zwitterions, such as 
sulfobetaine, carboxybetaine and phosphorylcholine, coordinate water molecules through 
hydrogen bonding and electrostatic interactions.24,26  This hydration layer allows the coating to 
resist protein fouling27–31 and thrombus formation.23,26,32   
 
Table 5.1: Chemical structure of PEG-silane, SBMA and MPC monomer. 
 
 
To apply coatings on SNMs, several requirements must be met: in addition to being non-
activating and non-fouling, the coatings must also be hydrophilic and sub-5 nm for pore patency.  
For this purpose, we have chosen to explore three different coatings presented in Table 5.1: PEG, 
zwitterionic poly(sulfobetaine methacrylate) (pSBMA), and poly(2-methacryloyloxyethyl 
phosphorylcholine) (pMPC).  Zwitterionic surface coatings are relatively new, and sub-5 nm 
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thick pSBMA and pMPC need to be further characterized under physiological conditions.  Since 
SNMs will be ultimately implanted, animal testing for compatibility and functionality is 
required.  However, before delving into expensive animal testing, we conducted a series of in 
vitro experiments to narrow down our coating choices.  Aside from the benefit of testing a 
variety of materials and conditions at lower cost, in vitro testing also allows for testing against 
fresh human blood.  Examining surface chemistry compatibility against fresh human blood is 
critical because reactions to blood may vary from one species to another.33   
In this chapter, we explore the hemocompatibility of PEG, pSBMA, and pMPC in vitro.  Protein 
fouling from single protein solutions of fibrinogen and albumin was first tested as was done in 
previous literature.29,34–36  However, where further in vitro testing of biomaterials and their blood 
interaction are concerned, it is difficult to utilize a standardized platform.  Often, experiments are 
conducted with blood components, such as platelet rich plasma37 or platelet poor plasma,35 rather 
than whole blood.  In some cases, static blood incubation30,38 is used while others use perfusion 
platforms, such as modified Chandler’s loop.39–42  In perfusion experiments, there are many 
variable that can be set: flow rates, shear rates, presence of reservoir, time of material contact, 
time of experimental run, type and amount of anticoagulants used, type of pump and etc.  Here, 
we conducted some preliminary static tests against standard materials such as 
polytetrafluoroethylene (PTFE) and titanium.  However, to better mimic the final conditions, in 
vitro flow experiments were also run in implant housing, as well as an in-house designed 
polyether ether ketone (PEEK) flow cell designed specifically for in vitro studies.  Following 
blood flow experiments, the surfaces were examined with scanning electron microscopy (SEM) 
and fluorescence microscopy for cellular and platelet adhesion and activation. 
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5.2  Materials and Methods 
5.2.1  Sample Preparation 
Double side polished, 400 µm thick, p-type silicon wafers were obtained from Ultrasil 
Corporation (Hayward, CA, USA) and diced into 1 cm2 chips and 1 by 6.5 cm2 long chips.  The 
chips were cleaned by “piranha,” a solution of 3:1 ratio of sulfuric acid (96%) to hydrogen 
peroxide (30%) for 20 min.  The chips were then rinsed with reverse osmosis purified water (RO 
water) at 5-minute intervals (3X).  Afterwards, they were exposed to hydrofluoric acid for 5 min 
to remove the layer of silicon dioxide that spontaneously forms on silicon surfaces exposed to 
atmospheric oxygen.   The chips were again rinsed with RO water at 5-min intervals (3X), 
followed by activation of the surface via a final piranha treatment and RO water rinse, as 
described above.  The silicon chips were then dried under a stream of nitrogen gas and allowed 
to completely dry on a hotplate at 110 °C for 1 hour. 
5.2.2  Surface Modification 
5.2.2.1  PEG Surface Modification 
Silicon surfaces were modified with PEG as previously described.10,11  Briefly, 2-
[methoxy(polyethyleneoxy)propyl]trimethoxysilane (PEG-silane) was purchased from Gelest, 
Inc. (Morrisville, PA, USA) and covalently bonded to silicon by immersing the substrates in a 
solution of 285 µl PEG-silane in 25 mL of toluene for 2 hours at 70 °C.  The substrates were then 
rinsed three times at 10 min intervals with toluene, ethanol, and water, respectively, to remove 
excess PEG, and stored dry under ambient condition until use. 
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5.2.2.2  Zwitterionic Surface Modification 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless stated 
otherwise.  Zwitterionic surface modifications were conducted as described previously.35  
Briefly, a surface initiator, 2-bromo-2-methyl-N-3[(trimethoxysilyl)propyl]-propanamide 
(BrTMOS), was synthesized.35  The substrates were placed in a 1% (v/v) BrTMOS solution in 
bicyclohexyl for 2 hours.  The surfaces were then rinsed with chloroform, ethanol, and water, 
respectively, to remove excess BrTMOS.   
Zwitterionic monomers, 2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium 
hydroxide (SBMA), and 2-methacryloyloxyethyl phosphorylcholine (MPC), are shown in Table 
5.1.  A degassed solution of 468 mg (3 mmol) of 2,2’-bipyridyl (≥98%) and individual 
monomers—SBMA: 1.06g (3.8 mmol), and MPC: 506 mg (1.9 mmol)—and 22.3 mg (0.1 mmol) 
of copper (II) bromide (99%) was prepared in 5:5 mL of methanol:water.  This mixture was 
added to a reaction chamber housing four substrates and 143 mg (1 mmol) of copper (I) bromide 
(99.999%) under nitrogen protection, and polymerization was allowed to run for 15 min and 7 
min for pSBMA and pMPC, respectively.  The substrates were then rinsed with chloroform, 
ethanol, Dulbecco’s phosphate buffered saline (D-PBS, UCSF Cell Culture Facility, San 
Francisco, CA, USA), and water respectively, and dried using a stream of nitrogen gas.    
5.2.3  In Vitro Protein Adsorption via Enzyme-Linked Immunosorbent Assay (ELISA) 
Protein adsorption on the surfaces of the substrates was determined by conducting enzyme-
linked immunosorbent assay (ELISA) following protocol published previously.35  Substrates 
were placed in 24-well tissue-culture polystyrene (TCPS) plates and incubated with D-PBS for 
1.5 hours.  D-PBS was replaced with 0.5 mL of single protein solution: 1 mg/mL concentration 
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of human fibrinogen (Sigma-Aldrich) or human albumin (Abcam, Cambridge, MA, USA) was 
added and allowed to incubate at 37 °C for 1.5 hours.  All substrates were rinsed five times with 
D-PBS.  Surfaces were then blocked using bovine serum albumin (BSA, ≥98%, Sigma-Aldrich) 
using 1 mg/mL BSA solution for 1.5 hours.  The substrates were rinsed five times with D-PBS, 
and transferred to a new 24-well TCPS well.  Next, the samples were incubated with 10 μg/mL 
anti-human proteins conjugated with horseradish peroxidase (HRP) for 1.5 hours: anti-human 
fibrinogen (coagulation factor I) (HRP) (USBiological, Salem, MA, USA) for fibrinogen ELISA 
and anti-human serum albumin antibody-HRP (Abcam) for albumin ELISA.  The substrates 
were washed with D-PBS five times and transferred to a new well.  A reaction mixture was made 
in 0.05 M citrate phosphate buffer (pH 5.0, Sigma-Aldrich) with 0.5 mg/mL of o-
phenylenediamine (OPD, VWR Inc. Visalia, CA, USA) and 0.03% hydrogen peroxide.  The 
reaction mixture (0.5 mL) was added to each well, and the reaction was allowed to run at 37 °C 
for 20 minutes.  The reaction was stopped by adding 0.5 mL sulfuric acid (1 M).  The solution 
was transferred to 96-well plates and light absorbance at 490 nm was determined using a 
microplate reader.  A minimum of 3 substrates were analyzed for each sample set and light 
absorbance reading was normalized to TCPS control.  
5.2.4  Blood Collection 
Informed consent was obtained prior to blood collection and experiments in all cases.  For static 
experiments, fresh blood was collected from a volunteer end stage renal disease patient (male, 
37, on aspirin).  Blood was collected into 8.5 mL BD Vacutainers with acid citrate dextrose 
(solution A, trisodium citrate 22g/L, citric acid 8g/L, and dextrose 24.5 g/L) (Thermo Fisher 
Scientific, Waltham, MA, USA).   
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For blood flow experiments, fresh blood was collected from a healthy human donor (male, 31) 
into 10 ml BD Vacutainers with 15.8 USP/mL lithium heparin (Thermo Fisher Scientific, 
Waltham, MA, USA).  Initial 2 mL of blood collected was discarded to minimize blood 
activation from effect of blood collection process.  Blood was stored on ice for approximately 15 
min until use in experiments.  
5.2.5  Fresh Blood Experiments Under Static Conditions 
Samples were placed in 24-well polypropylene plates, and 
rinsed 3 times with D-PBS.  After the final rinse, D-PBS 
was fully removed, and 1 mL of fresh human blood was 
added to each well, as shown in Figure 5.1.  The samples 
were incubated with gentle shaking at 37 °C, with 5% 
CO2.  After 2 hours, the samples were removed and rinsed 3 times with D-PBS, and preserved 
for imaging. 
5.2.6  Fresh Blood Experiments Under Flow Conditions 
5.2.6.1  Blood Flow Experiments with Titanium Implant Device 
The experimental setup of the blood flow experiments conducted using titanium implant device 
is shown in figure 2.  The titanium housing consists of three 1 mm high blood channels.  The 
fully assembled device is shown in Figure 5.2(b), while 5.2(c) and (d) shows the experimental 
setup.  Two devices were run in parallel: device 1 contained only uncoated silicon chips, while 
device 2 contained only pSBMA-modified chips.  Blood was circulated at a rate of 20 mL/min 
using a peristaltic pump for two hours.  This flow rate results in a wall shear rate of 73.3/s.  
Given the space constraints, devices were incubated at 37 °C while the pump was housed 
Figure 5.1: Static blood experiment 
setup. 
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immediately next to the incubator.  Approximately 50 cm of Masterflex, Tygon E-LFL L/S 14 
Tubing (1.6 mm inner diameter tubing from Cole-Parmer, Vernon Hills, IL, USA) was used to 
connect the inlet and outlet of the blood flow platform.  After two hours, the blood was removed, 
and D-PBS was circulated through the device until no trace of blood was visible (~200 mL of D-
PBS per device).  Then, the devices were disassembled, and the chips removed and preserved for 
imaging. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: a) exploded view of titanium implant device for blood flow experiment (b) titanium implant devcie, 
(c) and (d) experimental setup: titanium implant device was incubated at 37 °C and a peristaltic pump outside 
incubatro was used to circulate blood for 2 hours. 
a) b) 
c) d) 
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5.2.6.2  Blood Flow Experiments with PEEK Housing 
An in vitro blood flow platform was designed and fabricated out of PEEK as shown in Figure 
5.3(a) and (b).  Blood enters through the top PEEK piece inlet and flow is allowed to develop 
guided by 500 μm thick silicone gasket 1.  Developed blood flow enters through the slit in 
middle PEEK piece, and the test substrate is exposed to the blood flow.  Blood then leaves out 
the slit in middle PEEK piece and out the outlet of the top PEEK piece.  The blood flow channel 
over the test substrate has a height of 200 μm.  As shown in Figure 5.3(c), a peristaltic pump 
drives the blood flow at a rate of 4 mL/min, yielding a shear rate of 1000/s.  To avoid stagnant 
blood, no reservoir was used.  Rather, 100 cm of Tygon E-LFL L/S 14 tubing was used to 
connect the inlet and outlet of the blood flow platform.  Prior to blood experiment, the tubing and 
experimental setup was circulated with D-PBS containing 50 USP/mL heparin for 30 minutes.  
The setup was then washed out with D-PBS and circulated with D-PBS for 30 minutes to remove 
residual heparin.  The blood flow experiment was then conducted in a 37 °C, 5% CO2 incubator 
for 2 hours. 
After 2 hours, the blood was collected for activation assessment using flow cytometry.  The 
setup was run with D-PBS until no trace of blood was detected in the tubing.  The in vitro flow 
cells were then taken apart, and the blood channels were analyzed for gross clots.  The 1 by 6.5 
cm2 substrates were rinsed 3 times with D-PBS and broken into ~1 cm pieces for surface analysis 
for cellular adhesion using scanning electron microscopy (SEM) and platelet adhesion and 
activation using immunohistochemistry (IHC). 
157 
 
 
  
5.2.5  Post-Analysis Following Blood Experiments 
5.2.5.1  Scanning Electron Microscopy (SEM) 
Cellular adhesion was visualized using SEM.  Samples were fixed by incubation in a solution of 
3% glutaraldehyde (Sigma-Aldrich), 0.1 M sodium cacodylate (VWR) and 0.1 M sucrose 
(Sigma-Aldrich) for 48 hours.  Afterwards, the substrates were removed, washed two times with 
deionized water, and dehydrated in the following ethanol/water (v/v) solutions for 10 min in 
each: 35%, 50%, 70%, 95% and two times in 100%.  Samples were allowed dry overnight and 
mounted on aluminum stubs for imaging using a Carl Zeiss Ultra 55 Field Emission Scanning 
Electron Microscope (Zeiss, Dublin, CA, USA).  Prior to imaging, samples were sputter coated 
with gold-palladium. 
 
Figure 5.3: in vitro blood flow platform a) exploded view, 
showing the top PEEK piece containing the inlet and outlet, 
silicone gasket 1, developing uniform blood flow and 
directing the blood flow through the slits in middle PEEK 
piece.  Substrate surface is exposed to laminar blood flow 
with a channel height of 200 μm, and blood is directed out 
of the slit in middle PEEK piece and out the outlet on top 
PEEK piece.  Silicone gasket 2 and bottom PEEK piece 
supports the substrate.  b) cross section showing blood flow 
path through device. c) setup of 2-hour fresh human blood 
flow study in a 37° C incubator. 
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5.2.5.2  Immunohistochemistry (IHC) 
Immunohistochemistry (IHC) was used to image platelet adhesion and activation on the 
substrates.  Samples were fixed with 4% paraformaldehyde (Thermo Fisher Scientific) at room 
temperature for 30 minutes and allowed to remain in 1% paraformaldehyde at 4 °C until they 
were imaged (~1 week).  Before imaging, the samples were marked for human platelets and 
platelet activation using FITC-labeled anti-CD41 (Bioss Inc., Woburn, MA, USA)) and Cy3-
labeled anti-CD62p (Bioss Inc.) markers, respectively.  Samples were rinsed 3 times in D-PBS, 
and imaged using Nikon TI-E Microscope (Nikon Instruments, Melville, NY, USA).  Imaging 
was conducted at 100x, in at least 5 separate representative locations per chip, and at least three 
different chips per sample group.  A representative image per sample is reported.  For in vitro 
flow experiments using PEEK flow cells, IHC images were quantified using ImageJ software 
(National Institutes of Health).  To process an image, the threshold was first set, and the image 
were converted to binary format.  Next, the area covered by platelets was calculated.  This area 
was normalized by the average area taken by individual platelets in order to obtain a platelet 
count.  Quantified data presented is averaged over approximately 20 different locations per 
sample.  
5.2.5.3  Flow Cytometry 
Platelet activation in blood was analyzed by flow cytometry.  Positive and negative controls were 
prepared to realize maximum and minimum platelet activation.  Positive control was produced 
by activating blood using thrombin receptor activating peptide (TRAP) following blood 
collection.  Blood was activated for 20 min at room temperature without agitation with 200 
µmol/L TRAP final blood concentration.  The reaction was stopped with ice-cold 
paraformaldehyde (PFA), at a final concentration of 0.5% in the blood samples.  The samples 
159 
 
were stored on ice for 20 min for the PFA to take effect.  For negative control, samples were kept 
at room temperature for 20 min after blood collection without agitation and without activation.  
Ice-cold PFA was added to a final concentration of 0.5%, and the samples were placed on ice for 
20 minutes before labeling with antibodies. 
For each experimental sample, after 2-hour blood flow in PEEK flow cells, ~1-2 mL of blood 
was collected from each circuit.  Aliquots of 100 µl of blood was set aside for antibody labeling.  
Further activation was stopped by adding ice-cold PFA to a final concentration of 0.5%.  
Samples were placed on ice for 20 minutes before labeling with antibodies. 
Monoclonal anti-CD41-FITC specific to human was used for a platelet marker, and monoclonal 
anti-CD62P-APC specific to human was used as a platelet activation marker.  Both antibodies 
were purchased from Sigma-Aldrich.  The reaction was allowed to occur at 37 °C protected from 
light for 30 minutes, and stopped by adding 3 mL of cold 1% PFA.  All samples were stored at 4 
°C and cytometry was conducted within 6 hours of sample preparation. 
Cytometry was conducted using BD FACSAria IIu (BD Biosciences, San Jose, CA, USA), and 
BD FACSDiva Software was utilized in order to collect data.  Data analysis was conducted using 
FlowJo software (Ashland, OR, USA).  
5.3  Results 
5.3.1  In Vitro Protein Adsorption via Enzyme-Linked Immunosorbent Assay (ELISA) 
Preliminary protein fouling experiments from single protein solutions was assessed.  All data has 
been normalized to TCPS.  As shown in Figure 5.4, both human serum albumin (HSA) and 
human fibrinogen adsorption data showed similar trend: silicon adsorbed ~37-38% of TCPS, 
while PEG, pSBMA and pMPC reduced protein adsorption by at least 50% compared to 
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unmodified silicon.  pSBMA had the least protein adsorption, reducing protein adsorption by 
>80% compared to unmodified silicon. 
 
 
 
Figure 5.4: (a) human serum albumin (b) human fibrinogen adsorption from single protein solution.  All data is 
normalized to tissue culture polystyrene (TCPS). 
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5.3.2  Fresh Blood Experiments Under Static Conditions 
Following 2-hour incubation with fresh human blood, samples were analyzed for fibrinogen 
adsorption.  The adsorption data, normalized to unmodified silicon and presented in Figure 5.5, 
demonstrates that PEG-coupled silicon had approximately the same level of protein adsorption as 
unmodified silicon, while pSBMA-coupled silicon reduced adsorption by >50%.  Titanium and 
pSBMA-silicon performed similarly, while polytetrafluoroethylene (PTFE) had the highest 
adsorption. 
Samples were also analyzed for cellular adhesion using SEM.  Figure 5.6 shows there was a 
significant amount of leukocyte adhesion on PTFE, while titanium, PEG- and pSBMA-coated 
silicon had significantly lower amount of blood cell adhesion.  Some leukocyte spreading was 
evident on PEG-silicon and titanium surfaces. 
 
 
Figure 5.5: Fibrinogen adsorption from whole human blood.  Data is normalized to unmodified silicon. 
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Figure 5.6: Representative SEM images of surfaces following static fresh whole blood incubation.  a) PEG-silicon, 
b) pSBMA-silicon, c) titanium, and d) PTFE.  Examples of leukocytes, red blood cells, and platelets are annotated 
with white, red and yellow arrows, respectively.  
 
Figure 5.7 shows representative IHC images for a) PEG-silicon, b) pSBMA-silicon, c) titanium, 
and d) PTFE, where each sample is marked for presence of CD-62p, which indicates activation.  
PEG and pSBMA-modified silicon showed the least amount of activation, followed by titanium.  
PTFE showed the maximum amount of activation, with clots present on the surface. 
 
a) b) 
c) d) 
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5.3.3  Fresh Blood Experiments Under Flow Conditions 
5.3.3.1  Blood Flow Experiments in Titanium Implant Device 
Images from disassembly following 2-hour blood flow in titanium implant device is presented in 
Figure 5.8.  With the exception of one gross clot found in the flow path of uncoated silicon 
substrates, both flow paths for silicon and pSBMA-silicon were clear.  Following disassembly, 
the chips were removed and surfaces were imaged.  Representative SEM images, shown in 
Figure 5.9, demonstrates a significant amount of platelet adhesion as well as presence of platelet 
aggregates on unmodified silicon surfaces.  pSBMA-coated silicon exhibited an overall clean 
a) b) 
c) d) 
Figure 5.7: Representative IHC images of surfaces following static fresh whole blood incubation.  Samples are 
marked for platelet activation (CD-62p).  a) PEG-silicon, b) pSBMA-silicon, c) titanium, and d) PTFE.  Scale 
bar represents 25µm. 
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surface, with limited platelet and cell adhesion.  The substrates were also marked for activated 
platelets, and images are presented in Figure 5.10.  Here, as seen in the SEM images, there was 
significantly more platelet activation on unmodified silicon as compared to pSBMA-coated 
silicon. 
 
 
 
Figure 5.9: SEM images (a) unmodified silicon and (b) pSBMA-coated silicon following blood flow using fresh 
human blood for 2 hours. 
clot on the uncoated 
silicon cartridge 
Uncoated silicon cartridge pSBMA-silicon cartridge 
a) b) c) 
a) b) 
Figure 5.8: Images of titanium housing disassembly.  (a) gross clot found in flow path of cartridge containing 
uncoated silicon chips.  (b) uncoated silicon cartridge taken apart, and (c) pSBMA-silicon cartridge taken apart.  
No other gross clots were found. 
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Figure 5.10: Immunohistochemistry (IHC) showing platelet activation marked by CD-62p.  (a) unmodified silicon 
and b) pSBMA-modified silicon after 2 hours exposure to fresh human blood flow. 
 
5.3.3.2  Blood Flow Experiments with PEEK Housing 
 
 
 
 
After 2 hours of blood flow, the PEEK flow cells were disassembled.  The flow paths were 
mainly clear, as shown in Figure 5.11.  However, there was presence of white platelet clots 
adhered to the PEEK surface.  These clots may have formed because of high shear blood flow 
conditions.43  Silicon and modified silicon surfaces were analyzed using SEM (Figure 5.12) and 
IHC (Figure 5.13).  SEM imaging demonstrates that both zwitterionic coatings had minimal cell 
and platelet adherence, while unmodified silicon exhibited a significantly higher number of 
adhered platelets and platelet aggregates.  PEG-modified surfaces also had presence of adhered 
platelets on the surface.  IHC imaging showed a similar trend: there is an increased amount of 
adhered and activated platelets for unmodified and PEG-modified silicon, compared to pSBMA- 
10 μm 10 μm 
a) b) 
Figure 5.11: Disassembly of PEEK flow cell after 2-hour blood flow at 
a shear rate of 1000/s.  There were some presence of white platelet clots 
on the flow path. 
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and pMPC-modified silicon.  Following IHC, the number of platelets adhered and activated was 
quantified, and the data is presented in Figure 5.14.  pSBMA and pMPC-silicon had significantly 
lower platelet adhesion compared to unmodified silicon.  pSBMA also showed significantly 
lower activation compared to unmodified silicon.  However, modifying silicon with PEG did not 
improve platelet adhesion and activation compared to unmodified silicon.  Because of the non-
homogeneity of platelet adhesion to the surfaces, the error bars are high—for all sample sets, 
there are locations of high cell count and low cell counts. 
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a) b) c) 
d) e) f) 
g) i) h) 
j) l) k) 
Figure 5.12: SEM images following in vitro blood flow experiment. (a)-(c) Unmodified silicon; (d)-(f) PEG-
silicon; (g)-(i) pSBMA-silicon; and (j)-(l) pMPC-silicon.  Red arrow shows an example of red blood cell; 
yellow arrows show examples of adhered platelets and platelet aggregates, and black arrow represents an 
example of debris. 
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Figure 5.13: IHC imaging demonstrating non-fouling behavior of pBSMA and pMPC compared to unmodified and 
PEG-modified silicon.  (a)-(c) unmodified silicon; (d)-(f) PEG silicon; (g)-(i) pSBMA-silicon; (j)-(l) pMPC-silicon.  
Left image is marked with CD41-FITC, stained green, shows adhered platelets on the surface.  Middle images is 
marked with CD62-Cy3, stained red, shows activated platelets marked with CD62p, and images on the right column 
shows overlap of the first two columns, stained yellow indicating platelets that are activated.  
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Figure 5.14: IHC surface platelet adhesion and activation data quantified.  pSBMA-silicon followed by pMPC-
silicon had the least platelet adhesion and activation. Level of significance is indicated by the number of asterisks: p 
≤ 0.05 = *; p ≤ 0.01 = **; p ≤ 0.001 = ***; p ≤ 0.0001 = ****. 
 
Amount of activation in the blood was quantified using whole blood flow cytometry.  With 
forward scatter (FSC) as an indicator of size and side scatter (SSC) as an indicator of granularity, 
whole blood separated into two distinct populations.  An example of this plot is presented in 
Figure 5.15: The smaller population was gated as single platelets, labeled “platelets,” which 
consists of platelets and cellular debris.  The larger population labeled “cells” consists of red 
blood cells, white blood cells, platelet aggregates, as well as platelet-leukocyte aggregates. 
After gating based on size, as shown in Figure 5.15, the “platelet” and “cells” populations were 
individually analyzed for fluorescence.  CD-41, also known as integrin alpha-IIb, is a protein that 
is located on all platelets.  Therefore, platelets were marked with anti-CD41 labeled with 
fluorescein isothiocyanate (FITC) to isolate the platelet population.  CD62p, also known as p-
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selectin, is a protein that is only expressed on platelet surfaces following activation.  Therefore, 
platelets were marked with anti-CD62p labeled allophycocyanin (APC) to isolate the activated 
platelet population.   
 
Figure 5.15: Example of population separation based on size (forward scatter, FSC) and granularity (side scatter, 
SSC). Negative control (no activation) data is presented here. 
 
Figure 5.16 demonstrates how gates were set based on positive and negative control.  As shown 
in Figure 5.16 (a), when CD41-FITC-labeled for platelets, it forms two distinct populations, 
separating out platelets from debris.  The platelet-positive population (FITC-positive), was then 
further analyzed for activation (APC-positive) in Figure 5.16(b).  Although the positive and 
negative control populations overlap, there is a distinct shift.  Therefore, the gate was set at the 
intersection of positive and negative controls.  As shown in Figure 5.16 (c) and (d), gates were 
set in a similar method for the “cells” group.  When looked at the combined platelet population 
across the two populations, positive control had 85.8% activation, while negative control had 
3.1% activation. 
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a)      b) 
             
 
c)      d) 
         
Figure 5.16: a) positive and negative controls for “platelet” population as marked with anti-CD41-FITC; b) 
positive and negative controls for FITC-positive “platelet” population as marked with anti-CD62-APC; c) positive 
and negative controls for "cells” population as marked with anti-CD41-FITC; and d) positive and negative controls 
for FITC-positive “cells” population as marked with anti-CD62-APC. 
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a) 
 
b) 
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c) 
 
d) 
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e) 
 
f) 
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g) 
 
Figure 5.17: Representative dot plots from flow cytometry for each of the samples. Green dots represent particles 
that have a presence of CD41-FITC, indicating platelets.  Light green dots fall in the “platelet” population while 
dark green dots fall in the “cells and aggregates” population.  Red and magenta dots represent particles that are 
CD41-positive and have a presence of CD62-APC on the surface, indicating activation.  Red dots fall in the 
“platelet” population while magenta dots fall in the “cells and aggregates” population0.  a) negative control; b) 
positive control; c) unmodified silicon; d) PEG-silicon; e) pSBMA-silicon; f) pMPC-silicon; g) tubing only. 
 
Figure 5.17(a) – (g) shows a representative dot plot for each of the sample group.  Platelet 
population and activation of platelets are shown as a distribution of size and granularity.  
Negative and positive controls, where blood was not circulated for 2 hours, show a tighter 
distribution for granularity (SSC) of platelets compared to the other experimental groups.  While 
distribution varies from sample to sample, when averaged, there is no significant differences in 
activation between each of the experimental group.  Circulating blood through the tubing only at 
the same flow rate as the experimental groups shows no significant difference from any of the 
sample, as demonstrated in the summary plot of Figure 5.18.   
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Figure 5.18: Percent of platelets that are activated in controls and following 2-hour blood flow experiment at a 
shear rate of 1000/s over surfaces.   
 
5.4  Discussion 
While animal testing is critical for any novel biomaterial or implant, preliminary in vitro testing 
can significantly reduce sample size, lowering the number of animal sacrifices required as well 
as cost.  However, there are no standard methods for testing biomaterials in vitro.  Therefore, this 
chapter looked at surfaces via several methods, including under static and blood flow conditions. 
Protein Adsorption from Single Protein Solution: 
Adsorption from two separate protein solutions were tested: HSA and human fibrinogen.  HSA 
was chosen as model protein for non-specific surface binding, while fibrinogen was chosen for 
its role in thrombus formation.20,44,45 Overall, adsorption from both HSA and fibrinogen showed 
similar trend: compared to control TCPS, all silicon and modified silicon surfaces have lowered 
protein adsorption by more than 60%.  This may due to differences in surface chemistry and 
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surface roughness between the samples.  Following piranha treatment, water contact angle for 
silicon is <10° due to newly introduced hydroxyl groups on the surface.  Over time, silicon loses 
the hydroxyl groups and the contact angle slowly raises back up to ~43°.46  In the time frame that 
ELISA is conducted after piranha treatment, measured contact angle is ~30°, while coated silicon 
is ~10° for zwitterionic coatings and ~40° for PEG-silicon.  On the other hand, TCPS has a 
contact angle of ~55°.47  Along with surface chemistry, surface roughness also can increase 
protein fouling,48 and root mean square surface roughness (RRMS) for polystyrene is ~4.5 nm,47 
while RRMS for silicon is <0.2 nm.49  These two factors would favor silicon surfaces to be less 
fouling compared to TCPS. 
With surface modification protein adsorption decreased significantly.  For both HSA and 
fibrinogen, protein adsorption was reduced by more than 50%, 80% and 45% for PEG, pSBMA 
and pMPC, respectively, compared to unmodified silicon.  This demonstrates that at < 5 nm 
thickness, the surface coatings are able to maintain their non-fouling properties. 
Static Fresh Human Blood Experiment: 
Titanium and PTFE have been used for decades in implants such as hard tissue replacements in 
orthopedics and dentistry,50 pulmonary valve replacements51 and surface coatings.52,53  In 
addition to mechanical strength and toughness, titanium offers biocompatibility and corrosion 
resistance due to its chemically inert surface oxide.50,54–56  Hydrophobic PTFE is known to be 
non-toxic and stable under biological conditions.57,58  Therefore, in this chapter we compared 
PEG- and pSBMA-modified silicon to titanium and PTFE. 
Aside from imaging the substrates for cellular adhesion and activation, fibrinogen adsorption on 
the surfaces were also analyzed using ELISA.  Previous literature shows that protein adsorption 
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can differ when it is from whole blood or plasma compared to single protein solutions.35  Our 
results also show a poorer performance in fouling properties from whole blood compared to that 
from single protein solution.  After two-hour incubation in fresh human blood from an ESRD 
patient, PEG-modified silicon did not lower fibrinogen adsorption compared to unmodified 
silicon.  pSBMA and titanium reduced protein adsorption by only 50% compared to silicon, and 
PTFE almost doubled the protein adsorption.  The high fibrinogen adsorption of PTFE compared 
to the other surfaces could once again be due to surface roughness.  Among the surfaces tested, 
PTFE is also the most hydrophobic surface, which leads to increased fibrinogen adsorption.59 
PTFE also shows a high amount of cellular adhesion and activation on the surface.  Under SEM 
imaging, a large number of adhered leukocytes is evident on PTFE.  In comparison, other three 
surfaces tested—titanium, PEG-silicon, and pSBMA-silicon, had negligible cellular adhesion 
and activation.  However, PEG-silicon and titanium exhibit signs of leukocyte spreading.  
Spreading typically follows leukocyte adhesion, where cells rearrange their cytoskeleton and 
flatten to tightly adhere to the surface.60  PEG brushes are meant to deter cells from adhering.  
However, low grafting density of PEG (discussed extensively in Ch 3 and 4), may allow regional 
islands on which cells are able to attach and spread.   
Interestingly, although there are a large number of leukocytes on PTFE surface, they did not 
spread.  It is difficult to ascertain whether the adhered cells are unable to spread on the PTFE 
surface or if they were fixed before they had a chance to spread.  Nonetheless, when stained for 
p-selectin, which is only expressed when platelets are activated, clots were evident on PTFE 
surface.  While PTFE is inert, previous literature shows its hydrophobic surface properties can 
lead to inflammation.61 
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Based on SEM and IHC imaging, pSBMA and PEG had the least amount of cell adherence and 
activation.  Under SEM imaging, pSBMA surface shows some presence of red blood cells.  
However, red blood cells alone are not an indication of inflammation or activation.  There is also 
presence of a few platelets on the pSBMA-silicon surface.  However, as evident under IHC 
staining, they only negligible compared to titanium and PTFE controls.  
Fresh Human Blood Flow Experiments: 
To better mimic our implants in vivo, flow experiments were conducted in our current titanium 
implant device (Figure 5.2).  However, unlike in the static experiment, we used fresh human 
blood from a healthy donor.  At a blood shear rate of ~73/s over the surfaces, pSBMA was 
compared to unmodified silicon.  Over two hours, pSBMA-coated silicon was able to resist 
platelet adhesion and activation, while unmodified silicon showed a significant amount of 
platelet adhesion and activation (Figures 5.9 and 5.10).  This experiment demonstrated that <5 
nm pSBMA brushes maintain their functionality under whole blood flow conditions. 
The titanium housing has a channel height of 1 mm over test substrates.  However, to generate 
sufficient filtrate, the final bioartificial kidney hemofilter will require blood channel height of 
~200 nm in order to accommodate larger SNM area.  Therefore, we designed a PEEK flow cell 
with 200 nm channel to test our coated substrates.  This device allows us to test blood flow at 
high shear rate, unlike other in vitro flow testing devices used in previous literature.62  The flow 
experiments done in PEEK flow cell had the wall shear rate of 1000/s, which is more than 10 
times higher compared to the experiment in titanium implant device.  With the PEEK 
experimental setup, however, we found formation and attachment of white clots on the PEEK 
surface (Figure 5.11).  Closer examination under microscope revealed that these clots consist of 
mainly platelets, with very little to no presence of fibrin.  White clots typically occur in high 
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shear conditions.  Unlike red clots, which contain erythrocytes and are likely to form at low shear 
flow, high-shear thrombi do not follow the typical path of coagulation cascade.  Rather, it relies 
of platelet accumulation and platelet interaction with Von Willebrand factor (vWF).43  Although 
majority of the white clots were attached to the PEEK housing, the presence of these clots in the 
system may have elevated the total platelet adhesion and activation count. 
Imaging was conducted for all test substrates using SEM and fluorescence microscopy.  SEM 
images shows platelets and platelet aggregates attached to unmodified silicon and PEG-silicon, 
while pSBMA and pMPC had negligible attachment.  IHC imaging also showed a similar trend.  
Once quantified, as reported in Figure 5.14, it is noticeable that PEG-silicon had lower amount of 
platelet attachment compared to unmodified silicon.  Zwitterionic coatings had the least amount 
of platelet adhesion and activation, with pSBMA-silicon demonstrating the best performance.  
Although the quantified data agrees trend-wise with the visualized images and cell counting was 
done in similar method as was done before,66 it should be noted that the number of platelets were 
calculated from 2-dimensional images.  Therefore, overlapping platelets, for example, in a 
platelet aggregate, were under-counted using this method.  
In addition to doing surface analysis, activation of platelets in blood was also examined using 
flow cytometry.  While it is challenging to conduct flow cytometry on platelets due to their small 
size, fluorescent markers were used against CD41 to segregate platelets and platelet aggregates 
from the rest of the blood cells.  Positive control activated with TRAP led to >80% activation, 
while negative control had <5% activation.  These values are in agreement with positive and 
negative controls in previous literature,67 confirming the platelet population was properly 
managed and analyzed.   
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In conducting flow cytometry, we attempted to determine the amount of activation in blood due 
to exposure to different surfaces.  However, the amount of platelet activation in blood due to 
varying surface coatings could not be determined using flow cytometry because there was no 
significant difference in activation between any of the substrates.  As a control, flow through 
tubing alone was also tested.  Platelet activation in blood for control tubing was comparable to 
any of the samples run—~14%.  Therefore, it is clear that the platelet activation seen in the 
substrates is likely due to the flow system and experimental setup such as tubing, peristaltic 
pump, time and amount of blood flow, and etc., rather than the substrates themselves.  This is not 
unexpected, since blood in contact with other surfaces, such as tubing, connectors and PEEK 
flow cell, far outweighs the amount of time the blood is in contact with test surface:  At any 
given moment, only ~2% of the blood is in the flow chamber over the test surface.  Additionally, 
the effect of peristaltic pump on 5 mL of blood over 2 hours could be causing a significant 
amount of hemolysis.  Therefore, further studies need to be conducted to determine the best 
conditions under which flow cytometry can be used to differentiate blood activation due to 
various surfaces.  Static tests with lower hemolysis may be better suited for flow cytometry 
analysis.  For flow cytometry analysis following blood flow experiments, a shorter time length of 
experiment or lower shear rate may be better suited. 
5.5  Conclusions 
With preliminary in vitro experiments, number of in vivo experiments can be reduced.  Although 
there is no one standardized method of conducting in vitro testing, we looked at several methods, 
including static blood exposure and blood flow experiments.  Through this set of experiments, 
we found that at <5 nm thickness, zwitterionic coatings grafted to the surface outperformed 
grafted on PEG coating.  Among the zwitterionic coatings, pSBMA consistently reduces protein 
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adsorption, resists platelet and cellular adhesion and activation compared to pMPC.  As a next 
step, in vivo experiments need to be conducted; based on the results presented in this chapter, 
attention will be focused on pSBMA-coated silicon.   
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CHAPTER VI 
Ultrathin Polybetaine Methacrylate Surface 
Modifications on Silicon: Study In Vivo 
 
 
6.1  Introduction 
In the United States, majority of the ~600,000 patients suffering from end-stage renal disease are 
dependent on hemodialysis.1  While daily-extended hemodialysis has demonstrated better patient 
outcomes than in-center thrice weekly hemodialysis,2 the current healthcare infrastructure cannot 
support daily-extended hemodialysis as a viable option.  Although relatively inexpensive, current 
hollow-fiber dialyzers used for dialysis have limitations such as wide pore size distribution 
reducing their selectivity to permeability ratio and high resistance to flow requiring external 
pump for operation.  These constraints hinder technological advancements that can lead to an 
implantable kidney.  To address this issue, our lab has developed highly uniform, low resistance 
silicon nanopore membranes (SNMs) for hemofiltration and immunoisolation in implantable 
renal replacement therapy.3  SNMs offer controllable pore size on the order of ~10 nm and 
variation of <1% across the wafer.4  Additionally, SNMs’ slit pore design and tight pore size 
distribution allows for strict molecular cut-offs and increased hydraulic permeability, making 
them ideal for biological filtration and immunoisolation. 
Because such applications bring SNMs in direct contact with blood, hemocompatibility of the 
devices must be assessed.  Although silicon is non-cytotoxic, non-leaching and non-irritant,5–7 it 
must also be non-activating and non-fouling for implant applications.  In this chapter, we have 
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modified silicon with zwitterionic polybetaines—poly(sulfobetaine methacrylate) (pSBMA) and 
poly(carboxybetaine methacrylate) (pCBMA)—in order to improve its hemocompatibility.  To 
apply coatings on SNMs, in addition to being non-fouling the polymers must also be hydrophilic 
and sub-5 nm for pore patency.  Both pSBMA and pCBMA allows us to have these properties: 
using a methacrylate backbone polymer brushes and hydrogels can be grown to a desired 
thickness with atom-transfer radical polymerization (ATRP).8–10  Biomimetic zwitterions, such 
as sulfobetaine, carboxybetaine and phosphorylcholine are extremely hydrophilic and coordinate 
water molecules through hydrogen bonding and electrostatic interactions.9,11  This hydration 
layer resists protein fouling12–16 and thrombus formation.8,11,17   
Before clinical testing, ultrathin pSBMA and pCBMA needs to be assessed in animal model.  In 
this chapter, we present a summary of extracorporeal study using pSBMA and pCBMA over 6 
hours, as well as implant studies using pSBMA for up to 26 days.  We have chosen to use a 
porcine model, which has demonstrated very similar platelet behavior compared to human 
platelets in vitro.18  The study shows that pSBMA had low levels of platelet adhesion and 
activation, and over 26 days with optimized flow path, implant channels remained patent, which 
would enable the device to be functional for bioartificial organs. 
6.2 Materials and Methods 
6.2.1  Surface Modification 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless stated 
otherwise.   
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6.2.1.1  Synthesis of ATRP Initiator (BrTMOS) 
ATRP initiator, 2-bromo-2-methyl-N-3[(trimethoxysilyl)propyl]-propanamide (BrTMOS) was 
synthesized as previously reported,14,19 and described in Chapter 2.  Briefly, a 1.2:1 ratio of σ-
bromoisobutyryl bromide (98%) to (3-aminopropyl)trimethoxysilane (97%) was reacted in the 
presence of trimethylamine in anhydrous tetrahydrofuran (THF) under nitrogen (N2) protection.  
The exothermic reaction was allowed to complete overnight, and the precipitate was removed.  
THF was evaporated and the oil was dissolved in 20 mL of dichloromethane.  The solution was 
washed with 10% potassium bisulfate (2 x 20 mL), cold deionized (DI) water (1 x 20 mL), and 
saturated sodium chloride solution (2 x 20 mL), respectively.  The organic phase was collected 
and dried using anhydrous magnesium sulfate (MgSO4).  MgSO4 was removed and 
dichloromethane was evaporated off, yielding the final product, BrTMOS.  1H NMR (400MHz, 
CHCl3) was conducted on the colorless oil to verify BrTMOS formation: δ 6.90 (s, 1H, NH), 
3.49 (s, 9H, SiOCH3), 3.26 (t, 2H, CH2N), 1.95 (s, 6H, CH3), 1.66 (m, 2H, CH2), 0.66 (t, 2H, 
SiCH2).  NMR spectrum is included in Appendix A.  The chemical structure of BrTMOS is 
shown below: 
Si N
H
O
Br
O
O
O
 
6.2.1.2 Synthesis of Carboxybetaine Methacrylate Monomer (CBMA) 
Carboxybetaine methacrylate (CBMA) was synthesized as previously reported.14  Briefly, 10 
mmol (1.685 mL) of 2-(N,N’-dimethylamino)ethyl methacrylate (DMAEM) was dissolved in a 
flask containing 50 mL of dried acetone under nitrogen protection.  Then, 12 mmol (758.5 µl) of 
β-propiolactone was added dropwise over 20 min.  The reaction was allowed to run for ~5 hours 
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at 10 °C.  CBMA formed as a white precipitate, which was collected onto a filter paper and 
washed with anhydrous acetone and anhydrous ether.  As an additional drying step, CBMA was 
dried under reduced pressure overnight.  1H NMR (400MHz, D2O) was conducted to verify 
CBMA formation: δ 6.13 (s, 1H, =CH), 5.75 (s, 1H, =CH), 4.62 (t, 2H, OCH2), 3.77 (t, 2H, 
CH2N), 3.65 (t, 2H, NCH2), 3.16 (s, 6H, NCH3), 2.71 (t, 2H, CH2COO), 1.91 (s, 3H, =CCH3).  
NMR spectrum is included in Appendix A.  The chemical structure of CBMA is shown below: 
 
6.2.1.3 Sample Preparation 
Double side polished, 400 µm thick, p-type silicon wafers were obtained from Ultrasil 
Corporation (Hayward, CA, USA) and diced into 1 cm2 chips, 1 x 6.5 cm2 long chips and 3 by 
6.5 cm2 plates.  The chips were cleaned by “piranha,” a solution of 3:1 ratio of sulfuric acid 
(96%) to hydrogen peroxide (30%) for 20 min.  Afterwards they were exposed to hydrofluoric 
acid for 5 min to remove the silicon dioxide that spontaneously forms on silicon surfaces 
exposed to atmospheric oxygen, followed by activation of the surface and another piranha clean.  
The silicon chips were then dried off with nitrogen gas and used immediately for surface 
modification. 
6.2.1.4 PEG Surface Modification 
Silicon surfaces were modified with PEG as previously described.3,20  Briefly, substrates were 
dried on a hotplate at 110 °C for 1 hour.  PEG-silane, 2-
[methoxy(polyethyleneoxy)propyl]trimethoxysilane, was purchased from Gelest (Morrisville, 
PA, USA) and covalently bonded to silicon by immersing the substrates in a solution of 285 µl 
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PEG-silane in 25 mL of toluene for 2 hours at 70 °C.  The substrates were then rinsed three times 
at 10 min intervals with toluene, ethanol, and water respectively, to remove excess PEG.  The 
structure of PEG-silane is shown below: 
O
O Si
O
O
O
6-9
 
6.2.1.5 Zwitterionic Surface Modification 
Zwitterionic surface modifications were conducted as previously published.21  Briefly, the 
substrates were placed in a 1% (v/v) BrTMOS solution in bicyclohexyl for 2 hours.  The surfaces 
were then rinsed with chloroform, ethanol, and water respectively, to remove excess BrTMOS.   
The structure of 2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide 
(SBMA) monomer is shown below: 
O
O
N+ S
O
O
O
-
 
A degassed solution of 468 mg (3 mmol) of 2,2’-bipyridyl (≥98%) and individual monomers—
SBMA: 1.06g (3.8 mmol), and CBMA: 333 mg (1.5 mmol)—and 22.3 mg (0.1 mmol) of copper 
(II) bromide (99%) was prepared in 5:5 mL of methanol:water.  This mixture was added to a 
reaction chamber housing four substrates and 143 mg (1 mmol) of copper (I) bromide (99.999%) 
under nitrogen protection, and polymerization ran for 15 min for pSBMA and 25 min for 
pCBMA.  The substrates were then rinsed with chloroform, ethanol, Dulbecco’s phosphate 
buffered saline (D-PBS, UCSF Cell Culture Facility, San Francisco, CA, USA), and water 
respectively, and dried using a stream of nitrogen gas. 
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6.2.2  Extracorporeal Experiment in Titanium Implant 
a)       b) 
 
Figure 6.1: Titanium housing (a) fully assembled, and (b) exploded view, showing three separate blood flow 
channels of 1 mm height. 
 
The titanium implant device is shown in Figure 6.1, where (a) shows a fully assembled device 
and (b) shows the exploded view.  This custom designed implant, based on a design that has 
been previously published,1  has curved flow paths at the headers that divide into three 1 mm 
high channels.  The channels are capable of holding 18 1x1cm2 chips on each side.  Each of the 
three channels of the titanium implant held 18 single solid PEG-silicon, pSBMA-silicon and 
pCBMA-silicon chips, respectively.   
The methods used were approved by University of California, San Francisco Institutional 
Animal Care and Use Committee, and conducted at the UCSF Laboratory Animal Resource 
Center.  Tunneled catheters were placed in the carotid artery and jugular vein of a 55 kg 
Yorkshire female pig, and a closed external circuitry was set up as shown in Figure 6.2.  Blood 
flowed from the carotid artery through Masterflex, Tygon E-LFL Tubing (L/S 25, 4.8 mm inner 
diameter from Cole-Parmer) to the extracorporeal device, then back through Tygon tubing to the 
catheter connected to the jugular vein.  The pig was given 200 U/kg heparin, and a bolus of 
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heparin was given throughout the experiment in order to maintain a targeted activated clotting 
time (ACT) of ~300.  The pig was also given aspirin and clopidogrel prior to the experiment.  
Before connecting the device to the pig, the whole system was sterilized with chlorohexadine.  
The system was then flushed and primed with heparinized saline. The flow experiment was run 
for 6 hours, at flow rate generated by the heart, which was measured to be ~60 ml/min.  After 6 
hours, saline was flown through the device to remove the blood.  The device was taken apart and 
analyzed for gross blood clots.  Single chips were removed and prepared for imaging for platelet 
adhesion and activation analysis as described below. 
a)     b) 
 
Figure 6.2: Images from extracorporeal experimental setup: a) close up of titanium housing, indicating flow 
direction, and b) blood flows from the carotid artery through the titanium implant and returns to the animal via 
jugular vein. 
 
6.2.3 In Vivo Experiments in Polycarbonate Implant Device 
Two implant studies were conducted in porcine model.  The implant (Figure 6.3) holds four 
pSBMA-coated 6.5 cm by 1 cm solid silicon chips.  The device was implanted intravascularly in 
two juvenile Yucatan minipigs for durations of 7-, and 26-days, respectively, in order to allow 
continuous exposure to flowing blood.  Specifically, the device was implanted subcutaneously in 
inlet 
outlet 
inlet 
outlet 
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a dorsal-lateral cervical position. Six-mm expanded polytetrafluoroethylene (ePTFE) vascular 
grafts were anastomosed to the external jugular vein and common carotid artery, then tunneled 
and attached to the device, establishing an arteriovenous shunt across the device.  
After surgical implantation and acute recovery, swine were monitored for behavior, appetite, 
activity and responsiveness twice daily. Daily hematologic assessment included complete blood 
count, serum C-reactive protein (CRP), serum lactate dehydrogenase (LDH) and plasma free 
hemoglobin. Blood flow patency was assessed daily through evaluation for a thrill and/or bruit. 
Additionally, Doppler ultrasonography was performed once weekly, and fluoroscopic 
angiography performed at 7-days and prior to device removal. The device was recovered after 7- 
and 26-days via a terminal re-look procedure. After device removal, animals were euthanized. 
All animal procedures were performed at a contract research organization (PMI, San Carlos, 
CA), and underwent IACUC review and approval. 
 
                  a)        b) 
 
 
Figure 6.3: a) exploded view and b) polycarbonate housing diagram of implant used for 7- and 26-day flow 
experiment in porcine model. Grafts are connected to carotid artery and external jugular vein. 
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6.2.4 Post Experiment Surface Analysis 
Following blood experiments, the setup was flushed with D-PBS until no trace of blood was 
detected in the tubing.  The in vivo platforms were then taken apart, and the blood channels were 
analyzed for gross clots.  For extracorporeal study, the 1x1 cm2 substrates were removed and 
rinsed 3 times with D-PBS before preparation for analysis.  The 1 x 6.5 cm2 substrates in the 
implant study were rinsed 3 times with D-PBS and broken into ~1 cm pieces for surface analysis 
for cellular adhesion using scanning electron microscopy (SEM) and platelet adhesion and 
activation using immunohistochemistry (IHC). 
6.2.4.1  Scanning Electron Microscopy (SEM) 
Cellular adhesion was visualized using SEM.  Samples were fixed by being placed in 3% 
glutaraldehyde (Sigma-Aldrich), 0.1 M sodium cacodylate (VWR) and 0.1 M sucrose solution 
(Sigma-Aldrich) for 48 hours.  Afterwards, the substrates were removed and washed two times 
with deionized water and dehydrated by incubating in ethanol/water (v/v) solution for 10 min in 
each: 35%, 50%, 70%, 95% and two times in 100%.  Samples were allowed dry overnight and 
mounted on aluminum stubs for imaging using a Carl Zeiss Ultra 55 Field Emission Scanning 
Electron Microscope (Zeiss, Dublin, CA, USA).  Prior to imaging, samples were sputter coated 
with gold-palladium. 
6.2.4.2  Immunohistochemistry (IHC) 
IHC samples were fixed with 4% paraformaldehyde (Thermo Fisher Scientific) at room 
temperature for 30 minutes and allowed to remain in 1% paraformaldehyde at 4 °C until they 
were to be imaged (~1 week).  Before imaging, the samples were marked for porcine platelets 
and platelet activation using FITC-labeled anti-CD41 (Biorbyt, Berkeley, CA, USA)) and Cy3-
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labeled anti-CD62p (Bioss Inc.) markers, respectively.  Samples were rinsed 3 times in PBS, and 
imaging was conducted using a Nikon TI-E Microscope (Nikon Instruments, Melville, NY, 
USA).  Images were quantified for platelet adhesion and activation and averaged over 20 
randomized locations using methods described in Chapter 5.  Statistical significance was 
determined by two-way analysis of variance (ANOVA) using Sidak’s multiple comparison test, 
and significance was defined at p < 0.05.  Analysis was conducted using Graphpad Prism 
software (San Diego, CA, USA). 
6.3 Results 
6.3.1  6-Hour Porcine Extracorporeal Study 
Initially, a 6-hour extracorporeal study was conducted, where three coatings were compared side-
by-side: PEG, pSBMA, and pCBMA.  Surface analysis using SEM and IHC for platelet adhesion 
and activation are presented in Figure 6.4 and 6.5, respectively. 
There were no gross clots visible in the flow path.  However, surface analysis shows a significant 
amount of platelet aggregates attached to the pCBMA-silicon surface, compared to PEG and 
pSBMA surfaces.  Under visual analysis, PEG and pSBMA-modified silicon had similar levels 
of cellular adhesion. 
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a) PEG-Silicon b) pSBMA-Silicon 
c) pCBMA-Silicon 
Figure 6.4: Representative SEM images of surfaces following blood flow for 6 hours in extracorporeal porcine 
model for (a) PEG-silicon, (b) pSBMA-silicon and (c) pCBMA-silicon. 
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Figure 6.5: Representative IHC images after 6-hour blood flow in extracorporeal porcine model.  Top row (a-c) 
represents PEG-silicon, for platelet adhesion (CD41+), platelet activation (CD62+) and overlap of (a) and (b), 
respectively.  Middle row (d-f) represents pSBMA-silicon, for platelet adhesion, activation and overlap of (d) and 
(e), respectively.  Bottom row (g-i) represents pCBMA-silicon for platelet adhesion, activation and overall of (g) and 
(h), respectively. 
 
6.3.2  In Vivo 7- and 26-Day Porcine Implant Study 
For the two implant studies, both animals underwent successful device implantation and acute 
recovery without incident. Throughout the post-implantation period, behavior, appetite, activity 
a) b) c) 
d) e) f) 
g) h) i) 
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and responsiveness remained appropriate. Serum and hematologic parameters demonstrated an 
initial acute inflammatory response to surgery, characterized by elevated white blood cell count 
and CRP, which resolved within seven to ten days.  Following acute surgical blood loss, red 
blood cell counts and hemoglobin levels improved to pre-surgical levels five days after surgery. 
Serum plasma free hemoglobin remained at pre-surgical baseline, indicating negligible if any, 
hemolysis. Throughout the implantation period, both devices remained patent based on physical 
exam, Doppler ultrasonography, fluoroscopic angiography (Figure 6.6) and visual examination 
upon device retrieval. Devices were removed intact and disassembled for analysis.  As shown in 
Figure 6.7, there was no gross clots evident in the flow path. 
 
 
Figure 6.6: Fluoroscopic angiography of the implanted device at (A) 7-day and (B) 26-days.  The U-shaped blood 
flow path of the device (d), and arterial inflow (a) and venous outflow (b) grafts are widely patent at both time 
points. 
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Figure 6.7: Explant after 7 days shows clot-free flow path. 
Representative images of SEM and IHC surface analysis post-7-day and 26-day implant study 
are shown in Figure 6.8 and Figure 6.9, respectively.  These images show no presence of large 
clots.  However, there are platelets and platelet aggregates attached to the surface as evident in 
IHC.  Additionally, SEM shows a slight granularity at the surfaces, which may be due to protein 
adhesion.   
 
Figure 6.8: Representative SEM images of the pSBMA-silicon surfaces following (a) 7-day and (b) 26-day implant. 
a) 7-day implant b) 26-day implant 
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Figure 6.9: IHC images of pSBMA-silicon surfaces after exposure to blood flow in vivo for (a-c) 7-days and (d-f) 26 
days.  First column (a and d) represents platelet adhesion (CD41+), second column (b and e) represents platelet 
activation (CD62+) and last column (c and f) represents the overlap of the first two columns. 
 
The IHC images were quantified and presented in Figure 6.10.  After two-hour flow under in 
vitro conditions (as was presented in Chapter 5), pSBMA-modified silicon had adhered ~19 
platelets/mm2, of which ~9 platelets/mm2 were activated.  With implants, there was a positive 
trend in platelet adhesion.  Following 7-day implant, the adhesion increased to ~74 
platelets/mm2.  However, only ~14% of the platelets were activated.  After 26 days under blood 
flow, the number of adhered platelets increased to ~159/mm2, and ~36% of them were activated. 
a) b) c) 
d) e) f) 
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Figure 6.10: Quantification of platelet adhesion and activation on implanted pSBMA-silicon substrates for 7 and 26 
days in porcine model.  **** represents p ≤ 0.0001. 
 
6.4  Discussion 
Microelectro-mechanical systems (MEMS) technology has led to great advances in silicon-based 
biomedical implant applications, from diagnostic devices to artificial organs.22–25  Although these 
devices meet the physical and mechanical criteria for implantation, thrombus formation on the 
silicon surface could lead to complications such as embolism, as well as retard the performance 
of the implant.  Therefore, there is a need for stealth-mode, non-thrombogenic coatings to 
improve the hemocompatibility for long-term functionality.  In this chapter, we demonstrate that 
ultrathin polymeric surface modifications with pSBMA has minimal activation and thrombus 
formation under blood flow for up to 26 days in vivo in porcine model.  Even at sub-5 nm 
coating thickness, pSBMA on silicon has the potential to survive in long-term implants, clearing 
the way for devices such as the bioartificial kidney and pancreas. 
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A 6-hour study comparing coatings of PEG, pSBMA and pCBMA on silicon was initially 
conducted.  Previous research have shown excellent non-fouling properties for all three 
coatings.17,26,27  However, such a low coating thickness has not been previously studied for 
zwitterionic coatings.  pSBMA was measured at ~3.5 nm, and pCBMA was measured at 1.7 nm.  
These measurements include an initiator layer, which is ~0.5 nm in thickness.  This experiment 
showed that PEG and pSBMA had similar performance, with limited platelet adhesion and 
activation.  Although, from previous literature, pCBMA should have been as non-fouling as 
pSBMA,17 IHC and SEM imaging shows a large increase in platelet and cellular aggregates on 
pCBMA-silicon surface.  This is most likely due to the low degree of polymerization of pCBMA 
on silicon surface compared to pSBMA, since coating thickness and grafting density play a 
critical role in their non-fouling performance.28 
Results from the 6-hour extracorporeal study, as well as the in vitro data presented in Chapter 5, 
indicate that pSBMA is comparable to or outperforms PEG in its non-fouling and non-activating 
properties.  Since PEG is known to degrade over a month,21,29,30 pSBMA was chosen for further 
in vivo studies.  
In vivo experimental results demonstrated that with ultrathin pSBMA on silicon, the implant 
remained patent over 26 days.  There was no visible clot formation in the flow path, or on the 
pSBMA-silicon surfaces.  These findings are comparable to our previous research, where 
uncoated and PEG-coated silicon shard and was implanted in rat femoral artery over 28 days.31 
In that experiment, PEG-coated silicon showed no thrombus formation where silicon had 
significant amount of clots on the surface.  The porcine experiments conducted in this study 
demonstrated that pSBMA-silicon can also withstand clot formation on a similar time scale as 
PEG-silicon.  Using IHC, platelet adhesion and activation was also studied, since attached 
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platelets can initiate coagulation cascade.  While there were no presence of clots, individual 
platelet and platelet aggregates were found attached to the pSBMA-coated surfaces.  After 7 days 
under blood flow, there were ~74 platelets/mm2, with 14% activation.  With 26-day blood flow, 
>4 times the 7-day time point, there was ~159/mm2 adhered platelets, which is only about two-
fold increase, of which 36% was activated.  However, even with this positive trend, activated 
platelets on the surface did not lead to thrombus formation on the surface.  If activated platelets 
initiated the coagulation pathway downstream, it was not evident in the grafts or in the animal.   
6.5  Conclusions 
Silicon coated with ultrathin pSBMA was tested in vivo in porcine model and was found to have 
very promising non-fouling properties.  The implant remained patent over 26 days and there was 
minimal platelet adhesion and activation, with no thrombus formation on the surface.  Although 
both in vitro fresh human blood experiments as well as in vivo porcine experiments indicated that 
pSBMA-modified silicon is a viable option for implants, clinical testing has not been done.  
Therefore, we have yet to determine what the human response will be.  Additionally, for this 
study, the membrane features were not analyzed in order to isolate the effects of the surface 
coating.  However, the added surface roughness and additional removal of filtrate from the fluid 
near the surface could lead to higher platelet adhesion and activation and needs to be the subject 
of future studies. 
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CHAPTER VII 
CONCLUSIONS 
 
 
The research work presented in this dissertation addresses the issues of hemocompatibility 
associated with silicon-based implants.  Two ultrathin zwitterionic coatings of poly(sulfobetaine 
methacrylate) (pSBMA) and poly(2-methacryloyloxyethyl phosphorylcholine) (pMPC), were 
developed, characterized, and evaluated for hemocompatibility in vitro and in vivo.  pSBMA and 
pMPC coatings were optimized to be at the highest functionality under sub-5 nm thickness.  
Their surface characterization using x-ray photoelectron spectroscopy, contact angle, atomic 
force microscopy and ellipsometry is presented in Chapter 2.  The robustness of the coatings 
under biological shear (Chapter 3) and sterilization conditions (Chapter 4) were also evaluated.  
Data suggests the coatings are functional following shear up to 2000/s over 24 hours.  
Additionally, they are able withstand sterilization procedures, with best performance of pSBMA 
and pMPC after electron-beam sterilization and ethylene oxide gas treatment, respectively.  
Novel in vitro testing platform was designed, and modified silicon surfaces were tested against 
fresh human blood flow for 2 hours.  Scanning electron microscopy and immunohistochemistry 
presented in chapter 5 demonstrated that pSBMA-silicon reduced platelet adhesion and 
activation by >97%.  Finally, 6-hour, 7-day, and 26-day in vivo testing of pSBMA-silicon in 
porcine model in chapter 6 demonstrate that implants are patent with minimal platelet adhesion 
and activation.   
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Although these in vitro and in vivo results are promising, before application in bioartificial 
organs, such as on silicon nanopore membranes (SNMs) in the artificial kidney and pancreas, 
further studies need to be conducted.  SNMs in the artificial kidney will be used for blood 
filtration.  With the removal of fluids, blood components will become more concentrated at the 
surface of the membrane, which could raise additional challenge on hemocompatibility for the 
polymer coatings.  Therefore, experiments coupling SNM filtration rates and surface coatings are 
critical. 
In addition to coatings, there are other factors of an implant that play a critical role in blood 
activation.  For example, non-ideal blood flow path and the shear rate can trigger coagulation or 
hemolysis and inflammation.  Thus, experiments must be conducted to optimize the flow path 
and shear rate coupled with surface modifications to establish the best setup for the given 
application. 
As presented in Chapter 6, preliminary in vivo experiments in porcine model demonstrated that 
with pSBMA coatings on silicon, the implant was able to remain patent up to 26 days.  However, 
prior to application in long term implants, animal experiments need to be conducted for longer 
length of time as well, coupled with filtration to demonstrate functionality.   
Finally, while platelet activation on pSBMA-silicon surfaces was low in porcine model and in in 
vitro experiments with fresh human blood, the same material could still elicit a response when 
implanted in humans.  Therefore, carefully planned ex vivo clinical testing should be conducted 
in humans to test material hemocompatibility before its use in artificial organs. 
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Appendix A: 
 
NMR was conducted using Varian-400.  BrTMOS H-NMR spectrum shown below.  Based on 
the hydrogen atoms located on the BrTMOS molecule, each peak on the spectrum has been 
assigned by number.  Additionally, the expected chemical shift is reported on the top left of the 
chart, and the measured chemical shift is reported in red. 
 
BrTMOS (ATRP initiator) NMR: 
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NMR was conducted using Varian-400.  CBMA H-NMR spectrum shown below.  Based on the 
hydrogen atoms located on the CBMA molecule, each peak on the spectrum has been assigned 
by letter.  Additionally, the area under the curve, which indicates the number of hydrogen atoms 
is listed in red under the designated peaks.   
 
CBMA (Carboxybetaine methacrylate) NMR: 
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Appendix B: 
Mass spectroscopy was run on polyethylene glycol (PEG) silane solution as was received by 
Gelest, Inc.  Although expecting PEG chain on the order of 6-9 monomers in length, data shows 
a wide range of PEG chain distribution.  Each monomer is 44 Da in size. 
PEG (Gelest) Mass spectroscopy: 
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Appendix C: 
 
Porcine Implant Experiment in Titanium Housing 
Porcine model was used because of their similarity in immune response as well as comparable 
anatomy and physiology to humans. 
 
Date 09/03/15 09/03/15 11/20/15 12/14/15 01/15/16 02/08/16 02/29/16 
 
Animal 1 
(5823) 
Animal 2 
(5824) 
 
“Device 
2” 
   
Coatings PEG, 
SBMA, 
MPC 
PEG, 
SBMA, 
MPC 
PEG, 
SBMA, 
MPC 
PEG, 
SBMA, 
MPC 
PEG SBMA SBMA 
Implant 
duration 
3 days 3 days 4 days ~2 hours 4 days 8 day 3 days 
Notes thrombosed thrombosed Good 
Doppler 
signal x3 
days, 
Gone on 
4th day  
Immediate 
cardiac 
arrest 
post-op 
Flowed on 
POD3, day 
4 
catastrophic 
hemorrhage 
Thrombosed Thrombosed 
 
The device was connected at the aortic artery and iliac vein.  However, all the devices had 
thrombosed by the explant date.  Several changes were made throughout the experiments to 
improve the outcome 
• Changes the connectors (from just Dacron to Dacron and PTFE, to Dacron bonded to 
PTFE with the addition of silicone sleeve), as shown in left image below. 
• Lowering the weight of the device by switching over the exterior from titanium to PEEK 
(40% decrease in weight) 
• Anchoring (mesh jacket to anchoring points on PEEK housing) 
• Anticoagulation regimen 
• Surface coatings (PEG, pSBMA, pMPC) 
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Below are some images taken of the device after explant, and device disassembly: 
 
 
(02/08/16 Implant)  Images above shows that older clot (lighter in color) is present at the inlet 
and outlet rather than the channel itself. 
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As shown in the image above, the clots do not attach strongly to the surface.  Rather, they are 
anchored in the inlets and outlets of the channels.  Nonetheless, the surfaces show presence of 
activated platelets using scanning electron microscopy and immunohistochemistry (as shown 
below). 
From 8 day implant (02/08/16) 
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Appendix D: 
 
Detailed protocols of polysulfobetaine methacrylate surface modification: 
PolySBMA Coating on Silicon (10x10mm chips)  
Time required: ~5 days       [Adapted from Li, et al. J of Biomat Sci 22(2011) and Zhang et al. Lang 22 (2006)] 
 
DAY 1: Formation of Initiator (BrTMOS) Part I 
Materials: 
Chemicals 
 Tetrahydrofuran (THF, HPLC grade)  
 3-aminopropyltrimethoxysilane (MW = 179.29g/mol; density = 1.027g/mL) 
 Triethylamine (MW = 101.19g/mol; density = 0.7255g/mL) 
 Alpha-bromoisobutyryl bromide (BIBB, 98%) (MW = 229.9g/mol; density = 1.86g/mL) 
 Mineral Oil (Sigma: M5904-5x5mL) 
Equipment 
 N2 supply (tank) 
 1x hot plate/stir plate 
 Cork round-bottomed flask holder 
 2x Metal stand 
 3 clamps 
 3-neck flask 
 1x stir bar (medium size) 
 3 rubber septa 
 3 5ml syringes 
 1 20mL syringe 
 long needles (for transferring) 
 Gas bubbler 
 Connector Pipe from setup output 1 to gas bubbler (short, flexible) 
 Timer 
Method 
In organics fume hood 
Note: if glassware not dried immediately before these next step, vacuum dry (12 hours) at 110° C 
1. Setup system according to image 1  
a. Place in the magnetic stir bar 
b. Run N2 for 5 min to fill the chamber 
2. Place 50 mL of dried THF in 3-neck flask 
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3. Add 1.75mL (10 mmol) of 3-aminopropyltrimethoxysilane to 3-neck flask 
4. Add 1.39 mL (10 mmol) of triethylamine to 3-neck flask. 
5. Place in 1.35 mL (11 mmol) of BIBB in the addition syringe  
6. Slowly drip BIBB over 30 min: rate less than or equal to 1 drop/6 sec 
7. Keep setup overnight (12 hours) under nitrogen protection. 
 
 
 
DAY 2: Extracting Initiator 
Materials 
Chemicals 
 Tetrahydrofuran (THF, HPLC grade) dried by sodium before use. 
 Dichloromethane 
 10% KHSO4 solution 
 Brine solution 
 RO water 
 Mg2SO4 
Equipment 
 Glass funnel 
 Clamp 
 Metal stand 
 Pressure filtration system from sigma 
 N2 supply (tank) 
 Connector Pipe from N2 tank to input 1 of filtration setup (long, flexible) 
 Connector Pipe from input 2 of filtration setup  to vacuum (medium flexible) 
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 2x Frit funnel syringes 
 Recovery Flask 
 1x Polyethylene stopper 
 1x rubber stopper (size 4) 
 Rotary Evaporator 
Method 
1. Filter out precipitate using frit funnel under N2 pressure 
2. Evaporate off THF using Rotavap. 
3. Redissolve oil in 20 ml of dichloromethane (or ether). 
4. Transfer solution to separation funnel 
5. Wash solution 2x with 10% KHSO4 solution (20mL). 
6. Wash with cold water 20mL. 
7. Wash with 2x brine water 20mL (until solution is clear) 
8. Dry organic phase with anhydrous Mg2SO4. 
9. Separate out Mg2SO4 using frit funnel. 
10. Evaporate off dichloromethane using Rotavap. 
 
NMR sample preparation 
Materials 
Chemicals 
 Chloroform-D 
 3-aminopropyltrimethoxysilane 
 SYNTHESIZED FROM ABOVE: BrTMOS: 2-bromo-2-methyl-N-3-[(trimethoxysilyl)propyl]-
propanamide 
Equipment 
 2x NMR tubes 
 1x glass pipette 
 2x 50mL falcon tube to hold NMR tubes and falcon tube holder 
 1000µl Pipette and tips 
Method 
1. Label NMR tubes (C = control, S = sample) 
2. Using glass pipette, pick up some BrTMOS solution (approx. 3-5mm) 
3. Place glass pipette on top of NMR tube S. 
4. Add in 600-800 µl of Chloroform-D on top. 
5. For Control, place in 1ul of amino-silane in NMR tube labeled S 
6. Add in 600-800 μl of Chloroform-D on top. 
7. Do NMR. 
8. Clean out NMR tubes with chloroform. 
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DAY 3: Silicon Chip coating 
Materials 
Chemicals 
 DI Water 
 Ethanol 
 Sulfuric Acid (H2SO4) 
 Hydrogen Peroxide (H2O2) 
 BrTMOS (made as described above) 
 Bicyclohexyl 
 Copper (I) bromide (CuBr, 99.999%) 
 Copper (II) bromide (CuBr2, 99.999%) 
 2,2’-bipyridyl (BPY, 99%) 
 [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide (SBMA, 97%) 
 Hexane 
 Ethanol 
 Methanol  
 PBS 
 Water 
Equipment (sufficient for coating 8x [10x10 mm] chips) 
 1x hot plate/stir plate 
 1x stir bar (smallest available) 
 Size 4 rubber stopper with 1 hole (5mm) 
 5mm thick glass tubing 
 2x Glass jar (1 closed; 1 with N2 opening) 
 50mL falcon tube 
 2 petri dishes 
 Nitrogen Source 
Method 
1. Piranha 
2. HF 
3. Piranha 
4. transfer chips from water to ethanol 
5. rinse in ethanol 3 times (5 min each) 
6. Make a solution of BrTMOS and anhydrous bicyclohexyl (1% ,v/v) 
a. In a petri dish, add 25 mL of bicyclohexyl 
b. Add 250 μL of BrTMOS 
7. Cleaned Silicon chips were directly placed into solution made in step 3; leave for 2 hours 
8. Substrates were removed from solution and rinsed with chloroform and DI water (3x each)  
9. substrates remained in water. 
10. Place substrates (2-4), 214.5 mg of CuBr, and stir bar in plate inside jar. 
11. Place jar under nitrogen protection. 
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12. In a 50 mL falcon tube, add 7.5 ml of methanol, and 7.5 ml of water 
a. degas solution for 10 min 
13. To the degassed methanol/water mix: 
a. Add 1.59g of SBMA 
b. Add 702 mg of BPY 
c. Mix until SBMA and BPY is well dissolved 
14. Add 33.5 mg CuBr2 to mixture and degas for 10 min 
15. Transfer solution to jar containing substrates under nitrogen protection 
16. Allow reaction to occur for 10 min, and 20 min 
17. Remove substrates and rinse with ethanol and water, PBS 
18. Substrates stored dry. (or in water in case of membrane) 
BEFORE 
19. In a 50ml falcon tube, add 5 ml of methanol and 5 ml of water 
a. Attach to vacuum to it 
b. Degas solution for 10 min 
20. To the degassed methanol/water mix: 
a. Add 1.06 g (3.8 mmol) of SBMA 
b. Add 312 mg (2mmol) of BPY 
c. Mix until SBMA and BPY is well dissolved 
21. Add 67 mg CuBr2 (0.3 mmol) to mixture and degas for 20 min protection 
22. Add 143 mg of CuBr (1mmol), and mix well 
23. Transfer solution to jar containing substrates under nitrogen protection 
24. Allow reaction to occur for 15 min 
25. Remove substrates and rinse with ethanol and water 
26. Samples stored in water overnight 
27. Substrates dried in air before use. 
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Appendix E: 
Detailed protocols of polyethylene glycol (PEG) surface modification: 
 
Liquid PEG Deposition on Silicon (10x10mm chips) [Adapted from Lingyan Li, Cleveland Clinic] 
Time required: Day 1: 2 hr; Day 2: 5 hr 
 
Materials 
Chemicals 
• Acetone (JT Baker) 
• Methanol [MeOH] (JT Baker) 
• Isopropyl Alcohol [IPA, 2-Propanol] (JT Baker) 
• Ethanol anhydrous [EtOH] (Sigma Aldrich) 
• Toluene (JT Baker) 
• Sulphuric Acid [H2SO4] (JT Baker) 
• Hydrogen Peroxide [H2O2] (JT Baker) 
• PEG-silane (Gelest SIM6492.7 25g) 
Equipment (sufficient for coating 8x [10x10 mm] chips) 
• 1x hot plate 
• 1x stir bar (5/16 x 1/2 in) 
• 3x 100x20mm glass Petri dishes with covers 
• 1x 50 mL, 1x 25 mL glass graduated cylinders 
• 2x glass or plastic funnels 
  
Method 
In organics fume hood: 
Step 1. Clean all glassware (see Glassware General Cleaning Protocol) 
Step 2. Immerse SNM chips in 30 mL acetone ......................................................................................... [10 min] 
Step 3. Drain acetone in solvent waste; immerse SNM chips in 30 mL MeOH .......................................... [5 min] 
Step 4. Drain MeOH in solvent waste; immerse SNM chips in 30 mL IPA................................................ [5 min] 
Step 5. Drain IPA in solvent waste; rinse SNM chips in 30 mL DI H2O ............................................... [3x 5 min] 
In acids fume hood: 
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Step 6. Place a sign reading “DANGER: Piranha” with your name/number; place on ledge of acids fume hood 
Step 7. Use 1st funnel to pour 30 mL H2SO4 in 50 mL graduated cylinder 
Step 8. Use 2nd funnel to pour 10 mL H2O2 in 25 mL graduated cylinder 
Step 9. Combine H2O2 and H2SO4 in Petri dish (add H2O2 first, then H2SO4!) 
Step 9. Immerse SNM chips in freshly prepared Piranha 3:1 (30 mL: 10 mL) H2SO4: H2O2 ................... [20 min] 
Step 8. Remove SNM chips and rinse in 30 mL DI H2O ....................................................................... [3x 5 min] 
At lab bench: 
Step 9. Place SNM chips on clean Alpha wipe in plastic Petri dish and dry in air ................................ [overnight] 
In organics fume hood: 
Step 10. Rinse SNM chips; use 2 clean dishes for rinsing each group of chips so that one dish can be cleaned with acetone 
and DI H2O while the other is in use 
• 30 mL EtOH ............................................................................................................................. [3x 10 min] 
• 30 mL toluene .......................................................................................................................... [2x 10 min] 
Step 10. Completely dry SNM chips in glass Petri dishes on hotplate at 110 °C ........................................ [90 min] 
Step 11. Remove SNM chips from Petri dish, set hotplate to 70 °C ................... [wait for temperature to stabilize] 
Step 12. Add 25 mL toluene to dish 
Step 13.  Immerse SNM chips and magnetic stir bar in toluene dish 
Step 14. Add 285 µL PEG-silane; stir at speed 7 with cover on dish ............................................................... [2 hr] 
Step 15. Rinse SNM chips; use 2 clean dishes for rinsing each group of chips so that one dish can be cleaned with acetone 
and DI H2O while the other is in use 
• 30 mL toluene .......................................................................................................................... [2x 10 min] 
• 30 mL EtOH ............................................................................................................................. [3x 10 min] 
• 30 mL DI H2O .......................................................................................................................... [3x 10 min] 
At lab bench: 
Step 16. Place SNM chips on clean Alpha wipe in plastic Petri dish and dry in air ................................ [overnight] 
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Appendix F 
CBMA Synthesis 
Adapted from Zhang et al, Langmuir 2006 
 
Supplies: 
• 250 ml Round bottom flasks 
• ice and ice holder 
 
Chemicals: 
• Acetone 
• MgSO4 (drying agent) 
• DMAEM 
• beta-propiolactone 
 
 
1. Dry 75 mL of acetone with MgSO4 
2. Place in 50 mL of dried acetone in flask: flask with ice and stir bar 
3. Place in 1.685 mL (10 mmol = 1.5721g) of DMAEM 
a. keep DMAEM stored in 2-8C 
4. Keep nitrogen protected 
 
5. Add in 758.5 ul (12mmol = .87g) of B-propiolactone to 10 mL dried acetone into a falcon 
6. add dropwise into DMAEM/acetone 
7. let reaction run for 5 hours under ice 
8. collect white precipitate on filter paper 
9. wash precipitate with 50 mL of anhydrous acetone 
10. wash precipitate with 100 mL of anhydrous ether (or hexane) 
11. dry under reduced pressure 
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CBMA synthesis (precipitate forming) done under nitrogen protection.  
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